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Mass-spectrometry based proteomics has become an indispensable tool for molecular 
biology and clinical research because of its ability to identify and quantify thousands of 
proteins. When combined with laser capture microdissection (LCM), MS-based proteomics 
may be used to investigate disease-associated changes in the proteome of specific tissue 
regions or cell populations. Such specificity is essential because different anatomical 
regions often have distinct and diverse functions and may behave differently under 
pathological conditions. However, the number of proteins that may be identified and 
quantified decreases with smaller sample amounts. Strict anatomical/cellular specification 
usually yields micrograms or submicrograms of protein, and thus ultrasensitive 
microproteomics protocols are required to analyze these small sample amounts while 
maintaining high proteome coverage. 
Recent advances in liquid chromatography (LC) and MS equipment have improved the 
analysis of low sample amounts. The development of mass spectrometers with increased 
sequencing speed and ion transmission, have resulted in an increase in dynamic range and 
sensitivity. The advances in ultra high-pressure liquid chromatography (HPLC) has 
enabled the routine use of long columns (≥50 cm) with smaller internal diameter and 
smaller particle sized (< 5 µm) further increasing peptide separation resolution. However, 
the developments in LC-MS sensitivity have outpaced developments in sensitive sample 
preparation protocols. 
In this PhD thesis, I will present my 4-years research on the development of ultransensitive 
microproteomics strategies for the molecular characterization of tissues. During my PhD I 
developed and optimized an ultrasensitive proteomic workflow for the analysis of small 
sample amounts, and I applied it to biomedical case studies.  
First, I compared the digestion efficiency of the Filter-Aided Sample Preparation protocol 




the conventional urea based in-solution digestion (ISD) method for different amounts of 
HeLa cells. The SP3 protocol, based on the use of carboxylate coated paramagnetic beads, 
outperformed the FASP and ISD protocols for the analysis of small sample amounts, 
providing the identification of about 3000 protein groups from 1 µg of HeLa lysate. As a 
proof of principle, I applied the optimized SP3 protocol to the characterization of the brain 
of a mouse model of glioblastoma. Laser capture microdissection provided the specificity 
required to isolate different anatomical regions of the brain (healthy, border and tumor 
regions), while the SP3 digestion protocol provided the sensitivity required for the analysis 
of heterogeneous and complex samples.  
To ensure accurate relative quantification and increase the proteome coverage I optimized 
in-solution and on-column Tandem Mass Tags (TMT) labeling and peptide fractionation of 
low sample amounts. Preliminary experiments revealed very low labeling efficiency when 
standard labeling conditions were applied to volume limited samples. Following an 
exhaustive optimized of in-solution and on-column TMT labeling the final conditions 
provided a TMT labeling efficiency (for 1 µg of HeLa digest) even greater than that 
obtained using standard methods on high sample amounts (25-50 µg of digest). Moreover, 
high-pH reversed phase fractionation increased proteome coverage by approximately 
140% relative to single long gradient analyses. 
One of the challenges of working with microdissected tissues or other samples 
characterized by low total protein content, is the need to estimate total protein content 
(essential knowledge for accurate quantitation). Previously adjacent sections were used just 
for the protein content estimation, which is non-ideal because tissue histologies may differ 
(especially for small pathological features with a specific histology). To address this, I 
developed a colorimetric assay for protein content estimation. I modified the microBCA 
protein assay to be able to measure proteins in just 1 µL and in the presence of the reagents 
commonly used in lysis buffers (as SDS, EDTA, EGTA, etc.). This modified microBCA 
assay allowed a reproducible quantification of the protein content of each individual 
sample down to a concentration of 15 ng/µL. The final optimized quantitative workflow 
for the proteomic analysis of tissue samples comprised laser capture microdissection, 




labeling, high-pH reversed phase fractionation and injection in a nanoLC system coupled 
with an Orbitrap Fusion mass spectrometer. As a proof of principle, I applied the 
optimized workflow to the proteomic characterization of mouse kidney substructures.  
Finally, I applied the optimized workflow to the characterization of the central and 
peripheral nervous system of a mouse model of Krabbe disease (the Twitcher mouse). I 
compared the proteomes extracted from the corpus callosum, motor cortex and sciatic 
nerves of five Twitcher and five control wild type mice. The results on the proteome 
changes in the Twitcher mouse provided new insights into the molecular mechanisms of 
Krabbe disease showing neuroinflammation, activation of immune response, accumulation 
of lysosomal proteins, demyelination, membrane rafts disruption and reduced nervous 
system development. 
Altogether, the microproteomic protocol developed during my PhD represents a powerful 
tool for the proteomic characterization of pathological tissues. Moreover, the research 
study on Krabbe disease represents the first in-depth proteomic characterization of the 
Twitcher mouse and a starting point for future functional experiments to study the 





















1.1. Introduction to proteomics 
 
Proteins are large biomolecules that are made of a chain of hundreds to thousands of amino 
acids. There are twenty common amino acids that can be combined to make a protein. The 
amino acid sequence of each protein is encoded in the DNA and helps determine the 
specific protein 3D structure and function.  
All biological systems generate proteins via the transcription and translation processes, 
according to the central dogma of molecular biology [1]. During transcription the 
information stored in the gene’s DNA is transferred to mRNA. In the translation step, the 
mRNA molecule interacts with ribosomes, which are specialized complexes able to read 
the mRNA nucleotide sequence. A family of tRNA’s, which recognize the codon of three 
nucleotide bases that code for each amino acid, carry the amino acid to the ribosome where 
they are assembled into the protein one amino acid at a time.  
Proteins represent the main functional machinery of cells, as they carry out the tasks 
specified by the information encoded in genes. The term “proteomics” was coined in 1995 
and was defined as the large scale systematic study of all proteins, the proteome, of cells, 
tissues or organisms, in analogy to genomics [2][3]. This includes not only the 
identification and quantification of proteins, but also the determination of their cellular 
localization and the study of their interactions and functions [4]. The growth of proteomics 
was a result of the mapping and sequencing of the complete genome from different 
species, as they provided an essential resource for the identification of experimental 
protein sequences, namely the predicted amino acid sequences [5][6].  
Proteins are the primary functional units of all cellular processes, and many aspects of the 
proteome cannot be predicted from the study of genes alone. For example, perturbations in 
protein expression levels, proteolytic processing that changes the length of the primary 
amino acid sequence, and post-translational modification states are all directly related to 
the molecular mechanisms of diseases [7]. Thus, proteomics has become a powerful tool 
for systems biology as it can provide a global picture of the molecular state of cells. This 
information is used by biologists to study how alterations of signaling pathways influence 




cellular functions and by medical researchers to study the mechanisms of diseases and 
identify potential therapies.  
The complexity of the proteome far exceeds that of the genome. There are approximately 
20000 protein-coding genes in the human genome, which result in at least 20000 canonical 
proteins [8]. However many different protein variants can be produced from a single gene 
because of alternative splicing, single amino acid variants, post-translational modifications 
[9], and enzymatic cleavage (e.g. the protein proopiomelanocortin is a pre-protein that is 
enzymatically cleaved to produce more than 10 different neuropeptides). Protein 
expression levels also span a very wide dynamic range, >10
6
. These characteristics, high 
complexity and high dynamic range, represent a significant analytical challenge for protein 
analysis, more so because of the absence of protein amplification techniques analogous to 
PCR. Mass spectrometry (MS) and affiliated technologies have provided the sensitivity, 
selectivity and throughput required for proteomics analysis. The rapid technological and 





Figure 1.1. Schematic comparing genome, transcriptome, and proteome diversity. The changes at 
the mRNA level and the different post-translational modifications lead to a vast increase in 
proteome complexity. 




A recent study by Wang et al. compared proteome and transcriptome abundances in 29 
healthy human tissues [10]. The analysis revealed that hundreds of proteins could not be 
detected even for highly expressed mRNAs, that there are strong differences between 
mRNA and protein expression levels within and across tissues, and that protein expression 
can be more stable. The correlation between gene expression and protein expression is 
often poor, particularly in cancer. For example the Spearman correlation between gene 
expression and protein expression in pancreatic cancer is approximately 0.1, or barely 
above random [11]. It is thus essential to characterize which protein isoforms are expressed 
(protein identification) and at what levels (protein quantitation), particularly for biomedical 
applications. 
 
1.2. Mass spectrometry-based proteomics 
 
Mass spectrometry (MS) has established itself as the most powerful analytical tool for the 
analysis of proteins [12]. MS-based proteomics technologies have largely displaced earlier 
research tools for protein analysis, such as two-dimensional gel electrophoresis, because of 
their much higher sensitivity and their ability to deal with complex protein mixtures, as 
well as providing a much higher throughput [13].  
MS-based proteomics relies on the availability of genome sequence databases and has 
benefited from rapid technical and conceptual advances in MS technology, separation 
sciences, ion chemistry, and bioinformatics. The widespread use of MS for protein analysis 
started in the late 1980s with the emergence of the macromolecular ionization techniques 
electrospray ionization (ESI) [14] and matrix-assisted laser desorption ionization (MALDI) 
[15] (for which Prof. John Fenn and Koichi Tanaka were jointly awarded the 2002 Nobel 
Prize in Chemistry). Since then, the MS instrumentation developments have led to a terrific 
increase in sensitivity, mass accuracy and throughput, enabling the in-depth 
characterization of proteomes and expanding the knowledge about protein structure, 
function, modification and protein dynamics [16].  




Modern MS-based proteomics is overwhelmingly based on ESI instrumentation. These 
experiments can be divided into two different approaches for protein identification: 
bottom-up and top-down (Figure 1.2) [17]. In bottom-up proteomics, proteins are digested 
with a proteolytic enzyme, typically trypsin, and the resulting peptides mixture is analyzed 
by MS; in top-down proteomics MS analysis is performed directly on the intact proteins.  
Bottom-up, also called shotgun, proteomics is the most widely used approach for protein 
identification and the characterization of complex samples, since peptides are more 
amenable to MS-based analysis than intact proteins [18]. However, only a fraction of the 
total peptide population is typically identified. A consequence of the limited protein 
coverage is reduced information about post-translational modifications (PTMs), and the 
loss of any combinatorial information about PTM’s situated on different proteolytic 
peptides. In principle top-down mass spectrometry can provide almost complete sequence 
coverage of a protein, revealing their different modification states [19]. Indeed, the 
advantages of top-down proteomics are the potential access to the complete primary 
sequence of the protein and the ability to identify and locate PTMs. However, the long 
acquisition times required and the resulting very complex spectra make the coupling of MS 
with online chromatographic systems very challenging, limiting the applicability of top-
down to isolated proteins or simple protein mixtures [20].  
 
 






Figure 1.2. Schematic of bottom-up and top-down approaches in MS-based proteomics. 
 
Middle-down proteomics strategies have been developed to combine the benefits of 
bottom-up and top-down approaches [21][22][23]. Middle-down methods are based on the 
proteolysis of proteins with enzymes that target less abundant amino acids than trypsin, to 




generate longer peptides (20-100 amino acid residues), resulting in a less complex peptide 
mixture [24].  
The choice of the proteomics approach ultimately depends on the aim of the experiment. 
Bottom-up proteomics is the method of choice for the qualitative and quantitative 
characterization of the proteomes from cells/tissues, while top-down is mainly used for the 
characterization of PTMs and proteoforms (i.e. all the different molecular forms in which 
the protein product of a single gene can be found). 
A typical bottom-up proteomics workflow consists of four steps: (i) sample preparation, 
(ii) peptide separation, (iii) MS acquisition, and (iv) data analysis. The fine details of the 
analytical conditions are then dependent on the type of sample analyzed (e.g. in-vitro cell 
culture, whole organs, microdissected tissues) and the aim of the experiment (e.g. 
biomarker discovery, PTM analysis, quantitative analysis). The following paragraphs 
describe the different steps of a bottom-up proteomics workflow.  
 
1.2.1. Sample preparation 
 
Sample preparation is a critical step of the proteomics workflow as it influences the 
sensitivity, reproducibility and robustness of any experiment. In bottom-up experiments, 
all sample preparation protocols have five key elements: (i) protein extraction and 
denaturation, (ii) protein reduction, (iii) protein alkylation, (iv) protein digestion, (v) 
peptide clean-up/enrichment. 
Protein extraction is usually performed using lysis buffers containing chaotropes (urea), 
surfactants (SDS, SDC), salts (TrisHCl, NaCl) or organic solvents (ACN, MeOH, TFE) 
that are able to disrupt the intra- and inter-protein interactions, promoting protein 
denaturation and solubilization. Cell lysis can also be performed by physical procedures 
such as ultrasonication [25], freeze-thaw cycles [26], and pressure-cycling based 
systems[27].   




Proteins are then reduced and alkylated to open-up all disulfide bonds, thereby ensuring all 
protease cleavage sites are more accessible to the enzyme and the proteolytic digestion 
more complete. Protein reduction is usually performed using DTT or TCEP, which cleave 
the disulfide bonds [28], following which alkylation is performed with iodoacetamide or 
chloroacetamide to block the free–SH groups, preventing the reformation of disulfide 
bonds [29].  
Protein digestion is performed using proteolytic enzymes that cleave proteins at specific 
amino acid residues. The cleavage involves hydrolysis of the amide bond before or after 
specific residues. The proteolytic enzyme trypsin cleaves the protein chain at the carboxyl 
side of arginine and lysine, and is the enzyme most often used for bottom-up proteomics 
on account of its robustness and its generation of peptides with a basic N-terminal and C-
terminal (Arg/Lys). The basic termini are very useful during for identification of the 
proteolytic peptides using tandem mass spectrometry because it favors the detection of 
structural fragments that contain the N-terminus and, separately, the C-terminus.  
Trypsin is often used in combination with Lys-C to increase the digestion efficiency of 
complex protein mixtures [30]. The resulting mixtures of proteolytic peptides are then 
purified or subjected to an enrichment protocol for the analysis of specific PTM’s, e.g. 
protein phosphorylation. Enrichment is required for PTMs studies because many such 
peptides are frequently of lower abundance and would be masked by the non-modified 
peptides (without the enrichment step). Enrichment strategies are mainly focused on 
affinity chromatography or antibody-based immune-precipitation methods and the protocol 
of choice depends on the type of PTM of interest [31].  
The last step of the proteomics workflow before LC-MS/MS analysis is the purification of 
the peptide mixture. Most of the buffers and chemicals used in the proteomics sample 
preparation workflow are not compatible with LC-MS/MS systems, as they may contain 
salts, detergents, and other factors that can clog the chromatographic system and/or induce 
ion suppression, adversely affecting robustness and sensitivity. Peptides can be desalted 
off-line using reverse-phase solid phase extraction cartridges[32], tips [33], magnetic beads 
[34], or online using trap columns before MS analysis [35]. Ù 





1.2.2. Peptide separation 
 
The proteolytic digestion of a cell lysate or a tissue extract generates hundreds of 
thousands of peptides that then need to be detected and characterized by MS analysis. The 
success of a proteomics study depends on several factors; the extent of proteome coverage 
determines the ability detect lower abundant proteins, and the sequence coverage of each 
identified protein is intrinsically related to the confidence of the identification and the 
ability to characterize proteoforms (e.g. due to PTM’s) [36]. Liquid separations, such as 
liquid chromatography (LC) or capillary electrophoresis (CE), are used to distribute the 
high complexity of the peptide sample over the course of the LC/CE separation, and 
thereby reduce sample complexity.  
Advances over the last decade in ultra high-pressure liquid chromatography (HPLC) have 
enabled the routine use of long columns (≥50 cm) with smaller internal diameter and 
smaller particle sizes (< 5 µm), which have increased peptide separation resolution [37]. 
Moreover, the development of nanoLC/low flow rate electrospray (nanoESI) platforms, 
which operates at flow rates in the range of 20-400 nL/min, have led to a significant 
increase in sensitivity, enabling the analysis of sub-microgram sample amounts [38].   
The most common methods for peptide separation include reversed phase (RP) and strong 
cation exchange (SCX) chromatography, which separate peptides based on hydrophobicity 
and the number of positive charges, respectively [39]. Two dimensional LC may be used to 
further increase the separation capabilities of the LC step [40] and is most frequently 
performed using SCX for the first dimension and RP as the second dimension, because of 
the lower resolving power of SCX and its high orthogonality to RP. SCX is generally used 
to pre-fractionate the samples prior RP-LC-MS analysis, this offline pre-fractionation 
results in the conversion of a single highly complex peptide sample into multiple less 
complex peptide fractions, which are then individually analyzed by RP-LC and results in a 
significant increase in the number of peptide identifications. This setup takes advantage of 
the superior chromatographic resolving power of RP stationary phase and the compatibility 




of the eluent used in RP-LC with ESI, allowing it to be directly interfaced to the MS for 
instant peptide mass measurements [41]. Alternatively, two RP separations at different pH 
has established itself as a powerful and convenient option for in-depth LC-MS/MS based 
proteomics: a simple change in pH has been shown to provide identical orthogonality to 
SCX-RP [42].  
The choice of separation technology ultimately depends on the goal of the experiment, 
alternative forms of chromatography routinely used in proteomics include size exclusion 
chromatography (SEC), affinity chromatography (AC), hydrophilic interaction 
chromatography (HILIC) [43], and capillary electrophoresis (CE). CE has recently 
emerged as a technique complementary to RP-LC as the separation is based on differences 
in charge density, resulting in a high degree of orthogonality to RP-LC [44]. CE has been 
found to be particularly suited for the analysis of PTMs that can alter charge state, 
including phosphorylation and glycosylation [45][46]. Furthermore, the ultra-low flow 
capabilities of CE have been exploited for ultra-sensitive analysis, including single cell 
analysis; the ultra-low flow means minimal sample consumption, typically in the order of 
several nanoliters, and offers a high resolving power on short time scales [47][48].  
 
1.2.3. MS detection 
 
The mass spectrometer (MS) consists of an ionization source, a mass analyzer and a 
detector. The ion source generates gas-phase (pseuodo) molecular ions from the peptides in 
sample; ii) the mass analyzer separates these ions according to their m/z ratio; iii) the 
detector is used to record the abundance of each m/z-separated ion and convert that 
information into digitized signals. The following paragraphs describe in more detail each 
of these parts of the MS workflow. 
1.2.3.1. Ionization 
Proteomics is overwhelmingly based on the ionization techniques as electrospray 
ionization (ESI) [14] and, to a much lesser extent, matrix-assisted laser desorption 




ionization (MALDI) [49]. Both ESI and MALDI can generate intact pseudomolecular ions 
(i.e. [M+nH]
n+
) with minimal fragmentation [50].  
In MALDI the peptides/proteins are mixed in solution with an excessive of a matrix, which 
is usually a small organic acid that absorbs UV light (e.g. sinapinic acid, α-cyano-4-
hydroxycinnamic acid, 2,5-dihydroxybenzoic acid). Upon solvent evaporation, a solid 
deposit is obtained containing peptide-doped matrix crystals. The sample is then irradiated 
with a pulsed UV laser, pulse length <10 ns. Absorbance of the laser pulse energy, with 
pulse lengths shorter than the time required for energy redistribution throughout the matrix, 
leads to an almost-explosive phase change in the laser-super heated matrix. This phase 
change leads to a directed motion of matrix molecules, matrix clusters, and 
peptides/proteins into the gas phase (Figure 1.3.A). Singly protonated ions ([M+H]
+
) are 
formed in the hot plume by matrix-to-analyte proton transfers [51]. MALDI suffers from 
some disadvantages such as the impossibility to couple it online with a chromatographic 
system and strong dependence on the sample preparation methods [50][12]. The main 
advantages of MALDI are the low complexity of the mass spectra (MALDI mass spectra 
are characterized by singly charged ions), the relatively high compatibility with salts and 
detergents and the possibility to perform imaging experiments using focused laser beams 
[52][53].  
ESI was first introduced in 1989 by Fenn and workers as a soft ionization technique to 
analyze intact proteins [14]. ESI is characterized by little/ no fragmentation, and even weak 
non-covalent interactions may be preserved [54]. ESI is performed by applying a potential 
difference of 1-6 kV, under atmospheric pressure, between a liquid passing through a thin 
needle (e.g. the emitter) and a counter electrode (the MS inlet). The high electric field 
induces charge accumulation at the liquid emerging from the emitter. The forces applied to 
the ions in the liquid by the strong electric field leads to the formation of a Taylor cone, 
from which a jet of liquid emerges that releases charged droplets (Figure 1.3.B). These 
droplets are subject to solvent evaporation during their passage to and through the MS 
inlet; during solvent evaporation, the surface charge density increases until the droplet 
becomes unstable. Ostensibly one could consider the “Rayleigh” limit when coulombic 
repulsion exceeds surface tension, but in reality asymmetric fission events occur before the 




Rayleigh limit because the coulombic repulsion exacerbates any deviation from spherical 
droplets, and favors the emergence of highly charged jets that generate smaller, highly 
charged, satellite droplets. This process continues until gas-phase protonated 




Figure 1.3.  The most used soft ionization techniques used in proteomics experiments. (A) Matrix 










The pseudomolecular ions (i.e. [M+nH]
n+
) generated by ESI are characterized by different 
charge states. The basic sites on the peptide/protein can bind the protons present in the 
final droplets. The charge state distribution reflects the number of basic sites available in 
the peptide/protein (larger proteins have higher charge states), the number of protons 
available in the final droplets (a stochastic phenomenon and so resulting in a distribution of 
charge states), as well as the thermodynamics of protonation. This latter aspect is important 
because it dictates that the degree of ionization for any specific peptide/protein depends on 
how well it competes with all other peptides/proteins and other cofactors present in the 
final droplets of the ESI process. The presence of many different peptides/proteins means 
only the more abundant and basic peptides/proteins are likely to be ionized to a sufficient 
degree to be analyzed with sufficient sensitivity. Similarly, cofactors that compete for 
charge lower sensitivity.  
The multiple charging of ESI has numerous advantages, one in particular is that it enables 
the analysis of large molecules since the m/z values of the [M+nH]
n+
 ions fall in the range 
of where many mass analyzers offer higher performance (e.g. mass resolution). Another 
significant advantage of ESI is that it can be directly coupled with capillary electrophoresis 
and UPLC systems, enabling the analysis of small and large molecules of a wide range of 
polarities in complex mixtures [56]. The development of micro-ESI and nano-ESI sources, 
in which the flow rate is in the range of µL/min and nL/min respectively, have greatly 
improved sensitivity due to further improved ionization efficiency [57][58][59].    
1.2.3.2. Mass analyzers 
Mass analyzers separate ions according to their mass-to-charge ratio (m/z). Mass analyzers 
can be further divided into two categories, separate-ions-in-space (e.g. Quadrupole and 
Time of Flight mass analyzers) or separate-ion-in-time (e.g. Ion Trap, Orbitrap, and 
Fourier Transform Ion Cyclotron Resonance analyzers). Each mass analyzer has its 
advantages and limitations, and the choice of mass analyzer is ideally dependent on the 
goal of the experiment, but in practical purposes is dependent on the availability of these 
high cost instruments (to purchase and maintain). In proteomics higher speed, higher mass 




resolution, and higher mass accuracy equate with increased depth of coverage, i.e. more 
protein identifications. For targeted proteomics, selectivity and sensitivity are the key 
performance metrics. Mass analyzers are now routinely combined in the so-called hybrid 
instruments characterized by increased versatility, throughput and parallel MS and MS/MS 
detection.  
The most common mass analyzers used in proteomics are summarized below.  
 
Quadrupole (Q) – The Quadrupole analyzer acts like an ion filter using the stability of the 
ion trajectories in oscillating electric fields to separate ions [50][60]. The quadrupole 
analyzer is made up of four parallel metal rods that have a bias DC applied to all four rods, 
a fixed DC potential difference between adjacent rods, and a radio frequency (RF) time-
varying potential difference between adjacent rods (Figure 1.4A) [61]. Because of the 
oscillating RF voltage, each pair of rods will have successively positive and then negative 
potential. These oscillations result in complex ion trajectories dependent on the m/z ratio of 
the ions. The stability of the ions is best summarized with the Matheiu parameters and the 
stability diagram (Figure 1.4B): 
 
   
    
   
   
         
    
   
   
            
 
where Ω is the frequency of the RF potential, e = the charge of an electron; U = fixed DC 
voltage between adjacent rods, V = zero-to-peak RF voltage; m = mass of the ion, z= 
charge state of the ion, and r0 = the field radius of the quadrupole (i.e. the radius of the 
circle that touches the inner most edge of all four rods). 
Ion motion is only stable within defined ranges of the Mathieu parameters au and qu. Figure 
1.4B shows the stability diagram; only ions whose Mathieu parameters are within the 
stable region, highlighted in grey in the figure, will be transmitted through the quadrupole. 
For a given ratio of DC and RF voltages the quadrupole can be operated at close to the a0 




and q0 point, in which only a single mass is transmitted through the quadrupole. As the 
Mathieu parameters au and qu are both inversely proportional to m/z ratio, different ions 
can be transmitted just by changing the magnitude of the DC and RF voltages. 
 
Figure 1.4.  Quadropole mass analyzer. A) Schematic of typical quadrupole power supply 
connections. B) The Mathieu stability diagram in two dimension . Figures adopted from [61]. 
 
A quadrupole mass scan involves ramping the DC and RF potentials so that ions of 
increasing m/z ratio are transmitted through the analyzer (scanning mode). For targeted 
analysis the quadrupole is fixed at specific DC and RF potentials (selected ion monitoring 
mode). Selected ion monitoring enables signal averaging to increase sensitivity.  
Quadrupoles are often used in series for tandem MS (e.g. triple quadrupole (QqQ) MS), or 
in combination with other mass analyzers for hybrid MS (e.g. quadrupole time-of-flight 
(Q-ToF) MS) [62]. In these types of mass spectrometers a precursor m/z is selected in the 
first quadrupole (Q0), which is then accelerated into a second quadrupole (Q1) containing 
an inert collision gas, the resulting fragment ions are then analyzed in the third mass 
analyzer (Q2 or ToF).  
 
Time-of-Flight (ToF) – In ToF analyzers the m/z ratio of an ion is determined by its flight 
time through a drift tube of specified length that is under vacuum (Figure 1.5A) [63]. Ions 
are introduced into the ToF analyzer as a pulse, receiving the same initial kinetic energy. 
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As ions travel along the field free drift tube they are separated in time because differences 













where d is the length of the field free region, U is the accelerating voltage through which 
all ions were accelerated prior to entering the drift tube, m is the ion’s mass, q the ion’s 
charge state, and e is the charge of an electron.  
For a given kinetic energy the time taken for an ion to reach the detector is proportional to 
the square root of the m/z ratio [16]. In an ideal scenario all ions would be accelerated 
through the same acceleration potential and have identical kinetic energy, plus there would 
be zero dispersion through the mass spectrometer so all ions of identical m/z would have an 
identical time-of-flight. In reality, owing to the discrete size of the ion cloud in the mass 
spectrometer all ions (of the same m/z) do not experience the same acceleration voltage; 
furthermore thermal distributions in velocity, imperfections in the electric fields of the ion-
optics, and repulsion between ions, all combine to result in ions of identical m/z having a 
narrow range of flight times, leading to an experimental mass resolution that is 
substantially lower than the theoretical limit.  Delayed extraction and the reflectron 
represent two distinct technological solutions to compensate for the range in flight times 
and thereby improve mass resolution, Figure 1.5B [64]. The reflectron consists of a shaped 
electric field gradient that reflects the ions back along the flight tube; fine tuning of the 
reflectron voltage gradient is used to time-focus the ions at the detector.   
 






Figure 1.5.  Time-of-flight mass analyzer. Basic components of a linear ToF (A) and a reflectron 
ToF (B) mass spectrometer. Figure adopted from [63]. 
 
Linear Ion Trap (LIT) – The LIT analyzer (also referred to as a 2D ion trap) consists of a 
quadrupole with two end-cap electrodes that can be used to axially constrain ions inside 
the quadrupole (Figure 1.6.). In the LIT the ions are confined in the radial dimension by 
the quadrupolar field of an RF-only quadrupole (au=0, so ions of wide m/z range have 
stable trajectories, see Quadrupole equation) and in the axial dimension by the axial 
potential well created using the cap electrodes. After injection of ions into the LIT, and 
collisional cooling using an inert background gas [65], the ions are focused onto the axis of 
the LIT and within the potential well of the axial field. The frequency of the secular motion 
of an ion in a quadrupole LIT is directly proportional to its m/z ratio and the applied RF 
voltage. The secular motion of selected ions or a range of ions can be excited by the use of 
an auxiliary waveform, which can be used to excite the ions out of the trap for detection, or 
to excite their motion collision induced dissociation (CID) [66].  
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The fundamentals of ion motion in a 2D LIT are very similar to the 3D ion trap (in which 
the ions are focused at a focal point), but has the distinct advantage of reduced space-
charge effects as the ions are distributed along an axis, which results in a higher charge 
capacity (at least 400-fold higher) and increased sensitivity [67][68].  
LIT analyzers are frequently used for the sequential trapping, isolation, fragmentation, and 
MS analysis of fragment ions (tandem in time). This process can be repeated so that 
fragments from the first MS/MS experiment can be isolated and subjected to an additional 
round of MS/MS (commonly referred to as MS
3
). In principal the LIT enables MS
n
 but the 





A dual pressure LIT has been developed to increase trapping/fragmentation efficiency and 
sequencing speed [69]. The dual pressure LIT consist of two identical LITs separated by a 
center lens. The first LIT efficiently traps and fragments ions at high background gas 




Figure 1.6.  Schematics of a Linear Ion Trap analyzer. Basic design of a 2D linear ion trap. Figure 
adopted from [68]. 
 
Ion Cyclotron Resonance Mass Spectrometry (ICR-MS) was first applied in the mid 
1950’s [70] to measure very small mass differences at very high precision and remained 
mostly an academic tool until the application of FT methods in the early 1970’s [71][72]. 




Today FTICR is synonymous with ultra high mass resolution, and finds widespread use in 
applications that demand super high mass resolution [16][73][74].  
The mass analyzer of an FTICR consists of the ICR cell, which is situated inside a 





 mbar, in order to enable super high mass resolution measurements 
(collisions with residual gas molecules undermine such measurements).  
Ions in a magnetic field move in a circular motion under the influence of the Lorentz force. 
This motion, the cyclotron motion, has a frequency proportional to the magnetic field and 
the m/z ratio. At room temperature the radius of the cyclotron motion is small, and too 
small to detect. The application of an RF field at an ion’s cyclotron frequency, i.e. resonant 
excitation, will excite the ion’s cyclotron motion and increase its radius. The higher orbits 
of the excited cyclotron motion can be detected by amplifying the image current imparted 
into a pair of detection plates; the Fourier transform of the free induction decay of the 
time-domain signal generates the frequency spectrum, from which the mass spectrum is 
then calculated using a calibration [50].  
Hybrid FT-ICR instruments have been developed to provide parallelization of precursor 
mass selection and fragment ions detection. The major drawback of FTICR-MS is 




Figure 1.7.  Schematic of the FTICR-MS principle. Figure modified from [76]. 




Orbitrap (OT) – The OT analyzer is an electrostatic ion trap that uses the Fourier transform 
to obtain simultaneously determine mass spectra spanning a wide mass range. The Orbitrap 
was designed by Makarov in 2000 [77] and is based on the Kingdon trap [78] that was first 
described in 1923. The first commercial instrument incorporating an OT analyzer (a LTQ 
Orbitrap mass spectrometer) was introduced by Thermo Electron (now Thermo Fisher 
Scientific) in 2005 [79]. The OT consists of an outer barrel-like electrode cut into two 
equals parts separated by a dielectric and a central spindle-like electrode (Figure 1.8.A) 
[80]. An electrostatic voltage is applied to the central electrode while the outer electrode is 
at ground potential. The ions are injected tangentially through a small gap in the external 
electrode and are trapped in the OT because of the balance between the electrical attraction 
to the inner electrode and the centrifugal forces. The electrostatic field has a quadro-
logarithmic potential distribution that is obtained by the DC voltage applied between the 
outer and inner electrodes and the geometry of the trap. Stable ion trajectories combine 
rotation around the inner electrode and axial harmonic oscillation along its axis, resulting 
in intricate spirals (Figure 1.8.B). The frequency of the axial motion, which is independent 
of the kinetic energy and position of the ions, is proportional to the m/z ratio [77][81]. 
Axial oscillations are detected by the image current induced on the outer electrode, which 
is then converted to a voltage and amplified to produce a time domain transient. The 
transient signal is Fourier-transformed to the frequency domain from which the m/z 
spectrum is calculated (Figure 1.8.C) [82].  
 





Figure 1.8. (A) Cross-section of an Orbitrap mass analyzer (adopted from [80]). (B) Schematic of 
the Otbitrap geometry. Ions move in spiral trajectories around the inner electrode and their image 
current is recorded at the outer electrode resulting in a time domain transient. (C) The transient is 
Fourier-transformed resulting in the frequency domain spectrum, which is then converted to the m/z 
domain using a calibration routine to obtain the mass spectrum (adopted from [82]). 
 
Since the release of the first OT-based mass spectrometer, the expanding needs of the MS 
community have continuously inspired and contributed to the further development of OT-
based technologies. OT has become the most popular mass analyzer in the proteomics field 
because its high resolution and mass accuracy enable accurate analysis of complex and low 
abundant samples. The Orbitrap Fusion (released in 2013) and the Orbitrap Fusion Lumos 
(released in 2015) represent the state of the art technology in the proteomics field. The 
Orbitrap Fusion (the mass spectrometer used for all the proteomics experiments in this 
thesis) is a hybrid mass spectrometer that combines quadrupole, dual pressure linear ion 
trap and Orbitrap technologies (Figure 1.9.), providing ultrahigh resolution (routinely 60-
120K, going up to 500K) and high mass accuracy (<2 ppm) [83]. Ion isolation can be 
performed with either the quadrupole or the LIT, whereas fragment ions can be detected at 
high resolution in the orbitrap or at low resolution in the LIT. The hybrid configuration of 
this mass spectrometer enables fully parallelized operations as ion can be concurrently 
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isolated with one mass analyzer (quardupole) and detected with the other two mass 
analyzers (Orbitrap and LIT). The parallelization of operations maximize the use of the 




Figure 1.9.  Schematic of the Orbitrap Fusion mass spectrometer. Figure adopted from [79]. 
 
1.2.3.3. Detectors 
Ion detection consists of the conversion of the m/z-separated ions into a usable signal. As 
explained above, detection of ions in FTICR or OT mass spectrometers is achieved by 
means of a pair of plates within the mass analyzer region that detect the image current of 
the ions. For all other mass analyzers the most common detector is the electron multiplier 
(EM). A typical EM consists of a continuous dynode with a concave metal surface that 
catches the ions arriving from the mass analyzer. When an ion hits the surface it causes 
secondary electrons to be released from the atoms in the surface layer. These electrons are 
accelerated towards the exit of the dynode and they hit the wall of the dynode causing the 
emission of more and more electrons (Figure 1.10.), resulting in an exponential signal 




 for a single EM. The cascade 
of electrons is finally collected by a metal anode and the current is converted to a potential 
and measured [50].   







Figure 1.10. Schematic of the continuous dynode electron multiplier. 
 
1.2.3.4. Peptide fragmentation 
The determination of the m/z values of precursor ions is not sufficient to provide the 
unambiguous identification of large molecules. This is particularly true in proteomics as 
the m/z values of proteins and peptides are not unique, especially as mass accuracy 
decreases. Tandem MS provides information about the primary structure (amino acid 
sequence) of peptides, and thus their identity. In tandem MS, a peptide ion is isolated and 
fragmented. A mass spectrum of the resulting fragments (MS2 spectrum) is then acquired 
to get the m/z values of the fragment ions, which correspond to the peptide backbone 
cleavage fragments [55]. Figure 1.11. shows the Roepstorff–Fohlmann–Biemann 












Figure 1.11. Chemical structure of a peptide, together with the Roepstorff–Fohlmann–Biemann 
nomenclature of the peptide backbone fragments. Fragment ions generated by collision-induced 
dissociation (CID) are predominantly b- and y-ions. Fragment ions generated by electron-transfer 
dissociation (ETD) are typically c- and z-ions. 
 
Several fragmentation methods are now routinely used in proteomics research. Collision-
induced dissociation (CID) or collision-activated dissociation (CAD) is a widely used 
fragmentation technique in proteomics [85]. In CID peptide ions are accelerated by 
applying an electric field to increase their kinetic energy and allowed to collide with 
background gas molecules (typically nitrogen, argon, helium or xenon). With each 
collision part of the ion's centre-of-mass kinetic energy is converted into internal energy; if 
when the internal energy exceeds a bond energy it results in peptide fragmentation. The 
site of bond breakage and the fragmentation mechanisms are described by the mobile 
proton model [86]. According to this model, protons are initially localized at the most 
basic residues of a peptide and upon activation they migrate across the peptide backbone. 
The proximity of a proton to the backbone amino groups weakens the C-N bonds and, in 
combination with the increase in internal energy, results in peptide fragmentation and the 
generation of mainly b- and y- fragment ions. CID can be subcategorized into resonant-
excitation and beam-type CID. Resonant-excitation CID is performed in an ion trap (IT-
CID) and only a small amount of energy is deposited onto the peptide with each collision; 
sustained excitation of the ions and collisions with the background gas over the 
millisecond time scale results in the slow heating (or slow increase of internal energy) of 
the ions until they fragment.  




Beam type CID is applied in dedicated collision cells in tandem quadrupoles (QqQ, Q-
TOF) or multipoles (HCD). This type of fragmentation is conceptually similar to ion trap 
CID; however, the ions are accelerated to higher collision energies and then collide with 
the background collision gas under single collision conditions. Accordingly, the internal 
energy needed to effect fragmentation is deposited in a single instance and fragmentation 
occurs on a much faster time scale (microseconds). 
The slow heating nature and longer timescales of IT-CID means favor lower energy 
reactions, including slower rearrangement type reactions, are accessed. Conversely beam 
type CID is characterized by fewer chemical rearrangements. Furthermore  the impartation 
of higher internal energy with a single collision frequently activates additional reaction 
resulting in  more informative MS2 spectra. As a result, HCD fragmentation is particularly 
suited for the analysis of peptides modified with labile PTMs (such as phosphorylation) 
and with isobaric tags (as TMT) [87][88], which would otherwise be preferentially lost 
using IT-CID. 
In 2004, Electron Transfer Dissociation (ETD) was proposed as a new fragmentation 
method for the sequencing of peptides modified with PTMs [89]. In ETD electrons are 
transferred from a gaseous anion (e.g. fluoranthene) to a peptide cation when they are in 
close proximity in an ion trap. The electron transfer results in charge reduction and 
fragmentation of peptide backbone bonds at the amine (N-Cα) bond to produce c- and z-
type ions (Figure 1.11.) [90]. Labile modification such as phosphorylation and 
glycosylation are left intact during the ETD fragmentation process, and so ETD has 
enjoyed wide success for the analysis of PTMs [91][92][93]. ETD fragmentation efficiency 
is proportional to the peptide's charge density and increases as the peptide charge state 
increases, resulting in the generation of only a few fragments for doubly charged peptides 
[94]. Since CID fragmentation is less efficient on peptides with more than 2 charges, ETD 
has developed as a complementary fragmentation technique to increase protein and peptide 
sequence coverage [95][96].  
 




1.2.4. Data analysis 
 
The final output of a single MS/MS experiment is a mass spectrum that contains the m/z 
ratios of the fragment ions. These spectra need to be interpreted to identify the peptides 
and consequently the proteins from which the peptides originate. In shotgun proteomics 
experiments tens of thousands of MS/MS spectra are produced and thus manual 
interpretation is not feasible. Instead interpretation is performed using automated search 
engines that compare the MS/MS spectra against a protein database. The protein database 
is first converted into a peptide database using the cleavage specificity of the enzyme used 
to proteolyze the proteins, from which theoretical MS/MS spectra are calculated using the 
peptide cleavage specificity of the tandem mass spectrometry technique employed. The 
scoring algorithms seek to determine which peptide (theoretical MS/MS spectrum) best 
matches the experimental data. Several algorithms have been developed for automated 
spectral matching, including SEQUEST [97], MASCOT [98] and MS AMANDA [99]. 
Different search engines use different algorithms for the peptide-spectrum match (PSM) 
but the search pipeline is similar [100]. The first step is the generation of a list of 
theoretical peptides from an in silico digestion of the protein database of interest. The 
masses of the theoretical peptides are then compared to the experimental precursor masses 
(measured in the MS1 acquisition) and only the peptide candidates matching within a 
given mass tolerance are kept for further analysis. The next step is the in silico 
fragmentation of the theoretical peptides that matched with the experimental precursor ions 
in order to generate theoretical MS/MS spectra. The theoretical MS/MS spectra are 
compared with the experimental spectra and a similarity score is calculated. The peptide 
with the highest score is the top ranking assignment for the MS/MS spectrum. Only when 
the top ranking assignment is significantly more likely than any other assignment is it 
considered a peptide spectrum match (PSM) [101]. From PSMs the original proteins 
present in the sample are then inferred [102]. However, when tens of thousands of spectra 
must be compared the risk of random matches is likely. Several statistical methods have 
been developed to estimate the rate of false discovery (FDR) [103], the most common of 
which is to perform a second search with a decoy database (derived from reversed or 
scrambled protein sequences) [104][105]. All the matches to the decoy database are 




considered as false positives and the FDR can be estimated by dividing the number of 
PSMs that matched the decoy database by the total number of PSMs. The FDR can be 
lowered by applying stringent filters on the PSM parameters (e.g. matching score, peptide 
length, elution time and peptide charge). Generally, a 1% FDR is accepted for large-scale 
proteomics data [106].   
 
1.2.5. Quantitative proteomics 
 
A qualitative analysis of a proteome represents the identification of the proteins present in 
the sample. However, it is often also desired to know the amount of each protein, or the 
relative amount of proteins present in different samples. Protein quantitation is thus  
crucial as it allows the comparison of protein expression profiles between different 
conditions. The main challenge of MS-based protein quantitation is that the intensity of 
peptide ions is not solely dependent on the peptide concentration in the sample. The signals 
also depend on the sample preparation workflow (e.g. protein, extraction, digestion 
efficiency, peptide solubility) and on the ionization/transport/detection efficiency of each 
ion. The peptide ionization efficiency in turn depends on chemical-physical properties of 
the peptides (e.g. size, basicity, hydrophobicity), the composition of the solvent and the 
presence of co-eluting compounds [107]. Several strategies have been developed to allow 
accurate and reproducible quantitative proteomics experiments. The quantification 
methods can be divided into label-free and stable isotope labeling (Figure 1.12.) 
[107][108][109].  
 






Figure 1.12. Schematic of the different quantitative MS-based proteomics workflows. Grey boxes 
indicate un-labeled samples. Blue, orange and pink boxes indicate labeled samples. Horizontal lines 
indicate when samples are combined. Dashed lines indicate steps of the workflow that can be 
sources of quantification variance, as samples are processed separately. Figure modified from 
[110]. 
 
1.2.5.1. Label free quantification 
Label-free quantification methods aim to determine the relative amount of peptides 
between different LC-MS/MS runs. Quantification is based either on (i) the MS signal 
intensity of peptides (precursor signal intensity) [111] or (ii) the number of spectral 
matches (spectral counting) [112].  
In the precursor signal intensity method, the ion chromatograms of every peptide are 
extracted from the LC-MS/MS runs and the MS peak areas are integrated over the 
chromatographic time scale. Since the quantification is performed at the MS1 level, high 




mass accuracy mass spectrometers are preferred in order to reduce isobaric ions (same 
nominal m/z) adversely affecting quantitation precision.  
The spectral counting strategy is based on the empirical observation that the number of 
acquired MS/MS spectra increases as the amount of the corresponding peptide/protein in 
the sample increases. Thus, the relative quantification of proteins across different samples 
is performed by comparing the number of MS/MS spectra for each protein. Even if this 
approach is less affected by interfering molecules, as it is based on MS2 spectra, it is still 
controversial because it does not measure any physical property of peptides and it assumes 
a linear response for every protein. However, the extraction and ionization efficiency of 
different peptides is influenced by the peptide chemical-physical properties and their 
chromatographic behavior, resulting in a large number of MS/MS spectra being required 
for reliable relative quantification [107].  
Overall, the main advantage of label-free quantification methods is that no additional 
sample preparation steps are required. Moreover, there are no costs for labeling reagents 
and there is no limit to the number of samples that can be compared. However, label-free 
methods are the least accurate and reproducible because variations in sample preparation 
and LC conditions affect the peptide intensities determined by the mass spectrometer.  This 
variability between different LC runs can be alleviated by applying normalization methods, 
whether matching median intensities, using spike-in standards as well as algorithms for 
peak alignment [113][114].    
1.2.5.2. Stable isotope labeling quantification 
Protein quantitation via labeling is achieved by introducing stable isotopes into/onto the 
proteins. Since different isotopes have the same chemical properties but different masses, 
different samples labeled with different isotopes can be discriminated by MS analysis. The 
advantage of these methods is that samples can be combined before the LC-MS/MS 
analysis, thereby excluding all sources of errors due to sample preparation and LC-MS/MS 
analysis [115]. Stable isotopes can be introduced at the protein or peptide level in three 
ways: (i) metabolically, (ii) chemically or (iii) by using spiked synthetic peptides (Figure 
1.12.). 




Metabolic labeling – Stable isotopes are introduced into proteins by metabolic labeling 
during cell growth. Cells, plants or animals are grown with a heavy isotope enriched food 









[116][117]. In this way, the synthetized proteins will contain (< 90%) heavy peptides. The 
most popular metabolic labeling method in proteomics is Stable Isotope Labeling by 
Amino acids in Cell culture (SILAC) [118]. SILAC allows a quantitative comparison of 
the protein expression profiles between two (or three) different populations of cells. One 
cell population is fed with normal growth medium. The other cell population is fed with a 




C6-lysine, so that all tryptic peptides (the 
protease trypsin cleaves c-terminal to arginine and lysine) will carry at least one 
isotopically labeled amino acid. After metabolic labeling the two cell populations are 
combined, the proteins extracted and digested, and the resulting peptides analyzed by LC-
MS/MS. Relative quantification is provided by the ratio between the intensities of the 
heavy and the light peptides. Despite the high quantification accuracy, the use of SILAC is 
limited by the costs and time for maintaining the model system and by the limited number 
of samples that can be compared [119].  
 
Chemical labeling – Stable isotopes can be added onto post-biosynthetic samples that are 
not suited for metabolic labeling (e.g. tissues and body fluids) via chemical labeling. 
Chemical labels are targeted towards reactive sites on proteins or peptides, generally the 
side chains of lysine or cysteine. Several chemical labeling strategies have been developed 
for quantitative proteomics experiments. The first chemical labeling method to be reported 
for labeling samples at the protein level was Isotope-Coded Affinity Tags (ICAT) [120]. In 
ICAT two samples are labeled with a light or heavy tag that was designed to react with free 
cysteine residues (i.e. cysteines not involved in a disulfide bonds). After labeling, the two 
proteomes are combined and digested together in order to remove the variability related to 
protein digestion. The main limitation of ICAT is that only a small fraction of peptides 
(only those containing a cysteine) can be used for quantification.   
Another group of chemical labels target primary amines (free N-termini of peptides and 
lysine residues). Tandem Mass Tags (TMT) [121] and Isobaric Tags for Relative and 




Absolute Quantification (iTRAQ) [122] are examples of these and are arguably the most 
popular chemical labels in proteomics. Both iTRAQ and TMT tags consist of a mass 
reporter region, a cleavable linker, a mass normalization region and a protein reactive 
group. The mass reporter and mass normalizer regions incorporate stable isotopes in 
multiple configurations so that each mass reporter’s mass can be resolved in an MS2 or 
MS3 spectrum, while the masses of the intact tags are identical. As a result, the peptides 
originating from different samples will be identical at the MS1 level, leading to less 
complex spectra with higher precursor intensities. The higher precursor intensities favor 
peptide identification. Upon precursor fragmentation using LIT-CID the isobaric tags are 
cleaved and the reporter ion intensities can be used for relative quantification [123]. The 
most important advantage of TMT and iTRAQ methods is the high multiplexing 
capability. Up to 16 samples can be simultaneously compared using TMT (TMT 16-plex) 
and up to 8 samples with iTRAQ (iTRAQ 8-plex). It was demonstrated that accuracy and 
precision are affected by contaminating isobaric ions that are co-isolated and co-
fragmented together with the target precursor ions. This results in a compression of the 
reporter ion ratios, as the ratios tends towards unity due to interfering peptides originating 
from proteins with unchanged expression in the different samples [124].  The ratio 
compression is reduced by using MS3 acquisition methods, in which the reporter ion 
quantification is performed at the MS3 level, because the likelihood of co-eluting peptides 
having identical mass and fragment ions at the MS2 level also having identical mass 
(which is then selected for MS3) is much lower [125][126]. 
 
Stable isotope-labeled synthetic standards (SIS) – were originally described in 1983 for 
MS-based quantification of peptides [127] and can be used for relative and absolute 
quantification of proteins/peptides. Absolute quantification is achieved by the addition of a 
known amount of SIS to a protein digest and by comparing the MS signals to the 
endogenous peptides in the sample [110]. In contrast to metabolic and chemical labeling 
strategies, in which relative quantification is performed for a large number of proteins, SIS 
based methods require a synthetic peptide for every target peptide, and thus is normally 
used to quantify only a few proteins of interest, for instance for the validation of potential 




biomarkers [128]. Moreover, SIS methods do not require any labeling of the sample, 
resulting in a simpler sample preparation workflow but with a much higher accuracy and 
precision with respect to label-free methods. SIS can be introduced into the samples before 
LC-MS/MS analysis (AQUA method) [129] or before protein digestion using 
biosynthesized heavy proteotypic peptide concatemers (QconCAT) [130] or synthetic 
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Clinical microproteomics: tissue characterization 













2.1. Clinical proteomics for molecular pathology 
 
Proteins are intrinsic to all cellular processes, it therefore follows that the study of the 
proteome is crucial for the determination of disease pathophysiology [1]. The main goal of 
much present-day proteomics research is the development of new strategies for clinical 
diagnosis, prognosis, patient monitoring and the identification of drugable targets. [2]. In 
recent years, a lot of different technologies have been proposed for the proteomics 
characterization of both body fluids and tissues, and MS has rapidly become a powerful 
tool for molecular pathology.   
Histopathology is the gold-standard technique used by pathologists for disease diagnosis 
and it is used in research labs to validate the results of translational studies [3]. 
Histopathological characterization and associated molecular tests of patient tissue samples 
represents the definitive method for the confirmation of the presence/absence of disease, 
and for disease grading and progression. However, the manual examination under a 
microscope not only limits the throughput of tissue analysis, but it is also subjective as it 
depends on the pathologist’s experience.  
The application of proteomics technologies to tissue characterization has aided the 
pathologist in the diagnostic process [4]. The key advantages of MS-based methods over 
histopathological examinations are the much higher sensitivity and throughput. Moreover, 
the conventional histopathological annotation provides only a morphological 
characterization of the tissue, while MS-based methods enable the identification of the 
molecular signatures of the different cell populations present in the tissue. Such 
unambiguous molecular information can be used to determine the presence and the 
progression of a disease and the response to therapies, thus providing prognostic and 
diagnostic value [5]. 
MS-based proteomics approaches for clinical tissue characterization can be divided into 
untargeted and targeted methods. Untargeted proteomics refers to the analysis of clinical 
samples aimed at the identification of putative biomarkers. MALDI mass spectrometry 
imaging (MSI) represents a unique approach to assess the spatial distribution of hundreds 




of different molecules (proteins, peptides, lipids and metabolites) from tissue sections in a 
label-free fashion [6]. The MALDI-MSI molecular profiles can be aligned with 
histological images to translate the molecular information to tissue morphology and to 
complement histopathological evaluation for a better therapeutic management. MSI-based 
molecular pathology has been extensively used in clinical research to uncover molecular 
changes associated with disease progression, diagnosis and prognosis and to study the 
distribution of drugs and their metabolites [7][8].  
Shotgun proteomics by LC-MS/MS analysis represents the most common untargeted 
proteomics approach for tissue biomarker discovery studies [9]. LC-MS/MS provides high 
resolution analysis of complex samples, enabling the identification and quantification of 
thousands of proteins. Unlike MALDI-MSI, proteins must be extracted from the tissue 
prior to LC-MS/MS analysis, so the spatial information is lost. However, the combination 
of laser microdissection strategies with shotgun proteomics enables the analysis of specific 
regions of the tissue, enabling the in-depth characterization of histology-defined regions-
of-interest [10][11].  
Targeted proteomics experiments are focused on the identification and quantification of 
known biomarkers [9]. Targeted experiments provide high sensitivity, reproducibility and 
throughput because only a predefined set of peptides/proteins is measured [12]. Selected 
reaction monitoring (SRM) and multiple reaction monitoring (MRM) are established 
methods performed on triple-quadrupole (QqQ) instruments, where ion selection in Q1 and 
fragment ion detection in Q3 with narrow m/z windows (± 0.02 m/z) provide higher 
selectivity and sensitivity compared to full scan proteomics analysis [13]. Parallel reaction 
monitoring (PRM) is a method similar to SRM that can be performed on quadrupole-time 
of flight (Q-ToF) and quadrupole-Orbitrap instruments, in which the quadrupole selects the 
precursor ions and the full MS/MS spectra are acquired in the high resolution mass 
analyzer [14][15].  
Regardless of the acquisition method, protein extraction from tissue represents the first 
step in shotgun proteomics of tissues. In the last years, several strategies have been 
developed to enable the proteomics analysis of histology defined tissue regions for better 




tissue characterization. Such focused analyses are crucial for the molecular analysis of 
tissues characterized by a high degree of cellular heterogeneity. 
 
2.2. Tissue heterogeneity 
 
The main challenge in tissue proteomics is the heterogeneity of the tissue. For instance, 
malignant solid tumor tissues consist of tumor cells, tumor-associated normal epithelial 
cells and stromal cells, immune cells and vascular cells (Figure 2.1.). This complex 
network of different types of cells (tumor microenvironment) is crucial for tumor growth, 





Figure 2.1. Schematic presentation of components of the tumor microenvironment. Figure adopted 
from [17]. 
 




MS-based proteomics has been successfully applied to analyze tumor and non-tumor 
tissues, early detection, tumor typing, tumor grading and tumor margins [18][19]. Similar 
considerations are also true for the neuroscience field since the central nervous system is 
made up of several hundred different cell types, which play roles in distinct developmental 
and behavioral disorders [20][21]. Moreover, several neurodegenerative disorders (e.g. 
Alzheimer’s disease, Down's syndrome, Huntington’s disease, Amyotrophic lateral 
sclerosis, ischemic stroke, frontotemporal lobar degeneration and Parkinson’s disease) are 
associated only with specific cell types in the brain (Figure 2.2.) [22]. These disorders are 
characterized by a phenomenon called “selective vulnerability”, which refers to the 
observation that degeneration in a specific disease is not diffuse but cell type and neuronal 




Figure 2.2. Brain regions and neuronal cell types involved in neurodegenerative disease. Regions 
affected by different neurodegenerative diseases are indicated by different colors. Abbreviations: 
Basal ganglion (BG), Brain stem (BS), Cerebellum (Crbl), Corpus callosum (CC), Cortex (Cx), 
Hippocampus (Hp), Striatum (St), Substantia Nigra (SN).  Figure modified from [24]. 
 




Heterogeneous tissues may confound proteomics analysis because it is extremely difficult 
to separate the contribution of the different cell populations present in the sample. 
Different cell populations in the same tissue may exhibit different phenotypes because of 
the influence of the microenvironment [25]. The ability to investigate the proteome of 
single cell populations can provide information about interesting and important biological 
phenomena that may be obscured in bulk measurements. Population distributions can mask 
the presence of small subpopulations of cells, as the measured response is averaged across 
the bulk population. Since different cell populations generally do not contribute equally to 
the biology of the system, a bulk experiment can fail to illuminate the biological 
mechanisms [26]. In order to properly understand the molecular signals within these highly 
heterogeneous tissues, there is the need to focus the experiments on specific cells (specific 
cell type and specific environment). 
 
2.3. Laser Microdissection 
 
Laser microdissection strategies have emerged as the method of choice for the isolation of 
specific cells or specific tissue regions [27]. This technology is able to harvest the target 
cells directly from the tissue by means of a laser coupled with a microscope and can be 
applied to histological specimens, formalin-fixed paraffin-embedded (FFPE) or fresh-
frozen tissues and stained or unstained tissue sections. After delineation of the tissue 
region of interest, the target cells are automatically isolated and can be used for 
downstream molecular characterization, including DNA/RNA sequencing and proteomics 
analysis. 
Laser microdissection systems can use IR or UV laser sources and can operate in capture 
or ablation mode [28]. When operating in the ablation mode, a highly focused laser beam 
ablates the tissue surrounding the region of interest, which is then detached from the rest of 
the tissue. Laser-capture microdissection (LCM) is based on the direct isolation of the cells 
of interest [29]. The tissue slice is attached to a glass slide coated with a thermoplastic 
polyethylene naphthalate (PEN) membrane. A focused UV laser is used to cut around the 




ROI and a defocused laser pulse is used to generate a photonic force to catapult the tissue 
ROI directly into the cap of a collection tube (Figure 2.3.).  
LCM provides the isolation of the target cells (from several thousand cells to single cells) 
with high selectivity and it has become a powerful tool for tissue proteomics, since it 
represents a bridge between histology and LC-MS based proteomics methods. LCM has 
been widely used to address the tissue heterogeneity challenge in various medical research 
areas including neuroscience, oncology, forensic science and biomarker discovery [30]. 
Recently, LCM coupled with downstream shotgun proteomics analysis has been applied to 
study the neurons and protein aggregates in Alzheimer’s disease patients [10][31], neurons 
and blood brain barrier structures to study ischemia [32] and in oncology for early cancer 
detection, tumor microenvironment characterization and drug resistance [33][34][35]. 
 
 
Figure 2.3. Schematics of the laser capture microdissection process. A focused laser beam is used 
to cut the margins of an ROI, following which a defocused laser pulse catapults the piece of tissue 
in to the cap of a collection tube. 
 
The major limitation of LCM is the need to identify the target cells on the basis of 
morphological characteristics, which requires personnel trained in the histology of the 
organ/disease of interest. Any staining protocol used to aid histological characterization 
must be carefully selected to avoid interference with the downstream analyses. Moreover, 




the amount of tissue material retrieved from LCM can be very small if strict cellular and 
environmental specifications are imposed, resulting in lower proteome coverage [36].  
 
2.4. Microproteomics workflows for microdissected tissue analysis 
 
In the last few years, the development of sample preparation protocols that provide 
sufficient sensitivity for the processing of small microdissected samples has led to the 
initiation of the “microproteomics” era [37]. The aim of microproteomics is the 
development of high sensitivity strategies that can be applied to the analysis of the low 
protein amounts (in the order of few micrograms) that can be extracted from 
microdissected tissues. These microproteomics strategies generally combine LCM with 
efficient protein extraction procedures and specific digestion protocols that minimize 
sample losses to achieve high proteome coverage, which is required for a comprehensive 
molecular characterization. 
The conventional proteomics workflow is based on in-solution protein digestion (ISD) 
using urea as lysis buffer and solid phase extraction procedures for peptide purification 
prior to LC-MS/MS analysis. Urea is a chaotrope that stabilizes denatured proteins by 
hydrogen bonding promoting protein solubilization [38]. Although urea has been 
successfully applied to protein extraction from tissue samples ([39][40]) there are several 
drawbacks that can affect protein identification, especially when small microdissected 
tissues are analyzed. Urea leads to carbamylation and other chemical modification on 
lysine and arginine residues that not only can affect protein digestion, by interfering with 
proteolytic enzymes, but also can affect the protein identification process as peptides with 
an unknown chemical modification will not be identified [41][42]. Moreover, urea inhibits 
trypsin activity, thus samples have to be diluted prior to enzymatic digestion in order to 
reduce the urea concentration. In the case of small sample amounts, such dilution steps are 
best avoided because it increases peptide losses due to adsorption/absorption during 
sample handling; for microproteomics such losses are significant.  




A more efficient strategy to extract proteins from tissues relies on the use of strong ionic 
surfactants such as sodium dodecyl sulfate (SDS) and sodium deoxycholate (SDC). These 
detergents solubilize proteins by disrupting hydrophobic interaction and result in a higher 
protein extraction yield than urea-based buffers [43][44]. However, the detergents are 
frequently incompatible with LC-MS/MS analysis and must be removed prior to the 
analysis, because they would otherwise dominate the mass spectra.  
Several purification strategies have been developed to remove (or reduce) detergents 
including affinity-based methods, membrane filtration, electrophoresis and protein 
precipitation [45][46]. Although these purification methods provide an efficient removal of 
detergents, they introduce extra sample preparation steps that affect protein recovery 
because of extensive sample losses. Thus, microproteomics protocols have been developed 
that combine the high protein extraction efficiency of strong detergents with sample 
purification procedures that minimize sample losses, specifically protocols in which all 
steps are performed within a single vessel. These include Filter-Aided Sample Preparation 
(FASP) and Single-Pot Solid Phase-enhanced Sample Preparation (SP3).  
 
2.4.1. Filter-Aided Sample Preparation (FASP) 
 
The FASP protocol was reported by is iewski et al. in 2009 and allows the use of highly 
concentrated SDS for “universal” protein solubilization [47]. The sample purification is 
performed by ultrafiltration to remove the SDS prior to LC-MS/MS analysis. Samples 
(either cells or tissue specimens) are solubilized in 4% SDS and then retained and 
concentrated into microliter volumes in an ultrafiltration device. The filter unit represents 
the key element of the FASP protocol as it provides detergent removal, buffer exchange, 
protein alkylation and digestion (Figure 2.4.). The filter unit (3 or 10 kDa cut off) retains 
high molecular weight compounds (as proteins), while small molecular weight compound 
(SDS, salts, impurities and peptides) can pass through the filter. After lysis in 4% SDS the 
samples are diluted with an urea buffer and loaded on the filter unit. Buffer exchange is 




performed on the filter by centrifugation to remove SDS. Proteins are then alkylated and 
digested on the filter and peptides are eluted by centrifugation. 
The FASP protocol has proven to work efficiently with high sample amounts, while 
incomplete peptide recovery has been observed when applied to small sample amounts. 
The sample losses observed during the processing of small sample amounts were 
reportedly minimized by using alternative reagents, resulting in improved sensitivity, 
recovery and proteome coverage [48]. 
 
 
Figure 2.4. Schematics of the FASP protocol. Figure modified from [48]. 
 
The FASP protocol has been successfully applied to a wide variety of cells and tissue 
samples [49][50], including the analysis of 500 laser microdissected cells from an FFPE 
tissue specimens [51]. 
 
2.4.2. Single-Pot Solid Phase-enhanced Sample Preparation (SP3) 
 
The SP3 protocol was developed by Hughes et al. in 2014 [52]. The advantage of the SP3 
protocol is that all proteomics sample preparation steps are performed in a single tube, 
minimizing sample transfers. This results in a significant reduction of the sample losses 
associated with conventional sample preparation protocols. Moreover, cell lysis is 
achieved using an SDS-based buffer that maximizes protein extraction and solubilization.  




The SP3 protocol is based on the use of carboxylate-coated paramagnetic beads that are 
able to interact with proteins and peptides via a mechanism similar to HILIC [53] and 
ERLIC [54]. The addition of an organic solvent to an aqueous solution containing 
paramagnetic beads promotes trapping of proteins/peptides into a solvation layer that 
forms on the surface of the carboxylate coated paramagnetic beads. The interaction 
between proteins/peptides and the beads can be modulated by varying either the percentage 
of organic solvent or the pH. At high organic solvent percentages and low pH proteins and 
peptides are retained in the hydrophilic layer on the surface of the beads (HILIC like 
interaction). By decreasing the proportion of organic solvent and increasing the pH 
proteins/peptides are repelled by the beads because of the negatively charged carboxylate 
groups on the surface of the beads (ERLIC like mechanisms). Thus, once immobilized on 
the beads, proteins/peptides can be rinsed with different buffers while using a magnet to 
remove contaminating agents such as salts and detergents. In this way all the proteomics 
sample preparation protocol can be performed in a single tube (Figure 2.5.). After cell lysis 
in an SDS-based buffer, a protein cleanup step by buffer exchange is performed to remove 
SDS before enzymatic digestion. The buffer exchange is achieved by trapping the proteins 
in the solvation layer of the beads. Following enzymatic digestion the peptides can be 
labeled (if quantification is needed) or purified with a similar procedure for the protein 
cleanup. Once all sample preparation steps have been completed the peptides can be eluted 
and then analyzed by LC-MS/MS. 
 
  
Figure 2.5. Schematics of the SP3 workflow. Figure modified from [52]. 




The SP3 has been shown to be compatible with isotope labeling strategies for quantitative 
proteomics, providing a labeling efficiency higher that 97% [52].  
The SP3 method has been compared to FASP by analyzing 10 μg of a yeast lysate. A 
similar depth of proteome coverage was observed and the physicochemical properties of 
the peptides identified did not show significant differences, indicating that the 
functionalized beads did not introduce a bias into the type of peptides that were identified. 
The feasibility of SP3 for the analysis of small sample amounts has been demonstrated by 
testing the procedure on different amount of HeLa cells (from 500k to 1k cells) and on 
single Drosophila embryos. The high sensitivity of the SP3 protocol enabled the possibility 
to study the proteome changes associated with the developmental stages of embryos [52].  
 
2.5. Aim of the thesis 
 
This thesis describes the development and optimization of an ultrasensitive 
microproteomics workflow to perform MS-based proteomics characterization of 
pathological tissues. All the steps of the conventional proteomics pipeline have been 
optimized to increase the depth of coverage that can be achieved from the analysis of 
microdissected tissue samples. The combination of laser capture microdissection with the 
ultrasensitive proteomic workflow enabled the proteomics characterization of specific 
tissue substructures. The workflow was tested on different types of murine tissues (brain 
and kidney) and was applied to different biomedical case studies in the oncology and 
neuroscience fields.  
 
In Chapter 3 I compared three sample preparation protocols to find that most suited to the 
analysis of small sample amounts. The conventional urea based in-solution digestion (ISD) 
was compared with Filter-Aided Sample Preparation (FASP) and Single Pot Solid Phase-
enhanced Sample Preparation (SP3) on different amounts of cultured HeLa cells (from 1 
million down to 5000 cells). The different protocols were evaluated based on the depth of 




proteome coverage (i.e. number of proteins and peptides identified) and on the basis of the 
digestion efficiency. The SP3 protocol was found to perform best when analyzing small 
sample amounts, as it provided the highest number of protein identifications and the 
highest digestion efficiency. A further optimization of the SP3 protocol resulted in the 
identification of approximately 3000 protein groups from 1 µg of protein. The optimized 
SP3 protocol was successfully applied, in combination with laser capture microdissection 
(LCM), to characterize different histological regions of the brain of a mouse model of 
glioblastoma.  
 
In Chapter 4 I developed a quantitative ultrasensitive proteomics workflow for the analysis 
of tissue samples. The previously optimized LCM and SP3 digestion steps were integrated 
with a colorimetric assay for protein content estimation, a Tandem Mass Tags (TMT) 
labeling protocol and a peptide fractionation protocol. The integration of the different steps 
resulted in a complete quantitative ultrasensitive proteomics workflow that can be applied 
to characterize any type of microdissected tissue sample.  
The colorimetric assay (a modified microBCA assay) enabled the measurement of the 
protein content in just 1 µL of sample and in the presence of the detergents and salts 
commonly used in lysis buffers. The low sample volume required for protein concentration 
estimation allowed protein quantitation of each individual sample (a crucial step for 
proteomics as the amount of enzyme that must be used is dependent on the total amount of 
protein present in the sample).  
To ensure accurate relative quantification I optimized in-solution and on-column TMT 
labeling procedures for low sample amounts. Preliminary results revealed very low 
labeling efficiency when standard labeling conditions were applied to low sample amounts. 
Following an exhaustive optimization of in-solution and on on-column TMT labeling, the 
final conditions provided a TMT labeling efficiency (for 1 µg of HeLa digest) even greater 
than that obtained using standard methods on high sample amounts (25-50 µg of digest). 




An automated peptide fractionation protocol was also developed to increase the depth of 
proteome coverage. The high-pH reversed phase fractionation increased the proteome 
coverage by approximately 140% relative to a single long gradient analyses.  
The optimized workflow was then applied as a proof-of-principle to the characterization of 
mouse kidney substructures. The analysis provided the identification of more than 300 
protein groups that exhibited region-specific expression profiles.   
 
Chapter 5 describes the application of the quantitative proteomics workflow to the 
characterization of the central and peripheral nervous system of a mouse model of Krabbe 
disease (the Twitcher mouse). This work represents the first in-depth proteomics 
characterization of the Twitcher mouse. I compared the proteomes extracted from the 
corpus callosum, motor cortex and sciatic nerves of five Twitcher and five control wild 
type mice. The results on the proteome changes in the Twitcher mouse provided new 
insights into the molecular mechanisms of Krabbe disease showing neuroinflammation, 
activation of immune response, accumulation of lysosomal proteins, demyelination, 
membrane raft disruption and reduced nervous system development in the Twitcher 
mouse. 
 
In Chapter 6 an outlook is described regarding how a further increase in sensitivity and 
specificity can be used to achieve cell population-specific and single-cell proteomics. 
Recently, several strategies have been proposed to study the proteome and the molecular 
profile of single cells, opening exciting frontiers and a new era in biomedical research. 
Many pressing medical needs, such as disease diagnosis, stem cell differentiation, rare cell 
profiling, protein dynamics and biological heterogeneity, have long been limited by the 
lack of technologies to detect proteins in single cells. These technological advances could 
help revolutionize medicine and will further deepen our understanding of biological 
systems, both fundamental and involved in disease progression. 
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Optimization of a Protein Digestion Protocol for 
Label-Free Microproteomics: Application to the 













In this work I optimized a protein digestion protocol for the analysis of small tissue 
samples. I first compared Filter-Aided Sample Preparation (FASP) with Single-Pot Solid 
Phase-enhanced Sample Preparation (SP3) with a reference method based on in-solution 
proteolytic digestion (ISD) for the analysis of different amounts of material (from 10
6
 
HeLa cells down to 5×10
3
 cells). The SP3 protocol was found to perform better than both 
FASP and ISD protocols for the analysis of small sample amounts, in terms of number of 
identification (2036 protein groups from 5e3 cells) and digestion efficiency (80% of 0 
missed cleavages for the 5×10
3
 cell samples). A further optimization of the SP3 protocol 
(i.e. type of sample tubes, magnets and concentration of carboxylate paramagnetic beads 
solution) increased the number of identified proteins by approximately 35% (3000 protein 
groups identified from 1 µg of HeLa cells) with a very high inter-batch reproducibility 
(<6% variation coefficient).  
The performance of the optimized SP3 digestion protocol for microdissected tissue 
samples was then assessed by analyzing different histological brain regions of a mouse 













Mass spectrometry (MS)-based proteomics has matured into the method of choice for the 
large-scale identification and characterization of proteins associated with biological 
processes and disease [1][2]. Nevertheless, challenges remain. For instance the analysis of 
proteins and polypeptides from sample-limited sources such as single cells [3], purified 
cell populations[4], subcellular organelles, exosomes, or small histologically defined 
regions of tissue isolated by laser capture microdissection [5][6][7]. 
Recent advances in liquid chromatography (LC) and MS equipment have greatly improved 
the analysis of low sample amounts. The development of mass spectrometers has increased 
sequencing speed [8][9][10][11] and ion transmission [12][13], resulting in an increase in 
dynamic range and sensitivity. Advances in ultra-high-pressure liquid chromatography 
(HPLC) has enabled the routine use of long columns (≥50 cm) with smaller internal 
diameter and smaller particle sized (< 5 µm) further increasing peptide separation 
resolution [14], resulting in the identification of more than 4800 protein groups in a single 
LC-MS run [15][16]. However, the developments in LC-MS sensitivity have outpaced 
developments in sensitive sample preparation protocols.  
Several sample preparation steps are required for the proteomics analysis of samples; 
namely, cell lysis and protein denaturation, reduction and alkylation, proteolytic digestion 
and peptide purification before the LC-MS analysis [17]. To maximize the yield of protein 
extraction several detergents and chaotropes can be used. However, most of these 
chemicals inhibits protease activity and/or are not compatible with LC-MS. Thus, the main 
challenge in the proteomic analysis of small sample amounts is represented by sample 
losses occurring during the different steps of the sample preparation workflow.  
In this work, we optimized a highly sensitive protein digestion protocol suited for the 
analysis of small sample amounts.  We compared Filter-Aided Sample Preparation 
protocol (FASP) [18] and Single-Pot Solid Phase-enhanced Sample Preparation protocol 
(SP3) [19] with the conventional urea based in-solution digestion (ISD). The FASP and 
SP3 are two recently published digestion protocols based on the use of strong detergents 




(as SDS) to increase protein extraction. The SDS is then removed by a series of filtration 
steps on a molecular weight cutoff filter with the FASP protocol, or by retention of 
proteins/peptides on carboxylate modified paramagnetic beads with the SP3 protocol. 
These two protocols combine the benefit of using SDS to maximize protein extraction with 
a “single-pot” strategy to minimize losses during sample preparation.  e compared the 
digestion efficiency and the total number of identified proteins and peptides obtained with 
the FASP, SP3 and ISD digestion protocols for different sample amounts in order to 
determine which was best suited for the characterization of low sample amounts. We then 
further optimized the best performing digestion protocol to increase the proteome coverage 
and reproducibility.    
Finally, as a proof of principle, the optimized sample preparation protocol was applied to 
characterize the brain tumor of a mouse model of glioblastoma using just 0.8 mm
2
 tissue 
areas of 12 µm thick tissue sections, and benchmarked the results against data from 












Trypsin/LysC mix, Mass Spec grade, was purchased from Promega (Madison, WI). 
Tandem Mass Tags (TMT 6-plex) were purchased from Thermo Fisher Scientific 
(Rockford, IL). All other reagents and solvents were purchased from Sigma Aldrich (St. 
Louis, MO). Magnets were purchased from Supermagnete (Gottmadingen, Deutschland). 
 
3.3.2. Sample preparation 
 
HeLa whole cell pellets (2.5e9) were purchased from IpraCell (Mons, Belgium), 
suspended in PBS and divided into aliquots of 5e3 to 1e6 cells. Cell pellets were stored at -
80 °C until use. The optimization of the digestion protocol was performed on 1e6, 5e5, 1e5 
and 5e3 cell pellets applying the ISD, FASP and SP3 protocols (described below). The 
microdissected tissue samples were digested with the optimized SP3 protocol.  
3.3.2.1. In-Solution Digestion (ISD) protocol 
HeLa cell pellets were suspended in a lysis buffer consisting of 8 M urea in 50 mM 
ammonium bicarbonate, 1 tablet of Complete mini EDTA-free Cocktail (Roche) and 
sonicated for 20 s (5 cycles of 2 s ON, 2 s OFF) with a Q-Sonic sonicator (QSONICA, 
Newton, Connecticut). After centrifugation at 20000g for 1.5 h at 4 °C the supernatant was 
assayed for protein content using the Qubit protein assay standard procedure (Life 
Technologies). Protein reduction and alkylation were performed by adding 2 μL of 2 mM 
dithiothreitol (DTT) at 56 °C for 25 min and 4 μL of 4 mM iodoacetamide (IAM) at room 
temperature for 30 min, respectively. Alkylation was quenched by adding 2 μL DTT to a 
final concentration of 4 mM. Enzymatic digestion was performed in two steps. The first 
step was performed directly with LysC at 37 °C for 4 h (1:75 enzyme/protein). The second 




digestion was performed with trypsin (1:100 enzyme/protein) at 37 °C with overnight 
incubation after diluting the lysis buffer to 2 M urea with ammonium bicarbonate. 
Digestion was stopped by adding 1% formic acid. Desalting was performed by solid phase 
extraction using SepPak cartridges (Waters, 1 mg, C18) and a membrane vacuum pump. 
Cartridges were primed with 1 mL of 100% ACN and equilibrated twice with 1 mL of 
0.1% formic acid. Samples were acidified to pH 2 with formic acid and loaded on the 
cartridges. The loaded cartridges were then washed twice with 1 mL of 0.1% formic acid 
and the peptides eluted twice with 250 μL of 80% ACN 0.1% formic acid. The purified 
samples were then dried down with a speedvac and stored at -20 °C until they were 
analyzed. For LC-MS/MS analysis the dried peptides were resuspended in 20 μL of 10% 
formic acid. 
3.3.2.2. Filter-Aided Sample Preparation (FASP) protocol 
HeLa cell pellets were resuspended in a lysis buffer containing 4% sodium dodecyl sulfate 
(SDS), 0.1 M DTT and 1 tablet of Complete mini EDTA-free Cocktail (Roche)  in 100 
mM tris(hydroxymethyl)aminomethane hydrochloride (Tris/HCl) pH 7.6 [20]. After 
incubation at 95 °C for 5 min, the samples were sonicated for 20 s (5 cycles of 2 s ON, 2 s 
OFF) with a Q-Sonic sonicator. The protein content was quantified with the Qubit protein 
assay standard procedure (Life Technologies).  30 μL of protein extract were mixed with 
200 μL of UA buffer (8 M urea in 0.1M Tris/HCl pH 8.5) on a 10 kDa filter unit 
(Microcon YM-10, Millipore) and centrifuged at 14000g for 40 min. The filters were then 
rinsed twice with 200 μL of UA buffer and centrifuged at 14000g for 40 min. Alkylation 
was performed on the filters by adding 100 μL of 50 mM IAM in UA buffer. After vortex 
mixing and incubation at RT for 5 min, the filter units were centrifuged at 14000g for 30 
min. The filters were then rinsed twice with 100 μL of UB buffer (8 M urea in 0.1M 
Tris/HCl pH 8) and centrifuged at 14000g for 40 min.  
Enzymatic digestion was performed in two steps. The first step was performed by adding 
40 μL of LysC (1:50 enzyme/protein) in UB buffer. Samples were then incubated 
overnight in a humidified chamber at 37 °C. After the first digestion step the filter units 
were transferred to new collection tubes. The second digestion was performed by adding 
120 μL of trypsin (1:100 enzyme/protein) in 50 mM ammonium bicarbonate. Samples 




were incubated at RT for 4 h and then centrifuged at 14000g for 40 min. The filter units 
were then rinsed with 50 μL of 0.5 M NaCl (aq.) and centrifuged at 14000g for 20 min. 
The filtrate was acidified with 1% formic acid and purified by solid phase extraction with a 
SepPak cartridge. The purified samples were then dried with a speedvac and stored at            
-20 °C until use, whereby they were resuspended in 20 μL of 10% formic acid prior to LC-
MS/MS analysis. 
3.3.2.3. Single-Pot Solid-Phase-enhanced Sample Preparation (SP3) protocol 
HeLa cell pellets and microdissected tissue samples were suspended in a lysis buffer 
containing 0.5% SDS, 50% trifluoroethanol (TFE), 1 tablet  of Complete mini EDTA-free 
Cocktail (Roche) in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
pH 8.5 and sonicated at 4 °C using a Bioruptor Pico sonicator (Diagenode, Seraing, 
Belgium – 10 cycles of 30 s ON and 30 s OFF) [19]. For the analysis of fresh-frozen GBM 
tissues we used a lysis buffer containing 0.5% SDS, 50% TFE, 2.5 mM 
ethylenediaminetetraacetic acid (EDTA), 2.5 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA), 1 tablet  of Complete mini EDTA-free Cocktail 
(Roche) in 50 mM HEPES pH 8.5. The protein content was quantified with the Qubit 
protein assay standard procedure (Life Technologies). Samples were mixed with 2 μL of 
paramagnetic beads (20 mg/mL or 100 mg/mL solution of 50% Speedbeads A 
(GE45152105050250, Sigma) and 50% Speedbeads B (GE65152105050250, Sigma)). 
Proteins were denaturated at 95 °C for 5 min. Reduction and alkylation were performed by 
adding 2 μL of 200 mM DTT for 30 min at 45 °C, followed by 2 μL of 400 mM IAM for 
30 min at RT in the dark. The alkylation reaction was quenched with 2 μL of 200 mM 
DTT.  
Prior to the protein digestion step the proteins were purified on the beads by adding 100% 
ACN to get a final concentration of 50% ACN. After incubation for 8 min at RT the 
samples were placed on a magnet and incubated for 2 min. The supernatant was then 
discarded and the beads rinsed with 200 μL of 70% ethanol (EtOH). After 30 s of 
incubation on the magnet the supernatant was discarded and the EtOH wash was repeated 
one more time. Purified proteins were then eluted from the beads with 10 μL of 50 mM 
HEPES pH 8 and sonication at 18 °C for 5 min with the Bioruptor Pico. Protein digestion 




was performed overnight at 37 °C by adding 2 μL of a Trypsin/LysC equimolar solution in 
50 mM HEPES pH 8 (1:25 enzyme/protein). Peptides were then purified on the beads by 
adding 100% ACN to get a final concentration of 95% ACN. After incubation for 8 min at 
RT the samples were placed on a magnet and incubated for 2 min. The supernatant was 
then discarded and the beads rinsed with 180 μL of 100% ACN. After 30 s of incubation 
on the magnet the supernatant was discarded. The purified peptides were eluted from the 
beads with 10 μL of 2% DMSO and sonication at 18 °C for 5 min using the Bioruptor 
Pico. Samples were placed on the magnet, incubated for 2 min and the supernatant 
transferred to Lobind tubes (Eppendorf). Samples were then centrifuged at 20000g for 30 
min to pellet any residual beads. The supernatant was then stored at -20 °C and diluted 1:1 
with 10% formic acid prior to LC-MS/MS analysis. 
3.3.2.4. Mice 
The murine glioma GL261 cell line was grown in complete Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% newborn calf serum, 4.5 g/L glucose, 2 mM glutamine, 
100 UI/mL penicillin and 100 mg/mL streptomycin at 37 °C in 5% CO2 with media 
changes three times per week [21].  
To induce glioma formation, C57BL/6 mice (12-14 weeks old) received a stereotaxically 
guided injection of 40000 GL261 cells into the visual cortex (2 mm lateral to the midline 
and in correspondence with lambda) using fine glass micropipettes (tip diameter 40 µm) 
[21][22]. 
GBM mouse brains were obtained using in-situ funnel-freezing [23] three weeks after 
GL261 cell inoculation. Briefly, animals were anesthetized by intraperitoneal injection 
using avertin (2,2,2-tri-bromoethanol 20 µL/g of body weight). An incision was made to 
expose the skull and a funnel was placed onto the skull; the skin was then raised around the 
funnel and secured with four sutures. Liquid nitrogen was slowly poured for 3 min and the 
entire animal was then frozen in liquid nitrogen. This procedure was applied to preserve 
the molecular integrity of the tissues as many biomolecules are known to undergo fast 
post-mortem degradation [23][24][25]. Extracted brains were stored at -80 °C until use.  




All animal experiments conformed to the European Communities Council Directive n° 
86/609/EEC and were approved by the Italian Ministry of Health.  
All experiments were performed on two animals; laser capture microdissection, sample 
preparation and LC-MS/MS analysis were performed in technical triplicate for each 
animal.  
3.3.2.5. Laser Capture Microdissection 
Coronal tissue sections of 12 µm thickness were obtained using a Leica CM1950 cryostat 
and were then thaw mounted onto PEN membrane slides (previously conditioned in UV 
light for 30 minutes). After a light hematoxylin staining, laser capture microdissection 
(LCM) was performed using a PALM Technologies system (Carl Zeiss MicroImaging 
GmbH, Munchen, Germany) consisting of a PALM MicroBeam, a RoboStage and PALM 
RoboMover (PALM Robo software, version 4.6 Pro). LCM was performed using an x40 
ocular lens. Small regions of tumor, healthy and border tissue, each of approximately 0.8 
mm
2
, were isolated and collected into LoBind tubes and then stored at -80 °C until use.  
 
3.3.3. LC-MS/MS analysis 
 
Peptides were suspended in 10% formic acid, injected and analyzed using an Easy-
nLC1000 (Thermo Scientific) coupled to an Orbitrap Fusion (Thermo Scientific). For the 
comparison of sample preparation protocols (ISD, FASP, and SP3) peptides were first 
trapped online on a nanoviper trap column (2 cm x 100 μm, C18, 5 μm, 100 Å, Thermo 
Scientific) and separated using an Easyspray analytical column (ES803: 50 cm x 75 μm, 
C18, 2 μm, 100 Å, Thermo Scientific), a flow rate of 300 nL/min and a 100 min gradient. 
Briefly, peptides were loaded at 800 bar followed by a non-linear gradient: t=0-1 min, 
5%B; t=76 min, 22%B; t=85 min, 32%B; t=90 min, 90%B; t=100 min, 90%B. Buffer A 
consisted of 0.1% formic acid and buffer B of 99.9% ACN and 0.1% formic acid. MS 
analysis was performed using a top speed 3 s cycle time, with an MS1 scan in the Orbitrap 
at 120K resolution, 375-1500 m/z, and an AGC target of 4e5. MS2 scans were performed 




in the ion trap using a 1.6 m/z isolation window, HCD at 30% NCE, 2e3 AGC target and 
300 ms maximum injection time.  
Mouse GBM microdissected tissue samples were analyzed using a 75 min gradient: t=0-1 
min, 5% B; t=51 min, 25% B; t=58 min, 35% B; t=64 min, 90% B; t=75 min, 90% B. 
Buffer A consisted of 0.1% formic acid and buffer B of 99.9% ACN and 0.1% formic acid. 
MS analysis was performed using a top speed 2 s cycle time, with an MS1 scan in the 
Orbitrap at 120K resolution, 375-1500 m/z, and an AGC target of 5e5. MS2 scans were 
performed in the ion trap using a 1.6 m/z isolation window, HCD at 32% NCE, 2e3 AGC 
target and 300 ms maximum injection time. 
 
3.3.4. Data analysis  
 
Raw data files were analyzed using Proteome Discoverer 2.1 (Thermo Scientific) with the 
SequestHT search engine. For the comparison of sample preparation protocols (ISD, 
FASP, SP3) using HeLa cells the LC-MS/MS spectra were compared with the Swissprot 
Homo sapiens database (ver2015-07-22, 42082 sequences) supplemented with a common 
contaminant database (246 sequences) allowing 2 missed cleavages, cysteine 
carbamidomethylation as static modification and methionine oxidation as dynamic 
modification, 20 ppm precursor mass tolerance and 0.6 Da fragment mass tolerance. For 
the microdissected mouse brain tumor samples the LC-MS/MS spectra were compared 
with the Swissprot Mus Musculus database (v2015-07-22, 24751 sequences) supplemented 
with the common contaminants database.  
Results were filtered for 1% FDR using the Percolator algorithm [26] and additionally 
filtered for a minimum Xcorr score of 1.8. Protein intensities were calculated considering 
the three most abundant peptides with a co-isolation threshold of 50% and taking into 
account only unique peptides. Search results of the mouse brain tumor experiments were 
exported as txt files and processed with Perseus 1.5 [27]. Protein intensities were log2 
transformed and subjected to a median normalization. Data were filtered such that each 
protein was quantified in all the three replicates for each brain region. Principal 




Component Analysis was performed on the normalized and filtered datasets. Significantly 
different protein levels between the three different brain regions (tumor, healthy and 
border) were calculated using a two-sided Student’s t-test using a permutation-based FDR 
cutoff (250 randomizations, FDR 0.001, S0 0.5). Gene ontology was performed with 
WebGestalt software [28] using the Overrepresentation Enrichment Analysis (ORA) 
method. The reference protein list included all proteins groups identified in all nine 
samples. A Benjamini-Hochberg (BH) method for multiple test adjustment was used and 
the FDR was set at 0.05. 
 
  




3.4. Results and discussion 
 
3.4.1. Protein digestion protocol comparison 
 
We compared three protein digestion protocols using different sample amounts in to find 
which is the most suited for the analysis of small sample amounts. We compared In-
Solution Digestion (ISD) with Filter-Aided Sample Preparation (FASP) and Single-Pot 
Solid Phase-enhanced Sample Preparation (SP3). We assessed the protocols using HeLa 
cell pellets containing 1e6, 1e5 and 5e3 cells. Figure 3.1. shows the number of protein 
groups and PSMs identified with the three protocols for the different amounts of HeLa 
cells.   
 
 
Figure 3.1. Protein digestion protocol comparison. The bar graphs indicate the number of protein 
groups and PSMs identified using In-Solution Digestion (ISD, white), Filter-Aided-Sample 
Preparation (FASP, grey) and Single-Pot Solid Phase-enhanced Sample Preparation (SP3, black). 
Error bars represent standard deviation (N=3). 
 




The number of identifications for each protocol decreased with the amount of starting 
material. The ISD protocol led to the identification of 3544, 2830 and 1284 protein groups 
from the 1e6, 1e5 and 5e3 HeLa cell samples, respectively. The FASP protocol led to the 
identification of 2299, 2190 and 980 protein groups from the 1e6, 1e5 and 5e3 HeLa cell 
samples, respectively. The SP3 protocol provided the best results, with the identification of 
3083, 3178 and 2036 protein groups from the 1e6, 1e5 and 5e3 HeLa cell samples, 
respectively. The decreasing number of protein groups with decreasing sample amounts 
was not observed for the 1e6 and 1e5 cells samples digested with the SP3 protocol, 
presumably because of the interference of DNA with the paramagnetic beads: we observed 
that when the number of cells is too high, the paramagnetic beads used in the SP3 protocol 
become coated in DNA (data not shown). This coating is thought to adversely affect the 
ability of the beads to bind the proteins, and thus hinders the efficiency of the SP3 method 
during the on-bead purification steps.  
The results demonstrate that, in general, the number of identified proteins decreases with 
lower sample amounts. This is due to the fact that protein adsorption and losses during the 
different steps of the sample preparation protocols become more significant when the 
amount of starting material is very low. It is also known that digestion efficiency decreases 
with lower amounts of starting material, because of protein dilution (in the absence of a 
concomitant change in the working volume of the digestion). The FASP protocol provided 
the smallest number of protein identifications for all sample amounts investigated, 
suggesting that, despite the use of SDS to increase the protein extraction yield, a 
significant amount of material was lost during the different filtration steps. The ISD 
protocol provided the highest number of identifications for large amounts of starting 
material (1e6 HeLa cells), while the SP3 protocol outperformed both ISD and FASP for 
low sample amounts (1e5 and 5e3 HeLa cells).  
We further investigated the digestion efficiency of the three protocols by examining the 
peptide charges distributions (Figure 3.2.A) and the number of missed cleavages (Figure 
3.2.B). 
 





Figure 3.2. Protein digestion efficiency comparisons for samples containing 1e6, 1e5 and 5e3 HeLa 
cells. A) Peptide charge state distribution: percentage of PSMs with +2, +3 and >+4 charge states. 
B) Missed cleavages: percentage of PSMs with 0, 1 and 2 missed cleavages. White, grey and black 











The distributions of peptide charge states and missed cleavages provide insights into the 
efficiency of the digestion process. Across an entire proteome the peptide charge state 
distribution is related to the length of the proteolytic peptides, while the distribution of the 
missed cleavages indicate the efficiency of the proteolysis [29]. Tryptic peptides usually 
contain at least two positive charges: at the N-terminus and the C-terminal arginine/lysine 
residues (trypsin cleaves C-terminal to arginine and lysine residues). Higher charge states 
are due to the presence of basic residues that become protonated during the ESI process 
[30][31]. A complete tryptic digestion would lead to tryptic peptides in which the majority 
are doubly charged [32][33][34]. A higher percentage of higher charge state peptides 
indicates longer peptides and thus a less efficient digestion process. The percentage of 
doubly charged peptides and 0 missed cleavages was found to decrease with decreasing 
sample amounts (from 1e6 to 5e3 cells) except for the SP3 protocol, which gave the 
highest percentage of doubly charged peptides and 0 missed cleavages for the 5e3 cells 
sample. For high sample amounts (1e6 cells) the FASP protocol provided the highest 
percentage of doubly charged peptides and 0 missed cleavages (89.1% and 93.8%, 
respectively). Overall, all digestion protocols provided a high percentage of doubly 
charged peptides and 0 missed cleavages for the 1e6 and 1e5 cell samples, demonstrating a 
good digestion efficiency for high sample amounts. The observation that the FASP 
protocol generated a low number of identified proteins (despite a good digestion 
efficiency) indicates sample losses during the filtration steps and/or incomplete removal of 
SDS (which leads to ion suppression during the ionization process). For low sample 
amounts (5e3 cells), ISD and FASP provided a low percentage of doubly charged peptides 
(<60%) and 0 missed cleavages (<65%), indicating inefficient digestion. Conversely, the 
SP3 protocol showed a good digestion efficiency even for low sample amounts, with 
approximately 80% doubly charged peptides and 80% zero missed cleavages.  
Figure 3.3 shows Venn diagrams indicating the overlapping protein groups identified with 
the different sample preparation protocols for the three sample amounts. 
 





Figure 3.3. Venn diagrams showing the overlap in protein groups between the ISD (yellow circle), 
FASP (orange circle) and SP3 (cyan circle) protocols for the 1e6, 1e5 and 5e3 HeLa cell samples.  
 
The overlap between the ISD, FASP and SP3 protocols was 43% and 45% for the 1e6 and 
1e5 cell samples, respectively. The overlap decreased to 23% for the 5e3 cell sample 
because the SP3 method was much more effective for this low sample amount, and led to 
the identification of many more proteins (the overlap between ISD and FASP was still 
48%). The differences in proteome coverage demonstrate a higher sensitivity of the SP3 
protocol for experiments characterized by low sample amounts, with respect to the ISD 
and FASP protocols. In order to confirm that differences in proteome coverage were due to 
a higher sensitivity of the SP3 protocol rather than a bias towards specific cellular 
compartments, we performed a gene ontology analysis to classify the cellular localization 
of the protein groups identified with the three protocols. We checked the percentage of 
protein groups that are linked to the cellular components: nucleus, membrane, 
mitochondrion, cytoskeleton, endoplasmatic reticulum, chromosome, Golgi apparatus and 
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Figure 3.4. Gene ontology cellular component analysis. The bar graphs show the percentage of 
protein groups that are linked to a GO term for the 1e6 (A), 1e5 (B) and 5e3 (C) cell samples. 
White, grey and black bars indicate ISD, FASP and SP3 protocols, respectively.   
 
The coverage of cellular compartments was similar for all three sample preparation 
protocols and for all sample amounts investigated. This indicates that the different 
protocols did not bias protein extraction, and thus the higher proteome coverage obtained 
with the SP3 protocol for low sample amounts was due to higher detection sensitivity, 
which in turn may be the result of: (i) a lower number of sample transfers and sample 
losses, (ii) higher sensitivity due to the unbiased interaction between proteins/peptides and 
the carboxylated beads, (iii) a higher digestion efficiency.  
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On the basis of these results we decided to adopt the SP3 protocol as the digestion protocol 
of choice for the analysis of small sample amounts.  
 
3.4.2. SP3 digestion protocol optimization 
 
We optimized the SP3 digestion protocol to further increase proteome coverage from low 
sample amounts. The initial version of the SP3 protocol was performed in 96-well plates 
using neodymium ring magnets (outer diameter 10 mm, inner diameter 4 mm, height 5 
mm, magnetization N42, strength 24.5 N). We decided to test the SP3 protocol in PCR 
tubes because with the 96 well plates it was not possible to sonicate the samples with the 
Bioruptor Pico. When using the 96 well plate format samples had to be lysed and sonicated 
in an Eppendorf tube and then transferred to the 96 well plate. Furthermore the ring 
magnets were not strong enough to retain all the beads during the purification steps. Thus, 
we performed the SP3 digestion protocol in PCR tubes (Sarstedt) and using neodymium 
cube magnets (length 12 mm, magnetization N48, strength 6.3 Kg). With this 
configuration it was possible to completely eliminate sample transfers during the procedure 
(the samples were kept in the same PCR tube from cell lysis to the final peptide cleanup) 
and to reduce the amount of beads lost during the purification steps (the amount of beads 
in the purified samples was negligible).  
We also increased the number of beads used for the SP3 protocol to increase protein 
recovery. The original SP3 protocol used a stock solution of 20 mg/mL carboxylate 
modified paramagnetic beads, and we tested a 5x (100 mg/mL) and 10x (200 mg/mL) 
more concentrated bead solutions. The 10x bead solution was found to be too concentrated 
for the sample volumes used here (10-20 µL), as the sample solution was too viscous and 
many beads were lost during the purification steps. The 5x bead solution led to higher 
protein recovery and a higher number of identified protein groups, compared with the 1x 
bead solution. Figure 3.5. shows the number of protein groups identified with the final 
optimized SP3 protocol performed on 1 µg of HeLa cells (~3300 cells) and those obtained 
with the first version of the SP3 protocol applied on 300 µg of HeLa cells (~1e6 cells). 





Figure 3.5. Comparison between the optimized SP3 protocol (grey bars) performed on 1 µg of 
HeLa cells and the initial protocol (white bars) performed on 300 µg of HeLa cells. Number of 
identified protein groups, PSMs and acquired MS/MS spectra are reported. Error bars represent 
standard deviation (N=3). 
 
The results obtained with the optimized SP3 protocol on 1 µg of HeLa cells were with 
those obtained with the initial (non-optimized) SP3 protocol performed on 300 µg of HeLa 
cells. Almost 3000 protein groups were identified from 1 µg of HeLa cells, corresponding 
to approximately 35% more identifications when compared with the initial SP3 version (re. 
figure 3.1). 
We then assessed the intra-batch and inter-batch reproducibility of the optimized SP3 
digestion protocol by analyzing 1 µg of HeLa cells in triplicate on different days. Figure 
3.6. shows the number of identified protein groups, PSMs and acquired MS/MS spectra of 
two batches of triplicates performed on different days and the average between the two 
batches. The variability in the number of protein groups was found to be less than 6% 
(coefficient of variance) for both the intra- and inter-batch comparisons, demonstrating that 
the SP3 protocol is highly reproducible.  
 






Figure 3.6. Reproducibility of the SP3 protocol on 1 µg of HeLa cells (~3300 cells). Number of 
identified protein groups, PSMs and acquired MS/MS spectra for two sets of triplicates performed 
on different days (batch 1 and batch 2) and inter-day average. Error bars represent standard 
deviation (N=3 for batch1 and batch 2, N=6 for average). 
 
3.4.3. Characterization of a mouse model of glioblastoma 
 
To investigate the potential of the ultrasensitive proteomics technique for molecular 
pathology we applied the optimized SP3 protocol to characterize the proteome of a mouse 
model of glioblastoma. The proteomics analysis of tissues is more challenging than the 
analysis of cell lines because: 
i) the extraction and solubilization of proteins from tissue requires stronger 
conditions [19]; 
ii) laser microdissection has to be used to isolate specific histological regions of 
interest [35][36]; 
iii) the amount of protein extracted from small samples of microdissected tissue 
can be very small [37][38] and variable.  




In this study we applied the optimized SP3 protocol to study the proteome of different 
histological regions of a mouse model of GBM. We used laser capture microdissection to 
excise 0.8 mm
2
 regions from the tumor mass, tumor border and contralateral non-tumor 
region (Figure 3.7.). We isolated three technical replicates for each tissue region, isolated 
from three serial sections of the same mouse brain. The protein content estimation was 
performed on 0.8 mm
2
 regions excised from an additional serial brain section using the 
Qubit protein quantitation assay. After LCM, samples were lysed and digested using the 




Figure 3.7. Tissue section of the GBM containing mouse brain, stained with hematoxylin and eosin. 
Red, green and blue areas indicate ROIs isolated from the tumor, tumor border and contralateral 
non-tumor region, respectively, from an adjacent tissue section. 
 
The LC-MS/MS analysis of the small microdissected tissue samples resulted in the 
identification of 2903, 1814 and 2109 protein groups from the tumor mass, tumor border 
and non-tumor regions, respectively. Figure 3.8 summarizes the number of identified 
protein groups, PSMs and MS/MS spectra. The results demonstrate the high sensitivity of 
3mm




the optimized SP3 protocol even when applied to small microdissected tissue samples. 
Furthermore, the optimized protocol provided a higher proteome coverage compared to 
other recently published tissue proteomics investigations [39][40][41][42][43]. 
While the average number of identifications demonstrated the high sensitivity of the 
optimized SP3 protocol, the variability in the number of identifications indicated that the 
tissue analysis workflow required further optimization. While the variability of the number 
of protein groups identified from the tumor region was very low (CV<4%), for the tumor 
border and non-tumor regions the variability was higher (CV = 12% and 16%, 
respectively).  
 
Figure 3.8. Protein identification metrics: number of protein groups, PSMs and MS/MS spectra 
acquired from 0.8 mm
2
 microdissected tissue samples from the tumor (red), tumor border (green) 
and contralateral non-tumor (blue) regions. Error bars indicate standard deviation (N=3). 
 
The variability can be due to the heterogeneity in the brain tissue, in the number and type 
of cells, and thus the amount and type of protein extracted per unit of area. The tumor mass 
is characterized by very high cellularity and, consequently, is histologically quite 




homogenous. The cellular make-up of the border regions and the healthy regions is highly 
dependent on the anatomical region, and can differ between serial sections. Such cellular 
variation will contribute to differences in the levels and identities of the proteins that can 
be identified from localized regions of tissue. In this experiment we did not quantify the 
protein content of the microdissected tissue sample used for the LC-MS/MS analysis, but 
instead used sequential tissue sections for the protein estimation because the volume 
required for the Qubit protein quantitation assay was 20 µL (which represents the whole 
sample volume). For this reason, a protein quantification assay that allows the 
quantification of the protein content of each individual sample (subject to LC-MS/MS) is 
needed to reduce the variability due to tissue heterogeneity. This issue will be addressed in 
the next Chapter.   
We performed a statistical analysis on the protein expression levels to study the changes in 
the proteome associated with the tumor. Figure 3.9. shows the score plots following a 
Principal Component Analysis (PCA) of the normalized protein expression levels. It can be 
seen that the tumor samples formed a well-defined cluster, separated by PC1 from the 
tumor border and non-tumor samples. The high percentage of variance explained by PC1 
(67.9%) clearly demonstrated that the tumor proteome is highly different, in terms of 
protein expression levels, from the tumor border and non-tumor regions.  The tumor border 
and non-tumor samples were also separated by PC1, in which the tumor border lies 
between the healthy control regions and the tumor core (in agreement with the results of 
spatially correlated proteomics [44], which have demonstrated that tumor associated 
changes can extend beyond the histological borders into adjacent healthy tissues). 
In this study we considered as tumor border the tissue region within 150 µm of the tumor 
mass. Furthermore, the border region was isolated from all around the tumor. Recent work 
from our group using imaging mass spectrometry has demonstrated that the border region, 
as defined by having a perturbed proteome signature, may not be uniformly distributed 
around the tumor and maybe highly localized to the tumor interface zone [45].  
Accordingly a combination of imaging mass spectrometry to define the affected tumor 
border, and LCM and LC-MS/MS to quantify the region-specific changes in protein 




expression, would better uncover the molecular changes that occur in the tumor border 
region.    
 
 
Figure 3.9. Principal Component Analysis of the quantitative proteomics data from the tumor, 
tumor border and non-tumor samples. Red, green and blue circles indicate tumor, tumor border and 
non-tumor samples, respectively. 
 
Significantly different protein levels between non-tumor, tumor and tumor-border regions 
were calculated using a two-sided Student’s t-test with FDR correction for multiple testing. 
Figure 3.10. show the corresponding volcano plots, in which the significance (expressed as 
–log of the calculated p-value) is plotted as a function of fold change. 
When comparing the protein expression levels between non-tumor and tumor regions 
almost 40% of all quantified proteins were deregulated. Specifically, in the non-tumor 
region 156 protein groups were significantly up-regulated and 218 up-regulated in the 
tumor region. Moreover, we detected 87 marker proteins known to be up-regulated in the 
non-tumor region or in the tumor region [46][47][48][49][50][51][52][53][54][55][56] 
Tumor
Non-tumor / Tumor border
Tumor Tumor border Non-tumor
A
B




[57][58][59][60][61][62][63][64][65][66][67][68][69], demonstrating the reliability of the 
data. 
The comparison between the tumor-border and tumor region showed 286 protein groups 
significantly up-regulated in the tumor region and 77 up-regulated in the tumor-border 
region. Also in this case we detected 34 known tumor marker proteins among the protein 
groups up-regulated in the tumor region. 
We also compared the protein expression levels between the non-tumor and tumor-border 
regions. As discussed above the quantitative proteomics data from the healthy regions and 
the tumor border were more variable, reflecting the underlying cellular heterogeneity and 
the difficulty of defining the border zone affected by the tumor. This variability resulted in 
an increase in the standard deviation between the replicates. While it would have been 
possible to remove samples as outliers, such removal would be too arbitrary. Thus, we 
decided to perform the Student’s t-test considering all samples per region, in order to avoid 
false positives. The high variability in the dataset meant that only 5 proteins were found to 
be significantly up-regulated in the tumor-border region (with respect to the healthy 
region). The proteins up-regulated in the tumor-border region included GFAP, VIM, MSN, 
and YBX1, which are known to be involved in glioma progression, malignancy and poor 
survival [63][68][69].  
Gene Ontology (GO) analysis was performed to determine which pathways are represented 
in the differentially expressed proteins. We performed an Overrepresentation Enrichment 
Analysis (ORA) using WebGestalt on the protein groups that were found up-regulated in 
the non-tumor, tumor-border and tumor regions in the non-tumor vs tumor and tumor-
border vs tumor pairwise comparisons. The low number of differentially expressed 
proteins between the non-tumor and tumor-border regions was insufficient for the GO 
analysis. Figure 3.11. shows the enriched KEGG pathways, in which the bubble graphs 
show the number of differentially expressed proteins contributing to the terms and the FDR 
value. 
 

























Figure 3.10. Comparison of protein expression in tumor, non-tumor and tumor-border regions. 
Volcano plots for non-tumor vs tumor (A), tumor-border vs tumor (B) and non-tumor vs tumor-
border (C). Grey circles indicate protein-groups with non-significant changes in protein expression 
(log2(fold change) <1 and >-1, FDR >0.001). Blue circles indicate protein groups significantly up-
regulated in the non-tumor region (log2(fold change) >|-1|, FDR <0.001). Red circles indicate 
protein groups significantly up-regulated in the tumor region (log2(fold change) >|-1|, FDR 
<0.001). Green circles indicate protein groups significantly up-regulated in the tumor-border 
region (log2(fold change) >|-1|, FDR <0.001).  Dark blue and dark red circles indicate markers of 















Figure 3.11. Gene ontology Overrepresentation Enrichment Analysis (ORA) performed on the 
protein groups that were significantly up-regulated in the non-tumor, tumor-border and tumor 
regions for the non-tumor vs tumor (A) and tumor-border vs tumor (B) pairwise comparisons. The 
number in the bubble indicates the number of protein groups that contributed to the KEGG 
pathway. Blue, red and green bubbles indicate KEGG pathways enriched in the protein groups that 
were significantly up-regulated in the non-tumor, tumor and tumor-border region, respectively. 
 
The GO analysis revealed that the main pathways enriched in the up-regulated protein 
groups in the tumor region are related to gene expression regulation, translation and 
protein processing in the endoplasmatic reticulum. We found 45 ribosomal proteins up-
regulated in the tumor region. Ribosomes are the translational machinery for protein 
synthesis from messenger RNA. Ribosome biogenesis and protein translation are finely 
tuned to regulate cell growth, proliferation and differentiation during development [70]. 
However, this type of regulation is abnormal in cancer cells. Ribosomal proteins of both 
small and large subunits (40S and 60S) have been found to be expressed at higher levels in 
a number of different cancers, including glioblastoma and other brain tumors [71][72][73]. 




Among these, we found an up-regulation in the tumor region of ribosomal proteins S11, 
S15a and S20, which have been reported to be related to glioblastoma cell proliferation and 
poor patient prognosis [74][75][76].  
The main pathways enriched in the protein groups up-regulated in the non-tumor region 
were related to synaptic transmission (e.g. synaptic vescicle cycle, cGMP-PKG signaling, 
calcium signaling, long-term potentiation, Wnt signaling) and metabolic processes (e.g. 
metabolic processes, oxidative phosphorylation, glucagon signaling). Several marker 
proteins of different types of synapses (glutamatergic, dopaminergic, GABAergic, and 
cholinergic synapses) were found to be up-regulated in the non-tumor and tumor-border 
region, which is to be expected as GBM is a glial cell tumor [46][77]. We also found a 
down-regulation in the tumor region of several solute carrier transporter proteins, including 
SLC1A2, SLC17A7 and SLC8A2, which have already been shown to be down-regulated 
in glioblastoma and to be involved in metastasis and tumor growth [50][51].  
Among the pathways up-regulated in the non-tumor region we also found oxidative 
phosphorylation pathway. The down-regulation of oxidative phosphorylation in the tumor 
region is in agreement with the Warburg effect, in which tumor cells metabolism switches 
toward aerobic glycolysis [78]. Moreover, the down-regulation in the tumor region of 
several subunit of the mitochondrial complex 1 (e.g. NDUFA10, NDUFB9, NDUFB10, 
NDUFS3, NDUFS4, NDUFS5) is consistent with the mitochondrial dysfunction in 












We optimized a protein sample preparation protocol for the analysis of small sample 
amounts and microdissected samples. We compared three different protocols on different 
amounts of starting material to determine the best suited for the processing of small sample 
amounts. We compared the SP3 and FASP digestion protocols with the ISD protocol. We 
observed a dramatic decrease in the number of proteins and peptides identified with ISD 
when the amount of starting material was reduced from 1e6 to 5e3 HeLa cells. We 
observed the same trend when using the FASP protocol. The SP3 protocol provided the 
highest number of protein identifications for the 5e3 cell sample, with a 2-fold increase in 
the number of protein groups and PSMs identified (2036 and 12327, respectively) 
compared to the FASP and ISD protocol. The SP3 protocol was also found to have the 
highest digestion efficiency with 80% of peptides having zero missed cleavages for the 5e3 
cells sample. These results clearly indicated that the SP3 protocol is that most suited for 
the processing of low sample amounts. The high sensitivity of the SP3 protocol is due to 
the fact that it is a single-pot protocol, in which sample losses are minimized because of 
the use of carboxylate-coated paramagnetic beads to retain proteins and peptides and thus 
reduces sample-transfer-associated losses.   
We then tested different bead concentrations, different magnets and sample holders to 
reduce losses during the SP3 procedure, and thus increase further the proteome coverage 
from low sample amounts. In the final optimized conditions, the SP3 protocol led to the 
identification of 3000 protein groups from 1 µg of HeLa cells (3300 cells), the same 
number obtained from the analysis of 1e6 cells with the initial, non-optimized SP3 
protocol.  
As a proof of principle, the SP3 digestion protocol was tested on 0.8 mm
2
 microdissected 
tissues samples from a mouse model of glioblastoma. We characterized the proteome 
extracted from the tumor, non-tumor and tumor-border brain regions. The optimized SP3 
protocol provided the identification of more than 2000 protein groups per sample, 
providing a depth of coverage much greater than that in recent tissue proteomics 
publications. More than 300 protein groups were found to be significantly different 




between the tumor and non-tumor regions and between the tumor and tumor-border 
regions. We also detected 87 marker proteins known to be up-regulated in the non-tumor 
region or in the tumor region, demonstrating the high reliability of the data. 
The comparison between the non-tumor and tumor-border regions highlighted only a few 
proteins, all of them related to tumor progression and metastasis. This is thought to be due 
to the difficulty of defining the border regions affected by the tissue, which is affecting the 
variability within the replicates. Future work will focus on using imaging mass 
spectrometry to define the affected tumor borders, which can then be characterized further 
by the SP3 method (the optimized protocol reported in this thesis, or further refined 
variations thereof). Altogether, the results demonstrated that the SP3 protocol provided 
sufficient sensitivity to study the proteomes of specific histological regions of complex and 
heterogeneous tissues.  
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Development of a Quantitative Microproteomics 
Workflow for the Analysis of Small 
Microdissected Tissue Samples: Application to 












A quantitative microproteomics workflow for the analysis of small tissue samples is 
described. The conditions for in-solution and on-column tandem mass tags (TMT) 
labeling, for accurate relative quantification, were first optimized. It was found that the 
optimal conditions for in-solution labeling of 1 µg of HeLa cell digest (HEPES buffer pH 
8.5, 1:20 protein:TMT ratio) provided a labeling efficiency higher than 99% at both N-
termini and Lysine residues, with an overall overlabeling ratio lower than 2%. A good 
labeling efficiency (>96%) was also achieved using the optimized conditions for 
automated on-column labeling (NaH2PO4 pH 4.5, 1:40 protein:TMT ratio). We then 
optimized an automated high-pH fractionation protocol for low sample amounts and 
compared the LC-MS/MS results with those obtained using a single 4 h gradient run. The 
fractionation of 6 µg of HeLa cell digest doubled the number of unique peptides and 
increased proteome coverage 1.43 fold compared to the single long gradient experiment.  
To facilitate the analysis of microdissected tissue samples, in which different regions of 
tissue may be characterized by different protein content, a modified MicroBCA assay was 
developed that consumes and detects down to 15 ng of protein, enabling the protein 
content of each tissue isolate to be measured. The performance of the microproteomics 
workflow for microdissected tissue samples was assessed by analyzing kidney 
substructures, using just 0.5 mm
2
 and 1.0 mm
2 












Mass spectrometry is a powerful tool to assess the relative abundance of proteins in 
biological samples [1][2]. The characterization of changes in protein expression associated 
with pathological conditions can be used to investigate disease mechanisms and identify 
proteins that may act as biomarkers and/or therapeutic targets [3][4][5]. Several strategies 
have been developed for relative quantification measurements and to analyze relative 
protein expression patterns as a function of biological perturbation [6]. One of the most 
popular methods for protein relative quantification is stable isotope labeling [2]. Stable 
isotope tags have been introduced to proteins via metabolic labeling using heavy salts or 
amino acids (SILAC) [7][8], enzymatically via transfer of 
18
O from water to peptides 
[9][10], or via chemical reactions using isotope-coded affinity tags (ICATs) [11]. 
Commercial ICATs include tandem mass tags (TMTs) [12] and isobaric tags for relative 
and absolute quantification (iTRAQ) [13].  
TMT based relative quantification has distinguished itself as one of the most powerful 
techniques for relative quantitation because it enables multiplex comparisons of small 
sample cohorts [14]; recent advances now enable up to 11-plex comparisons [15][16][17].   
In a typical TMT labeling workflow the peptide sample obtained after proteolytic digestion 
of the protein extract undergoes multiple sample handling steps that invariably involve 
some degree of sample loss. For example the peptide sample is dried twice, after desalting 
the peptide mixture prior to TMT labeling, and after desalting the TMT-labeled peptide 
mixture for fractionation-compatible buffer exchange or for concentration prior to LC-MS 
analysis. The typical workflow is labor- and time-intensive, and sample losses inevitably 
occur when transferring samples between labware, which adversely affects sensitivity and 
reproducibility. In this work we optimized the conditions for in-solution and on-column 
isobaric labeling with tandem mass tags (TMT). We optimized the reaction buffer, pH, 
protein/TMT ratios, and incubation times for the labeling of low sample amounts (1 μg of 
HeLa digest), and compared the results with those obtained using the typical method (i.e. 
following manufacturer’s instructions) and a larger sample amount (50 μg of HeLa digest).  




We also optimized a peptide fractionation protocol for low sample amounts to further 
increase the number of proteins identified and quantified by the analysis, i.e. increased 
proteome coverage. Offline pre-fractionation is usually performed using several hundreds 
of micrograms of protein in order to dig deep into the proteome [18][19][20][21][22]. 
Volume-limited samples typically contain less than one to maximally several micrograms 
of protein, posing a significant challenge for in-depth proteome analysis. Therefore, 
optimized fractionation methods for several micrograms of sample are needed. First, we 
examined whether peptide fractionation could be performed on the carboxylate coated 
paramagnetic beads using the SP3 protocol. We then compared strong cation exchange 
(SCX) and high-pH reversed phase (RP) offline fractionation using the AssayMap 
BRAVO platform in a completely automatized fashion. We then compared the results 
obtained from best performing method, high-pH RP fractionation, with those obtained 
using a single 4 h gradient run using the same amount of starting material. This 
comparison was performed using 6 μg proteins from a HeLa extract, which corresponds to 
the total protein amount from 6-plex TMT in which each channel corresponds to a just 1 
μg of protein extract. 
Protein quantification assays represent a crucial step in a bottom-up proteomics 
experiment; an accurate estimate of the protein content of each sample is important to 
ensure equal loading of protein into the different TMT channels, and to ensure a constant 
ratio of protein-to-proteolytic enzyme. Differences in the ratio of protein-to-proteolytic 
enzyme would affect proteolysis rates and thereby the relative protein quantitation 
measurements. Finally when comparing between LC-MS/MS experiments it is equally 
important to inject approximately the same amount of peptides into the LC-MS system. 
Analyzing the protein content of small tissue sections or microdissected tissue samples 
remains challenging because of the low amount of protein present and the high degree of 
cellular heterogeneity, resulting in varying protein concentrations within sample 
subsections [23][24]. To determine the protein content of small sample volumes and 
amounts I modified the MicroBCA assay to measure samples down to 1 μL with a 
concentration down to 15 ng/μL. 




Finally, as a proof of principle, the newly developed microproteomic workflow was 
applied to quantitatively compare the proteomes of two mouse kidney substructures using 
tissue areas as small as 1 or 0.5 mm
2
 per sample, and benchmarked against data from the 
human proteome atlas. 
 
  








Trypsin/LysC mix Mass Spec grade was purchased from Promega (Madison, WI). Tandem 
Mass Tags (TMT 6-plex) were purchased from Thermo Fisher Scientific (Rockford, IL). 
All other reagents and solvents were purchased from Sigma Aldrich (St. Louis, MO).  
 
4.3.2. Sample preparation 
 
HeLa whole cell pellets (2.5e9) were ordered from IpraCell (Mons, Belgium), resuspended 
in PBS and divided into aliquots. Cell pellets were stored at -80 °C until analysis. For the 
TMT labeling and high-pH fractionation experiments HeLa cell pellets were lysed in an 
urea-based buffer and digested with the in-solution digestion (ISD) protocol (see paragraph 
2.3.2.1. of Chapter 2). For the on-beads SP3 fractionation experiments HeLa cell pellets 
were lysed and digested according to the SP3 protocol (see paragraph 2.3.2.3. of Chapter 
2). 
Mouse kidney tissue sections were cut at 15 µm thickness, and after hematoxylin staining 
an area of 0.5 or 1 mm
2
 per sample was excised from the cortex and medulla with a PALM 
microbeam laser capture microdissection system (Carl Zeiss MicroImaging, Munich, 
Germany). Protein extraction and proteolytic digestion was performed with the optimized 
SP3 protocol. Briefly, lysis and denaturation were performed in 20 µL of lysis buffer, 
sonicated for 10 min with a Bioruptor Pico (Diagenode, Belgium) and incubated for 5 min 
at 95 °C. After lysis 1 µL of sample was used for protein content estimation using the 
modified microBCA assay. Then 20 µL of 50% trifluoroethanol (TFE) in lysis buffer 
together with 2 µL of paramagnetic beads were added to the remaining 19 µL. The protein 
mixture was reduced, alkylated, washed and subsequently digested overnight at 37 °C 
using a Trypsin/LysC mixture (Promega) in a 1:25 ratio (protease/sample). After digestion 




the resulting peptides were recovered by collecting the supernatant and two additional 
peptide elution steps using 20 µL of 2% DMSO each with intermittent sonication. Peptides 
were acidified to 5% formic acid in a final volume of 110 µL prior to automated desalting, 
on-column TMT labeling and high-pH fractionation. 
 
4.3.3. Modified protein concentration assay 
 
The protein content of each volume-limited sample was determined with a modified 
microBCA assay (Pierce). Briefly, 2 µL of modified working reagent (MA:MB:MC ratio 
25:24:4) were mixed with 1 µL of sample and incubated at 60 °C for 1 h. Absorbance was 
measured at 570 nm on a spectrophotometer (Infinite 200 PRO with Nanoquant plate, 
Tecan). Calibration was performed using a BSA standard solutions (Pierce) prepared in 
SP3 lysis buffer and heated at 95 °C for 5 min. 
 
 4.3.4. In-solution TMT labeling of low sample amounts 
 
In-solution TMT labeling experiments were performed on digests (proteolytic peptides) 
desalted with SepPack cartridges that, after elution, had been dried down with a speedvac 
and resuspended in 100 mM triethylammonium bicarbonate (TEAB, pH 8.5), 50 mM 
HEPES (pH 8.5), or 50 mM NaH2PO4 (pH 4.5) in LoBind tubes (Eppendorf). TMT 6-plex 
reagent (Thermo Scientific) solutions were prepared fresh by resuspending 800 mg of label 
in 100% ACN and kept on ice until use. A 50 μg HeLa digest was labeled with TMT for 1 
h according to the manufacturer’s protocol in 100 μL of 50 mM TEAB 25% ACN, 
followed by hydroxylamine quenching. Low sample amount aliquots of 1 μg each were 
labeled in a final volume of 10 μL, consisting of 8 μL of sample in buffer and 2 μL of 
TMT label in ACN. The TMT label was added in two equal steps of 1 μL each, each 
followed by an incubation of 30 min. The labeling reaction was quenched by adding 2 μL 
of 1.6% hydroxylamine and incubating for 15 min. After labeling the samples were 




desalted using the peptide cleanup V2 protocol on the AssayMap BRAVO platform 
(Agilent). Briefly, C18 cartridges (Agilent, 5 μL bed volume) were primed with 100 μL 
ACN, equilibrated with 50 μL of buffer A (0.1% formic acid) and loaded with 100 μL of 
acidified digest at 5 μL/min. Subsequently, a cupwash and internal cartridge wash were 
performed with 50 μL of buffer A at 10 μL/min, followed by peptide elution with 30 μL of 
80% ACN 0.1% formic acid at 5 μL/min. Purified TMT-labeled peptides were dried down 
with a speedvac, stored at -20 °C and resuspended in 10% formic acid prior to LC-MS/MS 
analysis. 
 
4.3.5. Automated on-column TMT labeling of low sample amounts 
 
For on-column TMT labeling the cleanup steps before and after labeling were combined 
into a single automated protocol adapted from the peptide cleanup V2 protocol using the 
AssayMap BRAVO platform. In brief, after automated cartridge priming, conditioning and 
sample loading the buffer was exchanged with labeling buffer L (50 mM NaH2PO4 pH 
4.5). A random channel from a TMT 6-plex set was prepared fresh by solubilizing labels in 
100% ACN and after dilution in buffer L they were kept on ice and introduced on-deck 
immediately before use. Labeling was achieved by loading 10 μL of TMT in buffer L at 1 
μL/min, followed by a pause of 20 min and then repeated. The labeled peptides were then 
washed with Buffer A and eluted in 80% ACN 0.1% formic acid. When quenched, eluates 
were collected in wells containing 2 μL of 1% hydroxylamine and incubated for 10 min at 
RT. Desalted and labeled peptides were dried down in a speedvac, stored at -20 °C and 
resuspended in 10% formic acid prior to LC-MS/MS analysis.  
 
4.3.6. SP3 peptide fractionation  
 
SP3 fractionation was performed following the SP3 peptide cleanup. Peptides were eluted 
with five 10 μL elution buffers containing 90% ACN, 80% ACN, 60% ACN, 25% ACN 




and 2% DMSO at pH 7 (neutral fractionation) and pH 10 (basic fractionation). After the 
addition of each elution buffer the bead-containing solution was sonicated with a Bioruptor 
for 5 min (30 s ON, 30 s OFF cycle), placed on a magnet for 2 min and the supernatant 
collected in a LoBind tube (Eppendorf). Fractions were then centrifuged at 20000 x g for 
30 min to pellet any residual beads. The supernatant was stored at -20 °C and diluted 1:1 
with 10% formic acid prior to LC-MS/MS analysis.  
 
4.3.7. Automated Strong Cation Exchange (SCX) and high-pH reversed phase 
peptide fractionation  
 
Strong cation exchange (SCX) and high-pH fractionation were performed using the 
AssayMap BRAVO platform and SCX and reversed phase S (RPS) cartridges, 
respectively, and fractionation protocol V1.0.  
For SCX fractionation the SCX cartridges were primed and equilibrated with 100 μL of 
400 mM ammonium formate, 1% formic acid and 25% ACN in water, and 50 μL of buffer 
D (1% formic acid 25% can in water), followed by sample loading in 50 μL of buffer D at 
5 μL/min. Subsequently, cupwash and cartridge washes were performed with 50 and 10 μL 
of buffer D, respectively. Peptides were eluted with six 35 μL plugs at 5 μL/min using 40 
mM ammonium formate, 25% ACN at pH 3.5, 4.0, 4.5, 5.0, 5.5 and 9.5. 
For high-pH fractionation C18 cartridges were primed and equilibrated with 100 μL of 
ACN and 50 μL of buffer C (10 mM NH4OH pH 10), followed by sample loading in 50 μL 
of buffer C at 5 μL/min. Subsequently the cup and cartridge were washed using 50 and 10 
μL of buffer C, respectively. Peptides were eluted with six 35 μL plugs at 5 μL/min using 
12, 18, 24, 30, 36 and 80% ACN in buffer C. The elution buffer plates were stored at 4 °C 
and introduced on-deck just after cartridge washes. Fractions including sample flow-
through were transferred to a single 96-well plate and dried down with a speedvac and 
stored at -20 °C.  
 




4.3.8. LC-MS/MS analysis 
 
Peptides were resuspended in 10% formic acid, injected and analyzed using an Easy-
nLC1000 (Thermo Scientific) coupled to an Orbitrap Fusion (Thermo Scientific). Peptides 
were first trapped online using a nanoviper trap column (2 cm x 100 μm, C18, 5 μm, 100 
Å, Thermo Scientific) and separated using an Easyspray analytical column (ES803: 50 cm 
x 75 μm, C18,     2 μm, 100 Å, Thermo Scientific) and a flow rate of 300 nL/min.  
TMT labeling experiments were analyzed using a 75 min gradient: t=0-1 min, 5% B; t=51 
min, 25% B; t=58 min, 35% B; t=64 min, 90% B; t=75 min, 90% B. Buffer A consisted of 
0.1% formic acid and buffer B of 99.9% ACN and 0.1% formic acid. MS analysis was 
performed using an Orbitrap Fusion configured for a top speed 3 s cycle time with MS1 
scans in the Orbitrap (60K resolution, 375-1500 m/z, AGC target 4e5) and MS2 scans in 
the ion trap (1.6 m/z isolation window, HCD with 35% NCE, 2e3 AGC target, and 300 ms 
maximum injection time). 
SP3, SCX and high-pH fractions were analyzed using a 145 min gradient, whereas the 
single-shot analysis was performed with a 4 h gradient. The 145 min gradient was as 
follows: t=0-1 min, 5%B; t=105 min, 22%B; t=120 min, 32%B; t=130 min, 90%B; t=145 
min, 90%B. The 4 h gradient was t=0-1 min, 6%B; t=166 min, 23%; t=211 min, 33%B; 
t=226 min, 90%B; t=240 min, 90%B. MS analysis was performed with an Orbitrap Fusion 
configured for a top speed 3 s cycle time with MS1 scans in the Orbitrap (120K resolution, 
375-1500 m/z, AGC target of 4e5) followed by MS2 scans in the ion trap (1.6 m/z isolation 
window, HCD at 35% NCE, 2e3 AGC target and 300 ms maximum injection time).  
For the mouse kidney tissue experiments peptides were analyzed using the same 145 min 
gradient used for the SP3, SCX and high-pH RP fractions. MS analysis was performed 
with an Orbitrap Fusion configured for a top speed 3 s cycle time with MS1 scans in the 
Orbitrap (120K resolution, 375-1500 m/z, AGC target of 4e5) but with MS2 scans also in 
the Orbitrap (1.6 m/z isolation window, HCD at 37% NCE, 60K resolution, 5e5 AGC and 
80 ms maximum injection time).  
 




4.3.9. Data analysis  
 
Raw data files were analyzed using Proteome Discoverer 2.1 (Thermo Scientific) with the 
SequestHT search engine. For the HeLa experiments spectra were matched with a forward-
decoy Swissprot Homo sapiens database (ver2015-07-22, 42082 sequences) supplemented 
with a common contaminant database (246 sequences) and allowing up to two missed 
cleavages, cysteine carbamidomethylation as static modification and methionine oxidation 
as dynamic modification, 20 ppm precursor mass tolerance and 0.6 Da fragment mass 
tolerance. For the TMT labeled samples peptide N-terminal and lysine TMT 6-plex 
modifications were used as static modifications. For the assessment of TMT overlabeling 
the TMT tag was used as a static modification at the peptide N-terminal and at lysine 
residues, and as a dynamic modification at serine, threonine, histidine and tyrosine 
residues.  
For the mouse kidney tissue experiments the LC-MS/MS spectra were matched with a 
forward-decoy Swissprot Mus Musculus (v2015-07-22, 24751 sequences) database 
supplemented with the common contaminants database and allowing up to two missed 
cleavages, cysteine carbamidomethylation and TMT tag at peptide N-terminal and lysine 
residues as static modifications, and methionine oxidation as a dynamic modification, 20 
ppm precursor mass tolerance and 0.05 Da fragment mass tolerance. 
Results were filtered for 1% FDR using the Percolator algorithm and additionally filtered 
for a minimum Xcorr score of 1.8. Protein intensities were calculated based on label 
intensities of the three most abundant peptides with a co-isolation threshold of 50% taking 
into account unique and razors peptides and normalized to total peptide amount. Search 
results were exported as txt files and processed with Perseus 1.5 [25]. For each TMT 
experiment the protein intensities were log2 transformed and subjected to median 
normalization. Data were filtered such that each protein was quantified in at least three 
cortex and three medulla samples. Significantly different protein levels between kidney 
cortex and medulla tissues were calculated using a two-sided Student’s t-test using a 
permutation-based FDR cutoff (250 randomizations, FDR 0.001, S0 0.55). Gene ontology 
enrichment was performed with Panther [26] displaying only terms with a Bonferroni 




corrected p-value below 0.05 and an over/under representation of at least 2-fold compared 
to the set of all identified proteins. 
 
4.4. Results and discussion 
 
4.4.1. In-solution and on-column TMT labeling 
 
We optimized the conditions for the in-solution and on-column TMT labeling of low 
sample amounts in order to perform accurate relative quantification. Several TMT labeling 
protocols have been reported for relatively high sample amounts (from 25 μg and upwards) 
[27][28][29], but the optimal reaction conditions for the labeling of low sample amounts 
had not been investigated. All the optimization experiments were carried out on 1 μg 
aliquots of a digested HeLa lysate, in order to avoid any possible variability related to 
protein digestion and/or cell batch.  
4.4.1.1. In-solution TMT labeling optimization 
We assessed the efficiency of in-solution TMT labeling on low sample amounts (1 μg of 
HeLa digest) and compared it with the labeling of 50 μg of HeLa digest. First, we scaled 
down the labeling protocol recommended by the manufacturer (Thermo Fisher Scientific) 
in order to adapt it to the lower volume of the 1 μg samples. Then we investigated the 
effect of different reaction buffers, pH and protein/TMT ratios on the labeling efficiency. 
We tested three reaction buffers at different pH: 100 mM TEAB pH 8.5, 50 mM HEPES 
pH 8, 50 mM NaH2PO4 pH 4.5. TEAB and phosphate buffers are the recommended buffers 
for the in-solution and on-column TMT labeling, respectively. We tested also the HEPES 
buffer in order to assess SP3-TMT labeling. We also investigated the effect of the TMT 
excess by varying the protein/TMT ratio from 1/10 up to 1/40. Each experimental 
condition was tested in triplicate. We assessed the TMT labeling efficiency in terms of the 
percentage of PSMs with the TMT modification at lysine and N-termini residues (Figure 
4.1.A), and also assessed the undesired overlabeling rate in terms of the percentage of 









Figure 4.1. A) TMT labeling efficiency expressed as the percentage of PSMs with the TMT 
modification at N-termini and lysine residues. B) Over-labeling rate expressed as the percentage of 
PSMS with the TMT modification at serine, histidine, threonine and tyrosine residues. Error bars 
represent standard deviation (N=3). Buffers used: 100 mM TEAB pH8.5 (T), 50 mM HEPES pH8.5 
(H), and NaH2PO4 pH4.5 (P). 




When performing in-solution TMT labeling of 50 μg of digest using the manufacturer’s 
recommended protocol (TEAB buffer, 1:10 protein/TMT ratio) a good labeling efficiency 
is achieved (>98%). However, for 1 μg of digest a simple downscaling of the TEAB-based 
protocol resulted in poor labeling efficiency of N-termini (65%), even at high levels of 
excess TMT (1:20). Although HEPES and TEAB have the exact same pH (8.5), the 
labeling efficiency using HEPES was significantly greater. Even a 1:5 TMT excess in 
HEPES outperformed a 1:10 TMT excess in TEAB, with 95% versus 65% N-terminal 
labeling, respectively. This result indicates that TMT labeling in HEPES is more efficient 
but also more economical. The labeling of 1 μg digest in HEPES using a 1:10 TMT excess 
achieved similar labeling efficiencies (>98%) as obtained using the manufacturer’s 
recommended protocol with 50 μg digest and with a significant reduction in the undesired 
overlabeling rate. A 1:10 or even 1:20 TMT excess in HEPES resulted in <1.5% 
overlabeling compared with >10% observed for the 50 μg sample using the manufacturer’s 
recommended protocol. Even though labeling a 1 μg sample in TEAB (1:20 TMT excess) 
did not result in full labeling of primary amines, the rate of overlabeling was greater than 
that observed with complete labeling in HEPES. The phosphate-based buffer (indicated 
with P in the above figure) was found to be far from optimal, with poor lysine labeling 
efficiencies of 5 to 40% even for 1:10 to 1:20 TMT excess. 
The absolute number of PSMs was the highest for the labeling of 50 µg (Figure 4.2.) 
because of the much larger amount of protein available for the LC-MS/MS analysis. For 
the 1 µg samples the highest number of PSMs was obtained when using HEPES as 
reaction buffer. In summary for in-solution labeling of 1 μg samples 50 mM HEPES (pH 
8.5) and a 1:10 or 1:20 TMT excess ratio gave the best results in terms of labeling 
efficiency and overlabeling rate. 
 
 






Figure 4.2. Number of TMT labeled PSMs for all the tested conditions. Error bars represent 
standard deviation (N=3). 
 
Since HEPES is the digestion buffer used for the SP3 protocol, the in-solution TMT 
labeling can be easily performed after the SP3 digestion without the need to dry the 
samples or to perform a buffer exchange, representing a great advantage in terms of 
analysis time and avoiding peptide losses. 
4.4.1.2. On-column TMT labeling 
On-column TMT labeling was performed using the AssayMap Bravo platform. In all 
labeling experiments cartridges with RPS chemistry were used because pilot studies 
showed that although C18 cartridges show slightly less peptide breakthrough during the 
labeling process their labeling efficiency was significantly lower. On-column labeling was 
performed using 1 μg of digest in HEPES, the optimal in-solution buffer, or phosphate 
buffer, previously reported to be suitable for on-column TMT labeling [29]. Figure 4.3.A 
and 4.3.B show the TMT labeling efficiency and overlabeling rate, respectively, for all 
tested conditions.  




The optimal conditions for in-solution labeling, 1:20 TMT excess in HEPES buffer, 
exhibited poor on-column labeling efficiency and also led to a greater degree of 
overlabeling when compared with the in-solution protocol. In contrast with the very poor 
in-solution labeling obtained using the phosphate buffer, it provided the highest efficiency 
for on-column labeling. When comparing the complete on-column to complete in-solution 
labeling experiments the overlabeling rate was higher for on-column labeling. Even for 
HEPES, which displayed very low overlabeling in solution, a 9-fold higher overlabeling 
rate was observed on-column. It was found that the on-column overlabeling could be 
alleviated by eluting the peptide/TMT mixture into hydroxylamine to quench the reaction. 
This quench enabled the degree of overlabeling to remain low, <0.5 %, while  maintaining 
a high label efficiency (>95%) and provided the largest number of identified fully labeled 
peptides.  
 






Figure 4.3. A) TMT labeling efficiency expressed as the percentage of PSMs with the TMT 
modification at N-termini and lysine residues. B) Over-labeling rate expressed as the percentage of 
PSMS with the TMT modification at serine, histidine, threonine and tyrosine residues. Error bars 
represent standard deviation (N=3). Buffers used: 100 mM TEAB pH8.5 (T), 50 mM HEPES pH8.5 








Interestingly, on-column labeling increased the number of identified spectra (Figure 4.4.). 
A 146% increase in TMT labeled PSMs was observed when comparing the maximum 
number of PSMs for in-solution TMT labeling (1:5 in HEPES) with on-column TMT 




Figure 4.4. Number of TMT labeled PSMs for all the tested conditions. Error bars represent 
standard deviation (N=3). Buffers used: 100 mM TEAB pH8.5 (T), 50 mM HEPES pH8.5 (H), and 
NaH2PO4 pH4.5 (P). 
 
The best on-column labeling protocol (phosphate buffer, 1:40 TMT excess, quenched with 
hydroxylamine) provided the best performance for 1 μg of sample for all conditions 
investigated (on-column or in-solution), showing similar results to labeling 50 μg of 
protein using the manufacturer’s recommended protocol in terms of labeling efficiency 
(>96%).  
 




4.4.2. Peptide fractionation 
 
We optimized the conditions to perform peptide fractionation on the beads after the SP3 
digestion protocol, and on-column using the AssayMap BRAVO platform. Peptide 
fractionation is performed to reduce the very high complexity of the peptide sample 
obtained after trypsin digestion, and thereby to identify and quantify more proteins. 
Fractionation divides the starting material over multiple LC-MS/MS runs and is normally 
applied to larger sample amounts [30][31] to ensure that there is sufficient protein 
available that the lower abundant proteins are present above the lower limit of 
quantitation/identification. When the amount of starting material is low, the lower 
abundant proteins may not be present in amounts above the lower limit of 
quantitation/identification and peptide fractionation has limited benefit. However, when a 
TMT experiment is performed the samples from each TMT channel are pooled prior to 
LC-MS/MS analysis. In this scenario even if the amount of starting material is 1 μg, the 
pooled sample is 6 or 10 μg (for 6-plex or 10-plex TMT, respectively) and fractionation 
can be performed to increase identify and quantify lower abundant proteins. Thus, we 
sought to optimize the conditions for peptide fractionation on 6 μg aliquots of HeLa digest.  
4.4.2.1. SP3 fractionation 
Fractionation can be carried out within the SP3 protocol by modulating the interactions 
between the peptides and the paramagnetic beads [32]. After the protein digestion step the 
peptides can be selectively eluted from the beads by changing the percentage of organic 
solvent (ACN) in the buffer and/or the pH. The addition of an organic solvent to an 
aqueous solution containing paramagnetic beads promotes trapping of peptides in a 
solvation layer on the hydrophilic surface of the beads. Thus, the elution of the peptides 
from the beads is achieved by reducing the percentage of organic solvent. The interaction 
between peptides and the carboxylic groups on the surface of the beads is also pH 
dependent. Acidic buffers promote a hydrophilic-interaction-based retention of peptides, 
whereas basic buffers induce elution of the peptides because of the repulsion between the 
negatively charged carboxylate groups.  




The original report of the SP3 protocol [32] included a 2-step fractionation using two 
different elution buffers: 87% ACN in ammonium formate at pH 10 and 2% DMSO at pH 
7. We tried to further optimize the SP3 fractionation protocol in order to increase the 
number of fractions, and thereby increase proteome coverage.  
First we performed a pilot study using 1e5 HeLa cells (approximately 15 μg of proteins) to 
test the efficacy of SP3 fractionation. We eluted the peptides with five buffers at different 
organic solvent concentration: 90% ACN, 80% ACN, 60% ACN, 25% ACN and 2% 
DMSO. The effect of the pH was also investigated by performing the fractionation with 
buffers at pH 7 and 10. SP3 fractionation was assessed by determining the percentage of 
peptides shared between fractions: a lower percentage of overlap indicates a higher 
selectivity of the elution mechanism. Figure 4.5. shows the number of unique peptides 
identified in the six neutral and six basic SP3-fractions and the percentage of non 
overlapping peptides between adjacent fractions. 
The neutral SP3-fractionation provided the largest number of unique peptides for all of the 
fractions. However, we found a high degree of overlap between adjacent fractions for both 
the neutral and basic fractionations. These results suggest that below a certain ACN 
percentage threshold the peptides were eluted from the beads with low selectivity. We 
performed another fractionation experiment reducing the number of fractions (90% ACN, 
70% ACN, 40% ACN and 2% DMSO) but again the overlap between adjacent fractions 
was larger than 50% (data not shown). These results indicate that the interaction between 
the peptides and the carboxylate modified beads cannot be sufficiently modulated for 
effective on-bead fractionation. 
 






Figure 4.5. Neutral vs basic SP3-fractionation of 15 μg of HeLa digest. Bar graph display the 
numbers of unique peptides identified in each fraction (left y-axis). The lines refer to the percentage 
of peptides that were only found in the specified fraction number and not in adjacent fractions (right 
y-axis). 
 
4.4.2.2. Peptide fractionation with AssayMap BRAVO platform 
We optimized an automated peptide fractionation protocol using the AssayMap BRAVO 
platform. It is important that the fractionation mechanism is orthogonal to the reverse 
phase separation of the LC-MS/MS analysis in order to maximize peak capacity, resolution 
and proteome coverage. Strong cation exchange (SCX) and high-pH reversed phase (RP) 
fractionations have been extensively used for peptide fractionation of complex samples, as 
they provide a good orthogonality with the RP chromatographic separation [33][34][35]. 
SCX and RP separations are fairly orthogonal as they based on different separation 
mechanisms. In SCX negative functional groups interact with positively charged peptides 
at low pH, so peptides are separated according to differences in their electric charge by 




using elution buffers with different pH. The stationary phase used for high-pH 
fractionation and the chromatographic separation is the same, but a high degree of 
orthogonality is achieved by changing the pH of the mobile phase. Since peptides are 
charged molecules comprised of acidic and basic functional groups, the change in pH 
influences their protonation state and thus their retention behavior. Neutralization of a 
charged residue decreases its hydrophobicity and consequently leads to a better retention. 
Generally acidic peptides are better retained at lower pH in which the carboxylic groups 
are protonated (increased hydrophobicity), while basic peptides are better retained in high 
pH conditions because of the deprotonation of the basic residues. Thus, a high-pH 
separation (fractionation) and a low-pH separation (chromatography) provides a high 
degree of orthogonality, similar to that obtained with a SCX-RP strategy [36].  
We first compared the SCX and high-pH fractionation with the AssayMap BRAVO 
platform using 100 μg aliquots of HeLa digest. Figure 4.6. shows the number of unique 
peptides identified in the six SCX and six high-pH fractions and the percentage of non 
overlapping peptides between adjacent fractions. Even though SCX fractionation led to the 
identification of more unique peptides in most fractions, the total number of unique peptide 
sequences identified was greater for the high-pH fractionation because of a lower degree of 
overlap between adjacent fractions, indicating higher selectivity of the fractionation.  
Since the high-pH fractionation provided the highest selectivity and number of identified 
peptides, we tested it on the fractionation of low sample amounts. We fractionated 6 μg of 
a HeLa digest to mimic the analysis of 1 μg of samples in a TMT 6-plex experiment and 
compared the results with a non-fractionated sample. A single 4 h run was compared with 











Figure 4.6. SCX vs High-pH fractionation of 100 μg of HeLa digest. Bar graph display the numbers 
of unique peptides identified in each fraction (left y-axis). The lines refer to the percentage of 





Figure 4.7. Base peak chromatograms of the six fraction and flow through obtained with the 


















































To prevent overloading of the LC column in the single-run analysis, only 5 μg were 
injected. Figure 4.8. shows the number of MS/MS acquired, unique peptides and protein 




Figure 4.8. Low sample amount proteome coverage for 6 μg of sample: single 4 h LC-MS/MS runs 
versus LC-MS/MS analysis of offline high-pH fractionated sample (seven fractions x 2 h gradients).  
 
The high-pH fractionation provided a higher proteome coverage compared to the single-
run analysis even for small sample amounts. The fractionation increased the number of 
acquired spectra 2.6 fold and doubled the number of unique peptide identifications (23946 
vs 47220). As a result proteome coverage was increased by 143%, from 4237 to 6052 
protein groups (grouped from 10277 and 14645 identified protein accessions, 
respectively). 




The number of unique peptides and protein groups identified with high-pH fractionation 
exceed that reported using custom designed Stagetips [37][38] or spintip-based [39][40] 
fractionation approaches to fractionate 200 μg of protein. However, in this study the 
amount of starting protein was 6 μg and we used commercial reversed-phase cartridges 
handled by a robot using controlled flowrate and volumes to ensure high-throughput and 
reproducible sample handling. Moreover, this fractionation strategy is easy to implement in 
a modular, offline and robotized proteomic workflow. 
 
4.4.3. Protein determination of minute sample amounts 
 
One of the challenges of working with microdissected tissues or other samples 
characterized by low sample amounts is the need to know the total protein content. Protein 
content quantification is a crucial step in shotgun proteomics not only for the estimation of 
the proper amount of proteolytic enzyme required for the digestion, but also for accurate 
quantitation of protein expression levels between different samples. Previously adjacent 
sections were used for the protein content estimation, which is non-ideal because tissue 
histologies may differ, especially for small pathological features with a specific histolog.  
Many direct (tyrosine and tryptophane absorption method [41]), colorimetric (Lowry [42], 
Bradford [43] and BCA [44]) and fluorescence-based assays (Qubit [45], FluoroProfile 
[46] and Nano-Orange [47]) have been developed to quickly and reliably quantify protein 
amounts. However, many are incompatible with the lysis buffers commonly used for 
proteomics sample preparation. The microBCA assay is tolerant to detergents and a range 
of buffers. Although the microBCA protein determination assay is highly sensitive for 
medium sample volumes (2-40 ng/μL for 150 μL sample), it does not suffice if only a few 
microliter of sample can be spared for the protein determination assay. Therefore, we 
modified the microBCA assay to use less sample while increasing the range of detection.  
Technological advances in spectrophotometers have enabled the measurements of only 1-2 
μL of sample [48]. However, due to the great reduction of the light path length, detection 
limits are reduced. In order to compensate for the decreased absorbance due to the 




shortened light path length and the presence of chelating agents in our lysis buffer (EDTA 
and EGTA) we increased the copper (MC buffer) concentration 4 times and increased the 
working reagent (WR) to sample ratio 2-fold. In this way by mixing 1 μL of sample with 2 
μL of modified working reagent (MA:MB:MC ratio 25:24:4) we were able to use 2 μL for 
the absorbance measurement with the Nanoquant plate (Tecan). We obtained a 
reproducible BSA standard calibration curve between 5 and 120 ng/μL using only 1 μL of 






Figure 4.9. Modified microBCA assay optimized to improve sensitivity and consume less sample 
(only 1 μL). Calibration curves obtained using BSA standard solutions prepared in SP3 lysis buffer 
(5-120 ng/μL linear dynamic range, corresponding to sample concentration of 15-360 ng/μL) using 
the original unmodified conditions (red) and the final optimized conditions (blue). Error bars 
represent standard deviation (N=3). 
 
 




The unmodified conditions (MA:MB:MC ratio 25:24:1, sample/WR ratio 1:1) showed low 
absorbance values and a low sensitivity, while the modified conditions provided almost a 
3-fold increase in sensitivity. With the optimized method we could reproducibly measure 
down to 15 ng of protein from only 1 μL of sample with an average CV of 3% (average 
from nine BSA standards). For our tissue lysis in 20 μL of lysis buffer, this translates into 
measuring tissue protein contents ranging from 300 ng to 7.2 μg while consuming only 5% 
of sample.  
We compared our modified MicroBCA assay with the most common protein quantitation 
assays in terms of analytical figures of merit, compatibility to SDS and costs (Table 4.1.). 
Altogether, considering the dynamic working range, sample volume required, lowest 
protein concentration detectable and percentage of SDS compatible with the assay, our 
modified MicroBCA assay represents the best method for protein quantitation, including in 
terms of costs.  
 
 














MicroBCA 4-80 or 1-40 150 or 1000 0.6 or 1 10% 6 or 43 [49] 
NanoOrange 0.25-250 100 25 0.25% 137 [50] 
Lowry 6.5-9750 40 or 200 0.26 or 1.3 6.6% 6 or 32 [51] 
Bradford 5100-76500 or 2-50 5 or 1000 25.5 or 2 6.37% 3 or 11 [52] 
Qubit 25-500 or 12.5-250 1 or 20 0.025 or 0.25 2-0.1% 15 or 14 [53] 
FluoroProfile 6-200 5 0.03 0.2% 2 [54] 
Modified 
microBCA 
15-360 1 0.015 10% 0.3  
 
*Initial sample concentration (based on BSA calibration) 
#Highest compatible concentration in the initial sample 
$Reagent costs per sample in USD cents. 
 




4.4.5. Mouse kidney tissue substructure proteome analysis 
 
As a proof of principle we applied the workflow to investigate the proteome of the 
anatomical regions of the mouse kidney. Laser capture microdissection (LCM) was used to 
excise and isolate cortex and medulla regions of fresh frozen mouse kidney (Figure 4.10.), 




Figure 4.10. Representative mouse kidney section stained with hematoxylin. Orange lines indicate 
ROIs isolated from the cortex, blue lines indicate ROIs isolated from the medulla. 
 
Five ROIs of 0.5 mm
2
 and five ROIs of 1 mm
2
 were microdissected from both the cortex 
and medulla. The resulting 20 samples were lysed using the SP3 protocol resulting in an 
average of 1.5 μg of protein per sample. After protein cleanup and digestion the proteolytic 
peptide samples were transferred to the AssayMap BRAVO platform for automated 
peptide desalting, 10-plex TMT labeling and high-pH fractionation. The peptides from 
each of the ten 0.5 mm
2
 and ten 1 mm
2
 samples were labeled with a different 10-plex TMT 
label. This resulted in two data sets, one from 0.5 mm
2
 samples and the other from 1 mm
2
 
samples, each containing five replicates from the cortex and medulla. As seen in Figure 




4.11. deep proteome coverage was achieved for a sample area of only 1 mm
2
 (5002 protein 
groups), even when using TMT labeling (which reduces sequencing speed). A lower 
proteome depth (3440 protein groups) was obtained from the 0.5 mm
2
 samples, reflecting 
the lower amount of protein available for the analysis. Nevertheless, when comparing our 
approach using only 1.5 μg per sample and analyzing only seven high-pH fractions in 
seven LC-MS runs, an equal or greater proteome coverage was achieved than that recently 
reported as part of a draft of the human proteome, and which used 450 μg of human kidney 
homogenate and which was separated into 24 high-pH fractions and analyzed by 24 LC-
MS runs [18]. This result reflects the high sensitivity of the workflow, which provided a 




Figure 4.11. Protein identification metrics: number of protein groups identified from the 1 mm
2
 
(black bars) and 0.5 mm
2
 (grey bars) datasets compared with those obtained by Kim et al. from the 
proteomics analysis of a human kidney homogenate [18]. 
 
A a number of differentially expressed proteins could be identified in the cortex and 
medulla, Figure 4.12. 






Figure 4.12. Protein expression comparison between kidney cortex and medulla. Volcano plots for 
the 1 mm
2
 (A) and 0.5 mm
2
 (B) data sets. Grey circles indicate non significant protein groups 
(log2(fold change) <1 and >-1, FDR >0.001). Orange circles indicate protein groups significantly 
up-regulated in the medulla (log2(fold change) <-1, FDR <0.001). Blue circles indicate protein 
groups significantly up-regulated in the cortex (log2(fold change) >1, FDR <0.001). Dark orange 
circles indicate cortex markers (LRP2, GGT1, HPD, HRSP12, PKLR, SLC22A8, DPYS, 













Several marker proteins known to be localized to the different kidney layers (Human 
Protein Atlas) were detected in the layer-specific proteomes. Interestingly, the 0.5 mm
2
 
proteome shows more variation (lower log p-values) and larger ratios. This may reflect the 
greater sensitivity of smaller tissue samples to cellular heterogeneity (less averaging across 
more cells). Despite a slightly higher variation the proteomes obtained from 0.5 and 1 mm
2
 
are very similar in terms of relative expression levels and the set of significantly regulated 
proteins, as can be seen from the consistently regulated kidney markers and the high 




Figure 4.13. Protein expression correlation between the 0.5 and 1 mm
2
 datasets. Significantly 
different protein groups between cortex and medulla in one or both datasets are indicated with 
orange and red, respectively.  
  




The in-depth proteomics data of the cortex and medulla were then subject to a gene 
ontology analysis to assess the functional roles of the differentially expressed proteins. 
Gene ontology over- and under-representation analysis supported the well established 
function of each layer (Figure 4.14). For example, the main function of the cortex is to 
resorb ions, glucose, amino acids and organic acids, whereas in the medulla salts and water 
are secreted and resorbed. The functions and biological processes enriched in the cortex 
proteome recapitulate the transporting activity. Interestingly, in addition to transport  
proteins many metabolic enzymes are also enriched in the cortex, which could indicate 
other important processes in the cortex, including the modification, transformation or 
clearance of the resorbed amino acids, carbohydrates and other organic compounds. In the 
medulla water transport/homeostasis and salt transport are strongly enriched due to the 
relatively high levels of aquaporins and specific ion transporters. 
The data also allowed the large-scale monitoring of kidney substructure-specific protein 
paralogue expression (Figure 4.15.). Whereas most of the detoxifying glutathione S-
transferase proteins are expressed at similar levels in each substructure some are 
specifically expressed in the cortex (GSTA2, GSTM5, MGST1) or medulla (GSTM2, 
GSTM6). A Similar analysis was also performed for membrane transporter proteins from 
the solute carrier and ATPase families. Specific bicarbonate transporters (SLC family 4) 
are expressed in the medulla (SLC4A2 and SLC4A7) or cortex (SLC4A4), whereas only 
organic ion transporters (SLC family 22) were found to be significantly elevated in the 
cortex. Regarding ATPases, alpha, beta and gamma subunits (ATP1A1, ATP1A4, 




 transporting ATPase assembly were significantly up-
regulated in the medulla, whereas many different H
+
 transporting subunits showed elevated 
but insignificant up-regulation in the cortex. 
 






Figure 4.14. Gene ontology over/under representation of proteins significantly up-regulated in the 
kidney cortex or medulla compared to all identified proteins using Panther analysis (1 mm
2
 dataset, 













Figure 4.15. Kidney substructure specific expression pattern of protein class members. Three 
classes of proteins were clustered to visualize high (>2-fold above median; red) or low (<2-fold 
below median; yellow) protein levels in all samples. Proteins/clusters marked in red showed 
significantly different protein levels between two tissue types, grey indicate not quantified protein 
levels due to lack of unique peptide sequences. Cluster analysis was performed on solute carriers 
family, ATPases family, glutathione S transferase family.   
  






We developed a quantitative microproteomic workflow for the analysis of small sample 
amounts and microdissected tissue samples. It was demonstrated that scaling down TMT 
labeling to 1 μg of sample using current protocols for in-solution or on-column labeling 
resulted is a poor labeling efficiency (< 50%). Therefore, new in-solution and on-column 
TMT labeling protocols were developed for low sample amounts. The optimal conditions 
for in-solution TMT labeling were obtained using HEPES buffer, which is the same buffer 
used for the SP3 digestion protocol, indicating that TMT labeling can be integrated within 
the SP3 digestion protocol. Automated on-column TMT labeling with a phosphate buffer 
was found to provide good labeling efficiency, representing an amenable alternative to in-
solution labeling when high sample throughput is needed. Because of the 96-well parallel 
format of the AssayMap BRAVO platform, the same amount of time will be spent to label 
1 sample as for 96 samples.  
In addition to a reproducible quantitative workflow for low sample amounts, we sought to 
increase proteome coverage from limited amounts of sample. On-bead fractionation within 
the SP3 protocol exhibited poor selectivity as the percentage of overlapping protein groups 
between adjacent fractions was found to be greater than 50%. Conversely, automated on-
column high-pH fractionation provided not only a good selectivity but also an increase in 
proteome coverage of about 143% when compared to a single long gradient analysis.  
As a proof of principle the quantitative microproteomic workflow was tested on mouse 
kidney medulla and cortex substructures, using areas of 0.5 or 1 mm
2
 of 15 μm thick tissue 
sections. We first developed a protein assay to quantify the total protein content from the 
microdissected tissue samples because established methods lacked the required sensitivity, 
and were incompatible with the reagents used for sample lysis. I developed a modified  
microBCA assay that enabled the quantification down to 15 ng of proteins using only 1 μL 
of sample. 
The depth of proteome coverage for the 0.5 mm
2
 kidney samples was comparable to the 
data from the recently described human proteome atlas; however, in our study >200-fold 




less starting material (450 vs 1.5 μg per sample) and 20-fold less LC-MS run time was 
used (36 h per sample vs 17 h for 10 samples). The differences between the two studies is 
mainly due to the use of a more sensitive protocol and multiplexing. The selection and 
microdissection of cortex and medulla kidney substructures was used to create a detailed 
list of region-specific protein expression. Many well-documented functions of the different 
regions were molecularly confirmed and in addition further specified in detail because of 
the protein isoform-specific expression patterns.  
The optimized set of microproteomics protocols has the potential to be used to study the 
proteomes of other heterogeneous low sample amount sources such as ex vivo tumors or 
specific histological tissue regions. 
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Krabbe disease is a rare, childhood lysosomal storage disorder caused by a deficiency of 
galactosylceramide beta-galactosidase (GALC). The major effect of GALC deficiency is 
the accumulation of psychosine in the nervous system and widespread degeneration of 
oligodendrocytes and Schwann cells, causing rapid demyelination. The molecular 
mechanisms of Krabbe disease are not yet fully elucidated and a definite cure is still 
missing.  
Here we report the first in-depth characterization of the proteome of the Twitcher mouse, a 
spontaneous mouse model of Krabbe disease, to investigate the proteome changes in the 
Central and Peripheral Nervous System. We applied a TMT-based workflow to compare 
the proteomes of the corpus callosum, motor cortex and sciatic nerves of littermate 
Twitcher and wild-type mice. More than 700 protein groups exhibited differences in 
expression and included proteins involved in pathways that can be linked to Krabbe 
disease, such as inflammatory and defense response, lysosomal proteins accumulation, 
demyelination, reduced nervous system development and cell adhesion. These findings 
provide new insights on the molecular mechanisms of Krabbe disease, representing a 
starting point for future functional experiments to study the molecular pathogenesis of 
Krabbe disease. Data are available via ProteomeXchange with identifier PXD010594. 
 
  






Krabbe disease (KD), also known as globoid cell leukodystrophy, is a rare autosomal 
recessive sphingolipidosis and is one of a larger group of lysosomal storage disorders 
(LSDs). KD is a neurodegenerative disorder and occurs due to mutations in the β-
galactocerebrosidase gene (galc). These mutations lead to a reduced, or loss of, activity of 
the encoded enzyme (β-galactocerebrosidase, GALC), leading to a disruption of myelin 
turnover in the central nervous system (CNS) and peripheral nervous system (PNS) [1][2].  
The incidence of KD in the US is 1:100,000 and in 95% of cases onset occurs within the 
first 6 months of life (infantile KD) [3][4]. Patients develop progressive blindness, ataxia 
and psychomotor regression, with death typically occurring within 2 years [5][6]. Late 
onset KD (late infantile, late juvenile and adult form) is characterized by milder 
progression and severity [7][3]. Currently there are neither long-term therapies nor a 
definitive cure for KD. Hematopoietic stem cell transplantation (HSCT) is the only 
treatment available and has been shown to slow the course of the disease in pre-
symptomatic infantile patients [8]. Additional treatment strategies, including gene therapy, 
substrate reduction therapy, chemical chaperones and enzyme replacement therapy, are 
currently under investigation in animal models of KD [9][10][11][12][13][14]. The 
Twitcher mouse represents the most common animal model of human KD, as it shows 
similar clinical and histopathological features [15]. 
The “psychosine hypothesis” is the established explanation for KD pathogenesis [16]. 
Defective GALC leads to impaired degradation of the two glycolipids: galactosylceramide 
(Gal-cer), the primary substrate of GALC, and psychosine (PSY) [17]. Whereas Gal-cer is 
also degraded by GM1 ganglioside β-galactosidase [18], there is not another degradation 
pathway for PSY. PSY is a cytotoxic sphingolipid that is produced by galactosylation of 
sphingosine by ceramide galactosyltransferase (CGT or UGT8). CGT is mainly expressed 
in myelinating cells and so in KD psychosine accumulates in oligodendrocytes and 
Schwann cells and is believed to be the main cause of demyelination [19][20]. The 
pathophysiological effect is not limited to oligodendrocytes and Schwann cells death, but 
includes also other cell types of the nervous system because the consequent accumulation 




of myelin debris triggers an inflammatory response with astrocytosis and microgliosis 
[8][17][21]. Furthermore it has been shown that PSY accumulates in membrane 
microdomains affecting lipid rafts and signaling pathways [22][23][24].  
Metabolic profiling of the Twitcher mouse has identified metabolic pathways influenced 
by KD, revealing decreased levels of long chain fatty acids, increased levels of short chain 
fatty acids and alteration of several metabolites involved in mitochondrial fuel selection, 
energy production, inflammation, neurotransmitter metabolism and osmotic regulation 
[25][26][27][28]. However, the proteome changes associated with KD and the pathogenic 
mechanisms are still not well understood.  
MS-based proteomics has been used to study several LSDs, including Niemann-Pick type 
C disease [29][30][31], Gaucher disease [32][33] and Fabry disease [34][35]. Mass 
spectrometry has been extensively used to quantify psychosine in several tissues and cells 
used to study KD, including the Twitcher mouse brain [22], spinal cord [36], serum [37], 
newborn dried blood spots from infants [38] and a cell model of KD derived from the 
Twitcher mouse [39]. However, to date an in-depth proteome characterization of the 
central and peripheral nervous system during disease progression is lacking. Here we 
report the first in-depth characterization of the central and peripheral nervous system of the 
Twitcher mouse. 10-plex Tandem Mass Tags (TMT) based experiments were used to 
compare the proteomes of the corpus callosum, motor cortex and sciatic nerves of 
littermate Twitcher and wild-type mice. 
 
  




5.3. Experimental procedures 
 
5.3.1. Experimental design and statistical rationale 
 
We investigated the proteome changes associated with Krabbe disease by comparing the 
proteomes extracted from the corpus callosum, motor cortex and sciatic nerves of 
littermate homozygous Twitcher and homozygous wild-type mice. We performed a TMT 
10-plex experiment for each tissue region using independent biological replicates (n = 5) 
for each mouse type. The five TWI and five WT samples within each TMT 10-plex set 
were randomized using the Random.org list randomizer (www.random.org), and the 
expression levels of the confidently identified proteins compared using a two-sided 





Trypsin/LysC mix Mass Spec grade was purchased from Promega (Madison, WI). Tandem 
Mass Tags (TMT 10-plex) kits and microBCA protein assay kit were purchased from 
Thermo Fisher Scientific (Rockford, IL). Polyethylene naphthalate (PEN) membrane slides 
were purchased from Carl Zeiss (Carl Zeiss Microsystems GmbH, Göttingen, Germany). 











Twitcher (strain B6.CE-Galctwi/J) animals were bred at the Center for Experimental 
Biomedicine of CNR in Pisa, authorized for the use of animals for scientific purposes by 
the Ministry of Health (Authorization No. 114/2003-A of 16/9/2003). Animals were 
maintained under standard housing conditions and used according to the protocols and 
ethical guidelines of the Italian (DLGS 26/2014; Permit number: PT5.15, July 2015) and 
European Union (2010/63/EU) laws. Experiments were conducted in parallel on Twitcher-
wild type mice (WT) and littermate Twitcher-mutant homozygous mice (TWI), while 
Twitcher-mutant heterozygous mice (Het) were used for the TWI colony maintenance. 
Genomic DNA was extracted from the clipped tails of mice by Proteinase K digestion and 
subsequent genomic DNA extraction (EUROGOLD Tissue-DNA Mini kit, Euroclone) as 
previously described [40][40]. The genetic status of each mouse was determined from the 
genome analysis of the Twitcher mutation (Figure 5.1.), following the method reported by 
Sakai et al. [41]. 
 











Figure 5.1. Genotyping of the Galc mutation. (A) Gel electrophoresis of the littermate mice, 
indicating the five homozygous WT and five homozygous TWI mice selected for proteomics analysis. 
Heterozygous animals were not included in the experimental design. (B) Gel electrophoresis of the 
WT mouse mislabeled as TWI, clearly confirming its WT genotype. The genotype was determined by 
PCR amplification of a genomic DNA fragment in intron 16 of the GALC gene using forward and 
reverse primers, 5'-CCACTCCCATCCTTTCTCC-3' and 5'-GGCCATCACATTCGTCAGA-3' 
respectively. 




Five WT (3 male and 2 female) and five TWI (4 male and 1 female) mice were sacrificed 
by cervical dislocation, dissected and the brain extracted [42] and snap frozen in liquid 
nitrogen for 15 s. Sciatic nerves were dissected by making a 5 mm vertical incision along 
the thigh [43]. The muscles were split until the entire length of the sciatic nerve in the 
thigh region was exposed. The nerves were then gently lifted using forceps and removed 
by cutting at the proximal and distal ends. Brains and sciatic nerves were stored at -80°C 
until analysis.  
 
5.3.4. Laser Capture Microdissection 
 
Consecutive coronal brain sections, 10μm thick, were cut at 0.74-0.98 mm from Bregma 
using a cryostat (CM1950, Leica Microsystems Srl, Milan, Italy) and thaw mounted onto 
PEN membrane slides (previously conditioned in UV light for 30 minutes). After a light 
hematoxylin staining, small regions of 2.5 - 3.3mm
2
 were isolated from the corpus 
callosum and the motor cortex using a PALM microbeam laser capture microdissection 
system (Carl Zeiss MicroImaging, Munich, Germany). Microdissection was performed 
using a x40 ocular lens and a 355nm laser for cutting the tissue and catapulting the isolated 
regions of tissue into adhesive cap tubes (Carl Zeiss). Samples were stored at -80°C until 
analysis.  
 
5.3.5. Protein extraction and digestion 
 
The isolated brain samples were dissolved in 20µL of lysis buffer consisting of 50% 
trifluoroethanol (TFE), 0.5% sodium dodecyl sulfate (SDS), 2.5mM 
ethylenediaminetetraacetic acid (EDTA), 2.5mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA), 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) pH 8.5 and protease inhibitor (cOmplete
TM
,  Mini, EDTA-free Inhibitor 
Cocktail). The sciatic nerves were homogenized in 100µL of the same lysis buffer. 




Proteins were extracted by sonication at 4°C using a Bioruptor Pico (Diagenode, Seraing, 
Belgium - 10 cycles of 30s ON and 30s OFF). Protein quantification was performed on a 
1µL aliquot of each sample using a modified microBCA assay [44].  
Each anatomical region was compared using an identical amount of extracted protein, and 
which corresponded to the maximum amount that could be obtained from all ten animals, 
namely 1.5, 2.5 and 3µg for the corpus callosum, motor cortex and sciatic nerves, 
respectively. Protein digestion was performed using a modified SP3 protocol [44][45]. The 
protein extracts were mixed with 20µL of lysis buffer and 2µL of paramagnetic beads 
(100mg/mL solution of 50% Speedbeads A (GE45152105050250, Sigma) and 50% 
Speedbeads B (GE65152105050250, Sigma)) in 0.2mL PCR tubes (Sarstedt). Briefly, 
proteins were denaturated at 95°C for 5 min. Reduction (DTT 200mM), alkylation (IAM 
400mM), protein purification and overnight trypsin/Lys-C digestion (1:25 enzyme/protein) 
steps were performed in the same tube.  
 
5.3.6. TMT labeling 
 
The protein expression levels in the tissue samples from all ten animals were compared 
using 10-plex TMT isobaric labeling. After digestion the samples were vortexed and 
sonicated for 5min with a Bioruptor Pico (5 cycles of 30s ON and 30s OFF). In-solution 
TMT labeling was performed using a 1:20 peptide/TMT proportion. Three TMT 10-plex 
reagents (0.8mg) were dissolved in 26, 16, and 13μL of ACN and used for the labeling of 
the peptides obtained from the corpus callosum, motor cortex and sciatic nerves, 
respectively (note the TMT solutions were made up using different volumes in order to 
ensure 2μL of the TMT solutions provided the correct excess for each tissue extract). The 
TMT label was added in two equal steps of 1μL, each followed by an incubation period of 
30min. TMT labeling was quenched by adding 2μL of 4% hydroxylamine and incubating 
for 15min. After TMT labeling, the samples were transferred to 0.5mL LoBind tubes 
(Eppendorf) for peptide purification. Samples were rinsed with 100% ACN to promote 
peptide binding on the carboxylate coated beads. Peptides were washed twice with 70% 




ethanol and once with 100% ACN. The purified peptides were eluted from the beads with 
a 2% DMSO aqueous solution. The samples from the five WT and five TWI mice were 
each labeled with a different, randomized TMT label; the labeled peptides from the ten 
mice were then combined in a 1:1:1:1:1:1:1:1:1:1 ratio. An aliquot corresponding to 1.5µg 
of total protein content was collected from each TMT set, diluted 1:1 with 10% formic acid 
and injected into a nanoLC system for the evaluation of the TMT labeling reaction 
efficiency. The remaining samples were dried down with a speedvac (Eppendorf) and 
stored at -20°C.  
 
5.3.7. Automated high-pH fractionation 
 
High-pH fractionation was performed using an AssayMap Bravo robot (Agilent 
Technologies) using the fractionation protocol V1.0 [44]. Briefly, the dried samples were 
resuspended in 10µL of 2% DMSO, mixed with 100µL of 10mM NH4OH (pH 10) and 
loaded on to reversed-phase (RP-S) cartridges. Peptides were isocratically eluted with 
35µL plugs of 12, 18, 24, 30, 36 and 80% ACN in 10mM NH4OH (pH 10). The six 
fractions and the sample flow-through were transferred to 0.5mL LoBind tubes 
(Eppendorf), dried down with a speedvac and stored at -20°C. 
 
5.3.8. LC-MS3 analysis 
 
Peptides were resuspended in 10% formic acid and injected into an Easy-nLC1000 
(Thermo Scientific) coupled to an Orbitrap Fusion (Thermo Scientific). Peptides were first 
trapped using a nanoviper trap column (2cm x 75μm, C18, 3μm, 100A; Thermo Scientific) 
and then separated using an Easyspray analytical column (ES803: 50cm x 75μm, C18, 
2μm, 100A; Thermo Scientific) using a flow rate of 300nl/min and a 140min gradient. 
Peptides were loaded at 800 bar followed by a non-linear gradient: 0-1min, 8%B; 




t=105min, 25%B; t=120min, 35%B; t=130min, 90%B; t=140min, 90%B. Buffer A 
consisted of 0.1% FA and Buffer B of 99.9% ACN and 0.1% FA. 
The Orbitrap Fusion was operated in a data dependent top-speed method using a 2 second 
maximum cycle time and multi-notch synchronous precursor selection (SPS) for MS3 
based TMT quantification. The survey scan was performed in the Orbitrap (m/z 375-1500, 
120k resolution, AGC target 2e5, 50 ms maximum injection time). Monoisotopic precursor 
selection and a dynamic exclusion of 70s were adopted. Ions with charge states from 2+ to 
7+ and intensity greater than 5e3 were selected for CID fragmentation (35% NCE) using 
an isolation window of 1.6 m/z.  
MS2 spectra were recorded in the linear ion trap with a rapid scan rate, 5e3 AGC target 
and 125ms maximum injection time. Following fragmentation, multinotch (synchronous) 
precursor selection was performed to select the 8 most abundant fragment ions for HCD-
MS3 (50% NCE). MS3 scanning was performed in the Orbitrap at a resolution of 60K, 
with an AGC target of 1e5 and 150ms maximum injection time. 
 
5.3.9. Data analysis 
 
Raw data files were analyzed using Proteome Discoverer 2.1 (Thermo Scientific). For each 
tissue type the raw files from the 7 fractions were merged and searched with the 
SEQUEST HT [46] search engine against the Mus Musculus Swiss-Prot protein database 
(July 2016, 16,808 entries) supplemented with a common contaminant database (246 
entries). Searches were performed using the TMT reagents (+229.163 Da, lysine and N-
termini) and carbamidomethyl (+57.021 Da, cysteine) as static modifications, methionine 
oxidation (+15.995 Da) as a dynamic modification, 20ppm precursor mass tolerance, 0.6 
Da fragment mass tolerance, and 20ppm reporter ions tolerance. The search was performed 
using fully tryptic peptides with a minimum length of 6 amino acids and up to 2 missed 
cleavages. Results were filtered for a 1% false discovery rate (FDR) using the Percolator 
algorithm and additionally filtered for a minimum Xcorr score of 1.8. At least one unique 
peptide was required for definitive protein identification. Protein intensities were 




calculated based on label intensities of the 3 most abundant peptides with a co-isolation 
threshold of 50% taking into account unique peptides. 
TMT labeling efficiency and over labeling rate were evaluated using 1.5 µg aliquots of 
each TMT set. TMT labeling efficiency was evaluated by setting the TMT modification 
(+229.163 Da) at N-termini and lysine residues as dynamic and determining the percentage 
of labeled PSMs. TMT over labeling was evaluated by setting the TMT modification at N-
termini and lysine residues as static, and TMT modification at serine, threonine, histidine 
and tyrosine as dynamic, and then determining the percentage of TMT-labeled serine, 
threonine, histidine and tyrosine.  
Search results were exported as txt files and processed with Perseus 1.5 [47]. For each 
TMT experiment the protein intensities were log2 transformed and subject to a median 
normalization. Figure 5.2. shows the boxplots of the log2 transformed protein intensities 
before and after normalization for all the datasets.  
Data were filtered such that each protein was quantified in at least four TWI and four WT 
mice. Principal Component Analysis was performed on the normalized and filtered 
datasets. Significantly different protein levels between TWI and WT mice for the three 
TMT experiments were calculated using a two-sided Student’s t-test using a permutation-
based FDR cutoff (250 randomizations, FDR 0.01, S0 1). Proteins were considered as 
differentially regulated if their adjusted p-value corresponded to an FDR lower or equal to 
0.01 and their fold change (expressed as log2 ratio) was <-1 or >+1. 
Gene ontology was performed with WebGestalt [48] using the Overrepresentation 
Enrichment Analysis (ORA) method. For each TMT experiment the input protein list 
included the proteins significantly up or down regulated in the TWI mice as well as the 
proteins that were quantified only in the TWI or WT mice (proteins quantified in at least 3 
TWI or WT mice and not quantified in at least three WT or TWI mice). The reference 
protein list included all proteins identified in the TMT experiment. A Benjamini-Hochburg 
(BH) method for multiple test adjustment was used and the FDR was set at 0.05.  
 
 






Figure 5.2. Tukey box plots with whiskers to 1.5 interquartile range of the log2 transformed protein 
groups intensities for the corpus callosum dataset before (A) and after median normalization (B), 
motor cortex before (C) and after (D) median normalization and sciatic nerves before (E) and after 
(F) median normalization. For each box plot the horizontal line represents the median value. 
 




5.3.10. Western blot analysis 
 
Western blot analysis of seven selected proteins were performed on the sciatic nerves 
extracts to validate the LC-MS/MS results. Proteins were extracted from the sciatic nerves 
and quantified identically as for the LC-MS/MS analysis (see Protein extraction and 
digestion section above). A WT mice pooled sample and a TWI mice pooled sample were 
prepared by combining the sciatic nerves extracts of three WT and three TWI mice, 
respectively. The western blot analysis was performed in technical triplicate on the two 
pooled samples. The samples were boiled in Laemli buffer containing b-mercaptoethanol 
(5% final concentration) for 5min and centrifuged at room temperature. The supernatants 
were used for gel electrophoresis (SDS-PAGE). Samples (25μg) were resolved by SDS-
PAGE using Gel Criterion XT-Precasted polyacrylamide gel 4–12% Bis-Tris (Bio-Rad, 
Hercules, CA) and subsequently transferred to nitrocellulose membranes [49]. 
Immunodetection was performed for ATG16L1 (Abcam, Cambridge, UK; catalog No. 
ab188642), VAMP8 (Abcam; catalog No. ab76021), UGT8 (Abcam; catalog No. 
ab170351), CTSB (Abcam; catalog No. ab58802), SQSTM1 (Abcam; catalog No. 
ab56416), HEXB (Santa Cruz Biotechnology, Dallas, Texas (USA); catalog No. sc-
376781), LAMP1 (Santa Cruz Biotechnology, Dallas, Texas (USA); catalog No. sc-
20011), and α-tubulin (Sigma Aldrich; catalog No. T6074). On the following day, the blots 
were incubated with the corresponding peroxidase-linked secondary antibodies and after 
incubation the membranes were developed with Clarity enhanced chemiluminescent 
substrates (Bio-Rad). The chemiluminescent signal was acquired with an ImageQUANT 
LAS400 scanner (GE Healthcare Life Sciences, Uppsala, Sweden), and the density of 









5.3.11. Data availability 
 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE [50] partner repository with the data set identifier PXD010594. 
 











We applied a quantitative microproteomics workflow for the characterization of the 
changes in the proteome of the central and peripheral nervous system of the Twitcher 
mouse, the most widely used animal model of Krabbe disease. For the characterization of 
the central nervous system we focused the analyses on the corpus callosum and the motor 
cortex. The corpus callosum represents one of the main regions of the brain showing 
extensive demyelination in Krabbe patients [51][52][53][54] and in the Twitcher mouse 
[55]. The motor cortex was selected because in humans and rodents KD leads to muscle 
weakness, spasticity and paralysis [2]. In order to investigate the effects of KD on the 
peripheral nervous system we chose the sciatic nerves as they show marked demyelination, 
decreased number of axons and axonopathy in the Twitcher mouse [40][56][57]. Figure 
5.3. shows an overview of the experimental approach. 10-plex TMT experiments were 
used to compare the proteomes of the corpus callosum, motor cortex, and sciatic nerve of 
five TWI and five WT littermate mice. The proteomic data were validated by western blot 
















Figure 5.3. Ultrasensitive microproteomic workflow for the characterization of CNS and PNS of the 
Twitcher mouse. The brains and sciatic nerves were collected from five TWI and five WT mice at 30 
days of age. Laser capture 
microdissection was used to isolate 
ROIs from the corpus callosum and 
motor cortex. Proteins were 
extracted from the corpus callosum, 
motor cortex and sciatic nerves, 
quantified with a modified 
microBCA assay and digested with 
the SP3 protocol. Peptides from 
each dataset were pooled and 
labeled with TMT 10-plex reagents. 
Labeled peptides were purified and 
fractionated on a RPS cartridge. 
MS3 spectra were acquired on an 
Orbitrap Fusion mass spectrometer 
and proteins were identified with 
Proteome Discoverer 2.1. Data and 
statistical analysis were performed 
with Perseus and WebGestalt 
softwares. The proteomic data were 
validated by Western blot analysis.  
  




5.4.1. Tissue sampling and protein extraction 
 
Laser capture microdissection (LCM) was used to isolate and excise small regions of 
interest (ROIs) from the corpus callosum and the motor cortex of the mouse brains. The 
brain morphology was found to be different between WT and TWI mice (Figure 5.4.). The 
corpus callosum of TWI mice exhibited a greater cell density and reduced white matter 
compared to WT mice. This morphological feature, due to demyelination of the corpus 
callosum, is consistent with the known histopathology of the Twitcher mouse brain [55]. 





Figure 5.4. Representative coronal brain sections stained with hematoxylin of a WT and TWI 
mouse. Violet dashed lines indicate ROIs isolated from the motor cortex, grey dashed lines indicate 
ROIs isolated from the corpus callosum. 
 
For each mouse, the small, localized regions of the corpus callosum and motor cortex were 
isolated from sequential tissue sections to ensure approximately 2μg of protein was 
available from each region of each mouse. The corpus callosum ROI was isolated from 4-8 
brain sections per animal (total area of 2.6-3.6 mm
2
) and the motor cortex ROI was 
isolated from 5-10 sections (total area of 2.5-4.2 mm
2
). The protein amount extracted from 
each sample was estimated using a modified microBCA assay performed on a 1 μL aliquot 




[44]. This assay allowed us to quantify the protein content of each sample using only 5% 
of its total volume. We extracted 1.5-2.4 μg of proteins from the corpus callosum samples 
and 2.5-4.2 μg from the motor cortex samples. Table 5.1. summarizes the number of tissue 
sections, ROI areas and protein amounts extracted from the corpus callosum and motor 
cortex.  
 
Table 5.1. Summary of the number of tissue sections, ROIs areas and protein amounts extracted 
from the corpus callosum and motor cortex microdissected samples. 
Brain region # sections ROIs area / mm
2
 μg proteins 
Corpus callosum 4 - 8 2.6 - 3.6 1.5 - 2.4 
Motor cortex 5 - 10 3.3 - 5.1 2.5 - 4.2 
 
 
5.4.2. Proteome profiling 
 
The quantitative microproteomics workflow combined SP3 protein digestion [44][45], in-
solution TMT labeling and high-pH fractionation followed by LC-MS3. The corpus 
callosum and motor cortex analyses used the maximum protein amount available from all 
mice for each microdissected region (1.5μg for the corpus callosum and 2.5μg for the 
motor cortex). The analysis of the sciatic nerve was performed on 3μg aliquots of the tissue 
extracts. 
We assessed TMT labeling efficiency on the three datasets in terms of percentage of PSMs 
with the TMT modification at lysine and N-termini residues (Figure 5.5.A). The labeling 
efficiency was greater than 96% for all the datasets for both lysine and N-terminal 
residues. We also assessed the over labeling rate (TMT labeling of serine, threonine, 
histidine and tyrosine), Figure 5.5.B shows a bar graph indicating the percentage of PSMs 
with a TMT modification at serine, threonine, histidine and tyrosine residues. The total 
over labeling rate was less than 5% for all datasets.  




The MS3 analyses of the high-pH fractionated TMT-labeled samples resulted in the 
identification of 3699, 4394 and 3388 protein groups from the corpus callosum, motor 
cortex and sciatic nerve isolates, respectively. Figure 5.5.C summarizes the number of 
identified protein groups, peptides PSMs and MS/MS spectra. For the determination of 
group-wise relative protein quantification the datasets were filtered such that each protein 
needed to be quantified in at least four TWI and four WT mice. This filtering reduced the 
number of protein groups to 2607, 3579 and 2350 for the corpus callosum, motor cortex 




Figure 5.5. (A) TMT labeling efficiency expressed as the percentage of PSMs with the TMT 
modification at N-termini and lysine residues. (B) Over-labeling rate expressed as the percentage of 
PSMS with the TMT modification at serine, histidine, threonine and tyrosine residues. (C) Protein 
identification metrics: number of identified protein groups, peptides, PSMs and acquired MS/MS 




spectra. Grey, violet and white bars refer to the corpus callosum, motor cortex and sciatic nerves 
datasets. 
 
Figure 5.6. shows a histogram of the mass errors of the identified peptides, which 
demonstrates that >95% of all peptide identifications were within 2 ppm, and that >99.9% 




Figure 5.6. Histograms of mass errors (ppm) for the peptides identified from the extracts of the 
corpus callosum, motor cortex, and sciatic nerve datasets, demonstrating that >95% of the 
identifications are within 2 ppm. 
 
 
5.4.3. Proteome changes in the CNS and PNS of the Twitcher mouse 
 
Principal Component Analysis (PCA) was performed on the filtered, quantitative data 
matrices to summarize differences in protein expression between TWI and WT mice. The 




PCA score plot revealed that one mouse, originally considered a TWI mouse, fell into the 
cluster of WT mice for each tissue region (Figure 5.7.). The incorrect assignment of this 
mouse was further indicated by a GALC enzymatic activity assay performed on the sciatic 
nerve extract, which showed a GALC activity comparable to that of WT mice. The initial 
genotyping of the littermate mice is shown in Figure 5.1., which clearly indicates the 
homozygous TWI and WT mice selected for the experiment. These results indicated a 
labeling error with one of the TWI mice selected for the experiment; a subsequent 
genotyping of the suspect TWI-annotated mouse confirmed its status as a WT mouse 
(Figure 5.1.). Thus, this mouse was considered as a WT in the subsequent statistical 
analysis.  
In the PCA score plots of the corpus callosum and the sciatic nerve datasets (Figure 5.7.A, 
C) the same WT mouse was well separated by PC1 (thus maximum variance in the data) 
from both the TWI and WT clusters.  
 





Figure 5.7. Principal Component Analysis performed on the filtered protein groups expression 
values and considering all the analyzed samples for the corpus callosum (A), motor cortex (B) and 
sciatic nerves (C) datasets. Blue circles indicate TWI mice, orange circles indicate WT mice. * 
indicates the mouse originally considered erroneously as TWI, # indicates the WT mouse 
considered as an outlier in the corpus callosum and motor cortex dataset. 
 
We repeated the TMT experiment on another aliquot of the sciatic nerve extracts, from the 
same cohort of mice, and the same mouse remained an outlier and was thus excluded from 
subsequent statistical analysis. Once the outlier was removed the TWI and WT mice were 
well separated as two distinct clusters, separated by PC1, for all tissue regions (Figure 
5.8.A-C). The percentage of variation explained by PC1 was 42.3%, 18.5%, and 68% for 
the corpus callosum, motor cortex, and sciatic nerve, respectively. 




Significantly different protein levels between TWI and WT mice for the three datasets 
were calculated using a two-sided Student’s t-test with FDR correction for multiple testing. 
Figure 5.8.D-F show the volcano plots for the datasets from the three tissue regions. 
We found 75, 14 and 387 protein groups differentially expressed in the corpus callosum, 
motor cortex and sciatic nerves of TWI mice, respectively. Specifically, in the corpus 
callosum 63 protein groups were significantly up-regulated and 12 down-regulated in TWI 
mice. In the motor cortex 9 protein groups were significantly up-regulated and 5 down-
regulated in TWI mice. The sciatic nerve dataset exhibited the largest difference in protein 
expression, with 16% of the total number of quantified protein groups being differentially 
expressed (244 protein groups significantly up-regulated in TWI mice and 143 down-
regulated).  
 





Figure 5.8. Principal Component Analysis performed on the filtered protein groups expression 
values for the corpus callosum (A), motor cortex (B) and sciatic nerves (C) datasets. Blue circles 
indicate TWI mice, orange circles indicate WT mice. Volcano plots for the corpus callosum (D), 
motor cortex (E) and sciatic nerves (F) datasets. Grey circles indicate non significant protein 
groups (log2(fold change) < 1 and >-1, FDR > 0.01). Blue circles indicate protein groups 
significantly up-regulated in the TWI mice (log2(fold change) >1, FDR < 0.01). Orange circles 
indicate protein groups significantly down-regulated in the TWI mice (log2(fold change) < -1, FDR 
< 0.01). 




The proteomics data was also searched for highly differentially expressed protein groups, 
namely those that were quantifiable in only one group of mice (TWI or WT). The data was 
filtered for protein groups quantified in at least three TWI (or WT) mice but not quantified 
in at least three WT or TWI mice. We found 73 (corpus callosum), 14 (motor cortex) and 
158 (sciatic nerve) protein groups that were quantified only in TWI mice, and 33 (corpus 
callosum), 18 (motor cortex) and 10 (sciatic nerve) that were quantified only in WT mice. 
Table 5.2. summarizes the number of protein groups identified, quantified and significantly 
different between TWI and WT mice for the three datasets. The total number of 
deregulated protein groups was 181, 46 and 554 for the corpus callosum, motor cortex and 
sciatic nerves datasets, respectively.  
 
Table 5.2. Summary of the number of protein groups identified, quantified, up-regulated and down-
regulated in TWI mice, quantified only in TWI and quantified only in WT mice for the corpus 








5.4.4. Gene Ontology Enrichment Analysis 
 
Gene Ontology (GO) analysis was performed to understand which GO terms are 
represented in the differentially expressed proteins. We performed an Overrepresentation 
Enrichment Analysis (ORA) using WebGestalt on the corpus callosum and sciatic nerve 







Identified 3699 4394 3388 
Quantified 2607 3579 2350 
Up-regulated in TWI 63 9 243 
Down-regulated in TWI 12 5 143 
Quantified only in TWI 73 14 158 
Quantified only in WT 33 18 10 




datasets (the small number of differentially expressed proteins in the motor cortex dataset 
was insufficient for the analysis). Figure 5.9. shows the enriched GO terms for both 
datasets, in which the bubble graphs show the number of differentially expressed proteins 
contributing to the terms and the FDR value. Most of the enriched biological processes in 
the TWI mice are related to inflammatory and defense response. In the sciatic nerves 
dataset we also found down regulation of processes consistent with axon demyelination 
(reduced axon development, reduced neuron ensheathment, and reduced nervous system 
development) as well as reduced microtubule cytoskeleton organization. KEGG pathways 
upregulated in the TWI mice included those related to inflammatory response (e.g. antigen 
processing and presentation, leukocyte transendothelial migration, and complement 
pathway) and to phagocytosis and lysosomes. The glycosaminoglycan degradation 
pathway, a subclass of the lysosome pathway, was also found to be up-regulated in the 
TWI mice.  
A cellular component ontology analysis was performed to investigate the subcellular 
localization of the deregulated proteins because Golgi apparatus, endosomes and 
lysosomes have previously been demonstrated to play critical roles in LSD’s [31][58][59]. 
Figure 5.10. demonstrates that a significant number of the differentially regulated proteins 
in TWI mice were linked to these organelles.  
 
 






Figure 5.9. Gene ontology Overrepresentation Enrichment Analysis (ORA) performed on the 
protein groups that are significantly up- or down-regulated between TWI and WT mice for the 
corpus callosum and sciatic nerves datasets. A) Biological processes enriched in the corpus 
callosum dataset, B) KEGG pathways enriched in the corpus callosum dataset, C) biological 
processes enriched in the sciatic nerves dataset, D) KEGG pathways enriched in the sciatic nerves 
dataset. The number in the bubble indicates the number of protein groups in the experimental 
dataset that matched with the corresponding GO term. Blue and orange bubbles indicate biological 
processes/pathways enriched in the protein groups that are significantly up- and down-regulated in 
TWI mice, respectively. 









Figure 5.10. GO - Cellular component analysis. List of deregulated protein groups that are localized on Golgi apparatus, endosomes and lysosomes 
for the corpus callosum (A), motor cortex (B), and sciatic nerves (C) datasets. Blue and orange indicate protein groups that are significantly up- and 
down-regulated in TWI mice, respectively. 




5.4.5. Validation by Western blot analysis 
 
A set of the differentially expressed proteins, including proteins related to lysosomes, 
autophagy and psychosine synthesis, were selected for validation by western blot analysis. 
These validation experiments were performed using sciatic nerves extracts. Figure 5.11. 
shows the western blots of the seven selected proteins. The relative expression of all the 
proteins selected for validation by western blot analysis was in agreement with the LC-
MS/MS data. ATG16L1 and UGT8 were down-regulated in the TWI mice. ATG16L1 
belongs to the autophagy-related proteins and plays a crucial role in the autophagy 
pathway as part of a complex with autophagy proteins ATG5 and ATG12 [60]. Down-
regulation of ATG16L1 may indicate a reduced efficiency of autophagosome assembly. 
UGT8 (or CTG) is the enzyme that catalyzes the synthesis of psychosine[61]. The down-
regulation of UGT8 in the TWI mice may indicate a homeostatic response of the cell to the 
accumulation of psychosine. LAMP1, HEXB, CTSB and VAMP8 are lysosomal proteins 
that were up-regulated in the TWI mice. Deregulation of the lysosomal pathway is a 
general hallmark of all LSD’s, including KD [58][62]. SQSTM1 (also known as ubiquitin 
binding protein p62) is an autophagy substrate and a marker used to study autophagic flux 















Figure 5.11. Western blots showing the expression levels of SQSTM1, VAMP8, ATG16L1, LAMP-1, 
HEXB, CTSB and UGT8 in the sciatic nerve extracts of WT mice compared to TWI mice. Results 
were normalized to α-tubulin.  A WT mice pooled sample and a TWI mice pooled sample were 
prepared by combining the sciatic nerves extracts of three WT and three TWI mice, respectively. 
The western blot analysis was performed in technical triplicate on the two pooled samples. *** P < 
0.001, ** P < 0.01, * P < 0.05; Student’s t-test. Blue and orange bars indicate TWI and WT mice, 
respectively. Error bars indicate standard deviation. 
 






This work represents the first mass spectrometry-based in-depth characterization of the 
Twitcher mouse proteome to study changes associated with KD. 10-plex TMT experiments 
were used to compare the proteomes of the corpus callosum, motor cortex and sciatic 
nerves of five TWI and five WT control mice. LCM was combined with a 
microproteomics approach [44] to focus the analysis on localized anatomical regions from 
individual animals; high pH fractionation [64] and multinotch MS3 was used to ensure 
high proteome coverage and higher relative quantitation precision [65][66], and together 
enabled the relative quantitation of 3000 to 4000 protein groups from the microdissected 
samples. Statistical analysis highlighted 181, 46 and 555 protein groups differentially 
expressed between TWI and WT mice in the corpus callosum, motor cortex and sciatic 
nerves, respectively. The expression levels of several proteins were further validated by 
western blot analysis of the sciatic nerve extracts. The roles of the differentially expressed 
proteins in the central and peripheral nervous system of the Twitcher mouse are discussed 
below. 
 
5.5.1. Proteome changes in the Peripheral Nervous System of the Twitcher mouse 
 
The analysis of the sciatic nerve extracts showed an activation of inflammatory response in 
the TWI mouse. Gene ontology analysis, Figure 5.9., revealed an up-regulation of several 
biological processes and pathways related to immune and defense response, antigen 
processing and presentation pathway, complement and phagosome pathways, indicating a 
marked inflammation of the peripheral nervous system.  
Thirteen proteins belonging to the complement pathway were up-regulated in the TWI 
mouse (C1QA, C1QB, C1SA, C3, C5, C5AR1, C8A, C8B, CFB, CD93, ITGAM, ITGAX, 
VTN). CD55, an inhibitor of complement activation, was also found to be significantly 
down-regulated in the TWI mouse, indicating an activation of the complement pathway. 




Moreover, the up-regulation of several macrophage markers (e.g. CSF1R, MPEG1, MSR1) 
suggests macrophage infiltration of the sciatic nerves. Complement activation has been 
shown to be involved in the initiation and/or progression of inflammation by attracting 
macrophages, stimulation of phagocytosis and tissue injury in diseases of both CNS and 
PNS, including Alzheimer’s [67] and Gaucher disease [68]. The observed up-regulation of 
21 proteins involved in phagocytosis (e.g. MCHI, MCHII, CORO1A, CALR and FCGR1) 
may be an effect of complement activation. 
Neuroinflammation is a well-known feature of KD that was believed to be a consequence 
of demyelination [69]. Recent studies showed a neuroimmune activation in murine models 
of KD several weeks before symptoms onset, suggesting that neuroinflammation precedes 
demyelination [70]. The finding that complement proteins are up-regulated in TWI mice 
may be of interest since complement activation has been shown to be involved in 
progressive demyelination of the PNS in Guillain-Barré syndrome [71] and Miller Fisher 
syndrome [72], and to induce tissue inflammation in Gaucher disease [68]. In addition, 53 
proteins associated with the PNS, axon development and neuron ensheathment (e.g. MAG, 
MPZ, MPZL1, JAM3, NEFL, NCAM2, STXBP1) were found to be down-regulated in the 
TWI mouse, indicating neuron damage and extensive demyelination. 
Our data show a marked neuroinflammation, demyelination and complement up-regulation 
at the terminal stage of the disease (the mice were sacrificed at postnatal day 30 and the 
mean lifespan of the TWI mouse is 35-40 days). Future work will focus on younger TWI 
mice to address the role of complement activation in the pathogenesis of KD. 
The lysosome pathway was found to be up-regulated in the TWI mouse (Figure 5.9.). 
Defective lysosomal function is a general hallmark of LSD’s and leads to an accumulation 
of nondegraded macromolecules and metabolites [58]. We found 40 lysosomal proteins 
up-regulated in the TWI mouse (Figure 5.10.), including lysosome membrane proteins 
(e.g. LAMP1 and VAMP8), hydrolases (e.g. CTSB, CTSK, CTSH) and vacuolar H+-
ATPases (ATP6V1C1). A subset of lysosomal proteins associated with glycosaminoglycan 
(GAG) degradation were also up-regulated in the TWI mice, specifically five hydrolases 
(GUSB, GLB1, HEXA, HEXB and GNS) and a transferase (HGSNAT), which are 
involved in the degradation of hyaluronan, heparan sulfate, chondroitin sulfate and keratan 




sulfate [73]. GAGs are important constituents of the cell membrane and the extracellular 
matrix and play important roles not only in cell adhesion but also in inflammation, 
neurodevelopment and neuropathology [74]. GAGs have been shown to be involved in 
leukocyte transmigration at inflammatory sites and in the modulation of chemokines [75]. 
Accumulation and impaired degradation of specific GAGs in mucopolysaccharidosis 
disorder leads to cell death and a chronic inflammatory response resulting in 
neurodegeneration [76]. Our data indicate altered GAG degradation in TWI mice, which 
has not been reported previously. Further studies are needed to elucidate the potential role 
of GAG dysregulation in KD pathogenesis and/or progression. 
The up-regulation of hydrolases suggests inefficient lysosomal degradation, while the up-
regulation of lysosomal membrane proteins (e.g. LAMP1) may indicate a larger number of 
lysosomes in the TWI mouse [77]. An accumulation of lysosomes was already observed in 
induced neurons derived from an adult onset KD patient [78]. The accumulation of 
lysosomes and lysosomal proteins may indicate a disruption of the autophagy pathway, 
which has previously been shown in several LSD’s [79][59]. Autophagy was shown to be 
active in a cell line model of KD after psychosine administration, and the treatment with 
Lithium (an autophagy stimulator) improved cell viability [80]. Here ATG16L1 was found 
to be down-regulated in the TWI mouse. ATG16L1 belongs to the autophagy related 
protein family and forms part of a large protein complex that is necessary for autophagy 
[81]. Specifically, ATG16L1 forms a complex with ATG12 and ATG5 that localizes to 
phagophores and pre-phagophore structures [82] and is essential for the proper elongation 
of the nascent autophagosome and for the lipidation of LC3 [83][84]. Down-regulation of 
ATG16L1 may lead to a reduced rate of autophagosome assembly, and thus a reduced rate 
of autophagy [85]. A deregulation of the autophagic flux in TWI mice also explains the 
observed up-regulation of p62. The ubiquitin-binding protein p62 can bind to LC3 on the 
autophagosome membrane and be degraded by autophagy or target other proteins for 
degradation[86]. Accumulation of p62 and formation of p62 aggregates have been 
observed to occur upon autophagy inhibition and in several LSDs characterized by a 
disruption of the autophagy pathway, including mucopolysaccharidoses, mucolipidoses, 
Niemann-Pick C1, Pompe, Gaucher and Fabry diseases [79]. Thus, the accumulation of 
p62 is consistent with a reduced autophagic activity due to down-regulation of ATG16L1. 




Lysosomal protein accumulation could also be due to decreased autophagosome-lysosome 
fusion. A significant down-regulation of 16 proteins associated with microtubule 
cytoskeleton organization (e.g. MAP6 MAP7D2, CHMP3, CLASP2) were observed in 
TWI mice (Figure 5.9.C), MAP6 and MAPK8IP3 have already been shown to be involved 
in the active transport of lysosomes [87][88]. The two kinesin motor proteins (KIF5C and 
KIF21A), which play an active role in the anterograde transport of lysosomes [89], were 
also found to be down regulated in TWI mice. Moreover we observed a down-regulation of 
CHMP3, which is a protein that forms part of the ESCRT-III complex whose inactivation 
has been shown to induce autophagosome accumulation and autophagy disruption [90].  
An accumulation of lysosomal proteins may also cause a destabilization of the lysosomal 
membrane that leads to lysosome membrane permeabilization (LMP) [91]. LMP have been 
shown to play a crucial role in lysosomal cell death (LCD) because of the release of 
lysosomal proteins in the cytosol. Cathepsins are believed to be the main mediators of 
LCD, even if they can also trigger LCD [92]. Among the lysosomal proteins that were 
found to be up-regulated in TWI mice there were 6 cathepsins: CTSB, CTSD, CTSH, 
CTSK, CTSS, CTSZ. In particular, CTSB and CTSD are involved not only in the 
triggering of LMP but also in cell death since they remain active at neutral pH, and so they 
remain active in the cytosol [93]. LMP may also be induced by reactive oxygen species 
(ROS) and apolipoproteins [91][94]. ROS production in Krabbe disease has been linked to 
psychosine accumulation, which activates secretory phospholipase A2 in oligodendrocytes 
MO3.13 [95]. Here we found an up-regulation in TWI mice of PLAA (an activator of 
phospholipase A2) and 5 apolipoproteins (APOA1, APOB, APOBR, APOD, APOE), 
supporting the hypothesis of LMP in the TWI mouse. APOE is a high density lipoprotein 
produced mostly by astrocytes in the CNS and secreted by macrophages at the site of 
injury in the PNS [96][97]. Accumulation of APOE has been shown to delay the 
regeneration of sciatic nerves, contributing to degeneration of the nervous system [97]. 
Moreover, APOE seems to impair autophagy in astrocytes leading to a reduced capacity of 
Aβ plaque clearance in the CNS of Alzheimer’s disease patients [98]. Apolipoproteins 
have not previously been reported to accumulate in the TWI mouse and future studies will 
be needed to establish their role in KD.  




Among the proteins down-regulated in the TWI mouse we also found UGT8, which is the 
enzyme that catalyzes the synthesis of psychosine. This result is in agreement with 
previous studies that reported a down-regulation of UGT8 in the brain and spinal cord of 
the TWI mouse at a late stage of the disease [99][100][61]. The down-regulation of UGT8 
in TWI mice is thought to be a homeostatic response of the cell to psychosine 
accumulation. 
 
5.5.2. Proteome changes in the Central Nervous System of the Twitcher mouse 
 
We characterized the Central Nervous System of the TWI mouse by analyzing the corpus 
callosum and motor cortex regions.  
The corpus callosum dataset contained a larger number of deregulated proteins than the 
motor cortex, consistent with the known mechanisms of KD in which the accumulation of 
psychosine occurs mainly in myelinating cells (such as oligodendrocytes and Schwann 
cells), impairing remyelination and damaging the brain’s white matter [2].  
The main biological processes up-regulated in the CNS of the TWI mouse are related to 
inflammatory and defense response and leukocyte infiltration (Figure 5.9.A-B), as we 
found in the PNS. We found an up-regulation of the Complement and JAK/STAT 
pathways in both the corpus callosum and motor cortex, indicating neuroinflammation in 
the TWI mouse brain. The JAK/STAT pathway is essential for both innate and adaptive 
immunity and its aberrant activation has previously been reported in the 
neuroinflammatory diseases Multiple Sclerosis and Parkinson’s Disease [101]. The use of 
JAK1 and JAK2 inhibitors in several murine models of Multiple Sclerosis has been shown 
to suppress clinical symptoms, reduce demyelination and suppress the production of pro 
inflammatory cytokines and chemokines [102]. The up-regulation of both STAT1 and 
STAT3 in the CNS of the TWI mouse suggests that the JAK/STAT pathway may be a 
therapeutic target for KD treatment.  




We also found an up-regulation in the TWI mouse of GFAP and VIM, which are markers 
of reactive astrocytes and microglia activation [103][104]. GFAP and VIM up-regulation 
in the TWI mouse have been previously shown to occur before demyelination and in 
concomitance with macrophage infiltration, suggesting that CNS astrogliosis and 
inflammation may precede demyelination [105][106].  
Several lysosomal proteins were found up-regulated in the corpus callosum of the TWI 
mouse (Figure 5.10.A-B), including HEXB, CTSB, CTSD and LAMP2. These results are 
in agreement with that found for the PNS of the TWI mouse, indicating that the 
accumulation of nondegraded material and the related biological alterations (see section 
“Proteome changes in the Peripheral Nervous System of the Twitcher mouse”) also occurs 
in the CNS of the TWI mouse.  
Five proteins involved in membrane raft organization (ANXA2, CAV1, FLOT1 and 
DOCK2) were found to be up-regulated in the corpus callosum of the TWI mouse. 
Disruption of lipid raft domains have been shown to occur in sphingolipid storage 
disorders and KD as a consequence of undigested lipids and psychosine accumulation 
[22][107]. Lipid rafts are involved in several signaling pathways and an alteration in raft 
composition can lead to altered membrane fluidity, and deregulation of cell signaling, 
influencing survival signals such as PKC, Akt and ERK [23][24]. 
Among the proteins down-regulated in the motor cortex of the TWI mouse we found 
UGT8, and which was also found to be down regulated in the sciatic nerve (see section 
“Proteome changes in the Peripheral Nervous System of the Twitcher mouse”). This result 
is in agreement with previous studies, which reported a down-regulation of UGT8 at late 
stages of KD in both CNS and PNS [99]. 
 
  






This work represents the first in-depth characterization of the Twitcher mouse proteome to 
study Krabbe disease. We applied a quantitative microproteomic workflow to detect 
changes associated with Krabbe disease in the Central and Peripheral Nervous System of 
the Twitcher mouse. The proteomes extracted from the corpus callosum, motor cortex and 
sciatic nerves of five Twitcher and five wild-type mice were compared at postnatal day 30. 
More than 3300 protein groups were identified for each dataset. Statistical analysis 
revealed a total number of deregulated protein groups of 181, 46 and 554 for the corpus 
callosum, motor cortex and sciatic nerves datasets, respectively. 
Most of the enriched biological processes and pathways in the TWI mice were related to 
neuroinflammation, immune response, accumulation of lysosomal proteins, demyelination, 
membrane raft organization and reduced nervous system development. These results on the 
proteome changes in the Twitcher mouse help provide new insights into the molecular 
mechanisms of Krabbe disease. Future experiments will focus on the proteomic 
characterization of younger mice (pre-symptomatic and at symptoms onset) in order to 
understand how these deregulated pathways are linked to the pathogenesis of Krabbe 
disease and specifically, which of these trigger damage to the CNS and PNS and can act 
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6.1. The future of MS-based proteomics: space and time resolved proteomics 
 
The recent groundbreaking technological improvements in MS-based proteomics have 
enabled the in-depth proteome analysis from minute sample amounts (< 1µg) of cell 
culture samples as well as clinical samples. The possibility to perform ultrasensitive 
analyses has opened new exciting application areas for MS-based proteomics. Proteomics 
characterization can now be performed in the space or in the time domains. Spatially-
resolved proteomics can be used to study localized pathological features or tissue 
heterogeneity, while time resolved proteomics can now resolve the translational response 
of a system to external stimuli. The combination of space and time resolved proteomics 
represents a unique strategy to study the proteome dynamics in specific cell types.  
Tissue heterogeneity occurs at the tissue level and also within the same cell type. Different 
cell populations in the same tissue exhibit a different phenotype because of the distinct 
regulation of gene expression and the influence of the microenvironment [1]. The ability to 
investigate the proteome of specific cell populations is expected to will help understand 
important biological phenomena which are obscured in bulk measurements. Population 
distributions can mask the presence of small phenotypic subpopulations of cells, as the 
response of these cells is diluted by the different populations. Different cell populations 
may not contribute equally to the biology of the system, for instance the presence of a 
small population of chemoresistant tumor cells may compromise <1% of all tumor cells 
but can lead to relapse. Tumor heterogeneity plays a crucial role in cancer onset, 
progression and resistance to therapy [2]. Differences in the microenvironment and 
proximity to blood vessels, immune cells, and stromal cells mean even cells of the same 
type are subject to different regulatory signals. Accordingly these cells will differ in their 
proteomes, and these differences may also have functional consequences [3][4][5]. In order 
to detect these differences any analysis will need to be performed at the single cell level. 
Genomics and transcriptomics are now established technologies for single-cell analysis, 
because of the possibility to amplify the copy number using PCR and the availability of 
high sensitivity next-generation sequencing analysis [6][7]. The absence of an analogous 




amplification method for proteins means single-cell MS-based proteomics demands 
extremely high sensitivity and reproducibity. The first single-cell proteomics study 
reported the proteome profiling of blastomers isolated from Xenopus laevis embryos 
[8][9]. These analyses were enabled by the high protein content of the blastomers (~10 
µg), which was compatible with a down-scaled conventional proteomics workflow (Figure 
6.1.). A custom-built single-cell CE-µESI platform allowed the identification of almost a 
thousand protein groups from just 20 nL of injected sample, and the results exhibited 
significant cellular heterogeneity at the protein level. 
 
 
Figure 6.1. Microanalytical pipeline enabling multiplex proteomics analysis of single cells in the 
16‐cell Xenopus embryo using microdissection, micro‐scale bottom‐up proteomics, and a 
custom‐built single‐cell CE‐μESI platform. Figure adopted from [8]. 
 
In 2018, two different strategies for the proteomics analysis of single mammalian cells 
were reported [10][11]. The small size of mammalian cells (~10-15 µm diameter) results in 
a protein content of about 0.1-0.2 ng per cell, which requires not only a highly sensitive 
instrumental platform but also a miniaturization of the proteomics workflow in order to 
allow the processing of such minute sample amounts. If the sample amount decreases 
without a concomitant reduction of the working volume then non-specific adsorption of 
proteins to the surface of the reaction vessel/pipettes/tubes leads to sample losses and 




lower sensitivity. For single cell analysis, such losses quickly lead to the almost complete 
loss of all available proteins. 
 
 
Figure 6.2. A) Schematic drawing of the nanoPOTS microfluidic platform structure. B) Photograph 
showing the nanoPOTS chip with each nanowell filled with 200 nL of colored dye. C) Schematic of 
the on-chip proteomic sample preparation  Figure adopted from [10]. 
 
Zhu et al. developed the nanoPOTS (nanodroplet processing in one pot for trace analysis) 
platform for the proteomics analysis of single-cells (Figure 6.2.). The key advantage of this 
platform is the miniaturization of the working volume to about 200 nL, thus minimizing 
adsorption based sample losses. The nanoPOTS platform consists of a glass slide 
microfabricated with photolithographically patterned hydrophilic pedestals surrounded by 
a hydrophobic surface to serve as nanodroplet reaction vessels. The patterned glass slide is 
assembled with a glass spacer sealed to a membrane-coated glass slide in order to 
minimize evaporation during the various incubation steps (Figure 6.2.A). A robotic 
platform is used to dispense cells and reagents with high accuracy into each nanodroplet 
reaction vessel, and to retrieve samples for subsequent nanoLC-MS/MS analysis. Cells are 
lysed using an acid-cleavable surfactant (RapiGest) and the proteins reduced, alkylated and 




digested with typsin. Peptide TMT labeling can also be easily performed after protein 
digestion for accurate protein quantification [12]. The solution is then acidified to 
inactivate the surfactant by precipitation, and the peptide solution retrieved from the 
nanoPOT well and finally injected into the nanoLC-MS/MS system.  
The efficiency of the nanoPOTS protocol was assessed using different amount of HeLa 
cells (from 139 down to 12 cells). The lysis efficiency, evaluated in terms of the 
percentage of zero missed cleavages, was found to be higher than 97% and comparable to 
that obtained in bulk experiments. Pairwise analysis of any two samples with similar 
sample amounts showed a Pearson correlation coefficient greater than 0.98 at the protein 
level and a coefficient of variation lower than 13.1%, demonstrating high reproducibility.  
The open structure of the nanoPOTS platform is suitable for hyphenation with upstream 
sample isolation procedures (such laser microdissection [10][13] or FACS [12][14]) and 
downstream transfer to LC-MS/MS systems. The possibility to integrate nanoPOTS with 
LCM (Figure 6.3.) makes this technology particularly powerful for tissue proteomics.  
 
 
Figure 6.3. Schematic workflow showing the identification, laser microdissection, collection and 
transfer of small tissue sections into nanowells. Figure modified from [10]. 
 
The nanoPOTS platform was used to analyze 10-µm-thick cross-sections of individual 
human islets that were isolated by laser microdissection from clinical pancreatic tissue 
slices. The proteomic profile of nine single pancreatic islets from non-diabetic donors 
(control) were compared to nine islets from type 1 diabetic patients (T1D). The highly 




sensitive nanoPOTS platform provided the identification of more than 2600 proteins, of 
which more than 300 exhibited altered expression between T1D patients and controls.  
The nanoPOTS platform has proven to be a promising tool for proteomics analysis of 
single cells but requires access to a nanostructuring facility. The fabrication of the device is 
relatively straightforward but requires specific expertise and facilities for its realization.  
In 2018 Budnik et al. developed Single Cell ProtEomics by Mass Spectromety (ScoPE-
MS) to study the proteome of single mammalian cells [11]. The major limitation of single 
cell proteomics is the low abundance of peptides that can be retrieved from single cells. If 
a peptide’s abundance is too low, the ion current will not be sufficient and the peptides 
cannot be identified. SCoPE-MS increases the effective abundance of peptides analyzed by 
the mass spectrometer by multiplexing the analysis. Specifically Tandem Mass Tags 
(TMT) are used to label peptides from single cells and a so-called carrier sample (see 
Paragraph 1.2.5.2. for more details about the TMT labeling mechanism). 10-plex TMT 
allows the simultaneous analysis of up to ten different samples, as ten tags are available for 
the peptide labeling. In SCoPE-MS eight single cell samples are analyzed as well as a 
carrier sample containing 200 cells to increase the available peptide ion current (Figure 
6.4.). The key element of this strategy is the carrier sample, which serves to increase the 
available peptide ion current and to reduce the loss of protein from the single cell samples 
due to adhesion on the surface of the equipment. Individual cells are isolated under a 
microscope and transferred into glass vials. Cell lysis by ultrasonication, protein 
denaturation and tryptic digestion are performed in the same glass vial. The resulting 
peptides are labeled with a 10-plex TMT tag, mixed and analyzed by LC-MS/MS. No 
sample clean-up is required before analysis as no detergents or contaminating agents are 
introduced into the samples.  





Figure 6.4. Conceptual diagram and workflow of SCoPE-MS. Figure adopted from [11]. 
 
The SCoPE-MS strategy has been successfully applied to study the differentiation of 
embryonic stem cells, providing the identification of more than 1000 proteins [11]. 
Principal Component Analysis and Gene Onthology analysis showed variation of the 
single-cell proteome during differentiation and were used to identify the molecular 
functions and biological processes involved in the cell differentiation process. SCoPE-MS 
represents a promising strategy for single-cell proteomics because it can be implemented in 
a proteomics lab with little extra costs or equipment. However, particular attention should 
be paid to the selection of the carrier cells, as it defines which proteins can be identified 
and quantified in the single cell samples.  
The recent advances in ultrasensitive proteomics have enabled tissue heterogeneity to be 
studied by comparing the proteome of minute tissue samples and even single 
microdissected cells. But what about proteome dynamics? Can proteomics be used to study 
the time evolution of the proteome of cells? 
The proteome is dynamic and tightly regulated. The primary function of protein turnover is 
to alter the levels of specific proteins in response to physiological changes, hormonal state 
or diet [15].  One of the main challenges in the study of protein dynamics is the turnover 




rate, which indicates the lifetime of a given protein in a cell [16]. If protein synthesis is 
linked to transcriptional control, protein degradation is more coupled to the metabolic 
activity [17]. In a steady-state condition the concentration of the protein pool is unchanged 
because protein synthesis and degradation are balanced (Figure 6.5.). 
 
 
  Figure 6.5. Schematic of protein turnover regulation. 
 
When the available protein pool needs to be increased this can be achieved by increasing 
the rate of protein synthesis (translation) or decreasing the degradation rate (metabolic 
activity). Conversely, a reduction in the available protein pool results from decreased 
synthesis and/or increased degradation. It has been noted that high abundance proteins 
exhibit the lowest turnover rate, as they are involved in “housekeeping” roles to maintain 
cell homeostasis. Regulatory proteins, which are more informative about cellular 
processes, are expected to have higher turnover rates [18] to enable more rapid adaption. 
The study of proteome dynamics can be achieved via incorporation of a label into nascent 
proteins. Radioactive isotopes have been used to detect newly synthesized proteins with a 
pulse-probe-methodology [19]. If an amino acid bearing a radioactive isotope, e.g. [
35
S] 
methionine, is administrated to a cell culture for a given period of time (amino acid pulse), 
all the proteins synthesized during this period will contain a radioactive methionine. The 
labeled proteins can then be detected and distinguished from pre-existing (unlabeled) 
proteins by electrophoretic separation followed by radiographic detection. More recently, 








In 2006 Dieterich et al. introduced Bio-Orthogonal Non Canonical Amino acid Tagging 
(BONCAT) to study nascent proteins by mass spectrometry [21]. Alternatively, nascent 
proteins can be visualized by conventional fluorescence microscopy with FlUorescent Non 
Canonical Amino acid Tagging (FUNCAT) [22]. A pulse of a non-canonical aminoacid 
(ncAA) is administrated to a cell culture in order to incorporate the ncAA in the newly-
synthesized proteins (Figure 6.6.).  
 
 
  Figure 6.6. Schematics of BONCAT and FUNCAT strategies. 
 
The use of non canonical amino acids (ncAA) bearing a reactive functional group, such as 
an alkyne or azide moiety, allows the newly synthesized proteins to be visualized/isolated 
by click chemistry [23]. In FUNCAT the ncAA are labeled with a fluorescent tag, while in 
BONCAT the ncAA are labeled with biotin in order to isolate the nascent proteins by 
affinity purification techniques. In the last years BONCAT has been widely used both in 
vitro and in vivo to study proteome dynamics [24][25][21][26][27]. 
A groundbreaking development in tissue proteomics came in 2017 with work that 
combined space and time resolved proteomics. Alvarez-Castelao et al. developed a strategy 
to study proteome dynamics in specific cell types in vivo [28]. Using a modified BONCAT 
procedure and a transgenic mouse model it was possible to study nascent proteins in 










Protein with canonical AA Protein with non canonical AA Fluorescent tag Biotin tag




The incorporation of ncAA requires processing by the endogenous cell machinery. A 
mutant form of methionyl tRNA synthetase (metRS) was used to allow the binding of 
azidonorleucine (ANL) instead of methionine, and thus the incorporation of ANL into 
nascent proteins. In the mouse model reported by Alvarez-Castelao et al. MetRS* 
expression is under the control of Cre recombinase. Thus, MetRS* is expressed only if Cre 
recombinase is also expressed. In order to promote cell-type specific incorporation, the 
authors engineered two other mouse models in which the expression of Cre recombinase is 
under the control of a cell type specific promoter: (i) CamK2a-Cre in which Cre 
recombinase is expressed only in excitatory neurons and (ii) GAD2-Cre in which Cre 
recombinase is expressed only in inhibitory neurons. By crossing the mouse model 
MetRS* with CamK2a-Cre they obtained a mouse model in which MetRS* is expressed 
only in excitatory neurons. This means that in this mouse model the ANL incorporation 
can be achieved only in excitatory neurons. Similarly by crossing  the mouse model 
MetRS* with GAD2-Cre incorporation can occur only in inhibitory neurons. In the in vivo 
experiment mice were fed with ANL for 21 days and after sacrifice the brain slices were 
used for FUNCAT and BONCAT (Figure 6.7. A).  
 





 Figure 6.7. A) Schematic of the in vivo experiment; B) FUNCAT signal in MetRS* mouse and 
BONCAT in WT and MetRS* mice. Figure modified from [28]. 
 
Nascent-labeled proteins, detected using FUNCAT, were clearly visible in hippocampal 
neurons, indicating that ANL incorporation occurred only in excitatory neurons (Figure 
6.7.B). Moreover, Western blot analysis revealed an abundance of biotinylated nascent 
proteins, spanning all molecular weights, in hippocampal tissue from the CaMK2a-Cre 
MetRS* mouse and much lower background levels of biotinylated proteins obtained from 
the WT mice, indicating the high selectivity of the BONCAT procedure. MS-based 
proteomics was also used to compare the proteomes obtained from the CaMK2a-Cre 
MetRS* mouse (or GAD2-Cre MetRS* mouse) with WT mouse. More than 1000 proteins 
were found to be enriched in the CaMK2a-Cre MetRS* mouse and Gene Onthoogy 
analysis found a significant enrichment in processes related to synaptic transmission and 
plasticity. The protein expression profiles obtained from the CaMK2a-Cre MetRS* and 
GAD2-Cre MetRS* mice were also compared from protein expression profiles obtained 
A
B




from whole hippocampal, cerebellar and glial cell populations. Principal Component 
Analysis (PCA) showed a net segregation between the different cell types (Figure 6.8.), 
confirming the high selectivity of the experimental procedure.  
 
 
Figure 6.8. Principal Component Analysis performed on protein expression levels of different cell 
types. Figure adopted from [28]. 
 
The results demonstrated that BONCAT enabled the identification of cell-type specific 
proteomes labeled in vivo in complex tissues without mechanical dissociation and isolation 
of specific cell types. The authors studied also the proteome dynamics induced by external 
stimuli. Since the sensory environment have been proven to modify brain circuits and 
synapses, they compared the proteomes of mice exposed to an enriched environment with 
those housed in standard conditions. The BONCAT strategy provided the identification of 
more than 200 proteins that exhibited significant differences in expression between the two 
groups of mice.  




In conclusion, all these works show that MS-based tissue proteomics is still improving. 
The technological and experimental developments achieved in the last years are opening 
exciting new application fields, from single cell analysis to personalized medicine. In the 
future MS-based proteomics will be useful to add a spatial and temporal dimension to our 
knowledge of cellular metabolism in both normal and diseased tissues.  
  




6.2. Personal considerations 
 
When I started to work in the proteomics field at the beginning of my PhD in 2014, there 
were only a few studies about ultrasensitive proteomics. The vast majority of the 
proteomics studies were focused on whole organs or whole tissue sections. In that scenario, 
the study of the proteome changes associated with disease was challenging because the 
technologies available were not able to characterize heterogeneous tissues with sufficient 
cellular/phenotypic specificity. The development of high sensitivity sample preparation 
protocols and the coupling of these procedures with laser capture microdissection have 
helped revolutionize the proteomics field, as it became finally possible to focus the 
analysis on specific tissue areas/cells of interest. 
The set of high sensitivity and high specificity protocols developed during my PhD 
provides a powerful tool for the proteomics community. The main strength of the 
procedures is not only the increased depth of coverage that can be achieved but also their 
versatility. Indeed, these procedures can be easily implemented in every proteomics 
laboratory and are compatible with a wide variety of applications. In this thesis I showed 
the application of these procedures to mouse kidney substructures, to the characterization 
of the brain tumor microenvironment and to the study of a neurodegenerative disorder. But 
the same set of protocols can be adjusted to study FACS sorted cells and to characterize 
every type of tissue.  
The advances reported here and developed by partner proteomics laboratories now the 
enable the analysis of the proteome of small numbers of mammalian cells. In my opinion 
the key strategy for the further development of single-cell proteomics is the coupling 
between microfluidics and proteomics. The possibility to use microfluidic technologies to 
manipulate sample volumes in the order of nL is crucial to reduce sample losses and to 
increase sensitivity. Indeed, the best results on single-cell proteomics were obtained using 
a microfluidic device (the nanoPOTS platform). On the other hand, I believe that 
microfluidics represents also the main limitation for the rapid establishment of single-cell 
proteomics. The use of microfluidics in proteomics is not a new idea; in the last decade 
many publications have reported different methods for the coupling of microfluidics and 




proteomics. However only two years ago the combination of these two technologies 
allowed the successful analysis of the proteome of a single cell. This partially reflects the 
fact that proteomics and microfluidics are two very distinct fields that require distinct 
expertise and technologies. Thus, a very close collaboration and cooperation between these 
two fields must be established in order to develop a powerful technology that can be 
widely implemented and used by the proteomics community. It is expected that the 
encouraging results obtained in these first studies will help promote such cooperation and 
that in the coming years numerous platforms will be developed for single-cell proteomics.  
Another aspect that should not be underestimated is the careful experimental design 
required for a single-cell study. In single cell RNAseq a large number of cells can be 
simultaneously analyzed, using genomic bar-codes to distinguish the contributions from 
different cells. In this manner RNAseq can examine the molecular variability of a cell 
population, as well as investigate the characteristics of specific subpopulations. The low 
throughput of single cell proteomics precludes such an approach and single cells must be 
selected from a larger number of cells prior to the proteomics experiment. The selection of 
the single cell is crucial and great care should be taken to ensure that the cell is 
representative of the biological process under investigation.  
In conclusion, I believe that the combination of microfluidics, single-cell genomics and 
single-cell proteomics will represent the winning strategy to understand the biological 
cellular networks that occur in cancer, neuroscience and stem cell biology and will provide 
new methods to diagnose and treat diseases. 
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